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Using mathematical models to evaluate and inform
immunisation strategies with MenAfriVac in the
African meningitis belt
Andromachi Karachaliou Prasinou
The countries of the African meningitis belt suffer from frequent epidemics due to meningo-
coccal meningitis. The introduction of a tailor-made vaccine, known as MenAfriVac, in
these countries through mass campaigns of 1-29 year olds has led to a remarkable decline
in the burden of disease due to Neisseria meningitidis serogroup A. The aim of this work
is to identify immunisation strategies with MenAfriVac that best sustain population
protection in the long-term and predict vaccine impact across all 26 meningitis belt
countries.
Firstly, I developed an age-structured transmission dynamic model to explore the
impact of a range of different immunisation schedules. Numerical simulations of the
model show a period of very low incidence following MenAfriVac introduction, while
strong resurgence is predicted in the absence of any long-term immunisation strategy. Of
the strategies considered, the introduction of the vaccine into the Expanded Programme
on Immunisation at 9 months, 5 years after the initial campaign, together with a mini
catch-up campaign resulted in the lowest average annual incidence.
Next, my model is compared to an existing model, published two years earlier through
a model comparison exercise. The comparison exercise identified a number of errors in
the other study which explained the different predictions made by the two models and
also led to a correction to the original study being published by the authors.
As part of the Vaccine Impact Modelling Consortium, the model was adapted and
used to provide estimates on the impact of MenAfriVac on disease incidence for the 26
countries of the meningitis belt under the current schedule of each country. The model
consists of 100 age groups and keeps track of the number of cases, deaths and Disability
Adjusted Life Years (DALYs) for each age group per year for the period 2010-2100.
Assuming that the current schedule continues unchanged until 2100, the model predicts
that more than 9 million cases will be prevented in total across all 26 countries.
Further, the routine immunisation of school-age children is simulated as an alternative
strategy to better understand the role of vaccine induced protection, as new data suggest
that antibody response is short-lived when children under the age of two years are
vaccinated. Assuming that vaccine protection lasts longer for individuals targeted after
the age of five years, model simulations suggest that vaccination of older children would
be more efficient in reducing the disease incidence and would also result in a smaller
number of people needed to vaccinate to prevent one case.
The main conclusion of this work is that sustained use of MenAfriVac is essential
to maintain high levels of direct and indirect population protection. Results from this
thesis have been used to inform the current immunisation strategy in the countries of the
African meningitis belt. Assuming that vaccine duration is shorter for children less than
5 years old, it may be wiser to change the age of routine immunisation and target older
children instead. This conclusion can be useful in the near future to inform strategies
which will include the new pentavalent vaccine.
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Neisseria meningitidis, the meningococcus, is an important cause of bacterial meningitis
[2]. Meningococcal meningitis is fatal in around 10% of cases and can cause severe brain
damage in survivors [3]. The epidemiology of meningococcal meningitis varies greatly
throughout the world, but an area of sub-Saharan Africa, known as the meningitis belt,
has by far the highest incidence of disease [4].
A new meningococcal group A conjugate vaccine, commonly known as MenAfriVac,
developed specifically for Africa [5, 6], was first introduced in 2010 through mass immu-
nisation campaigns targeting individuals between 1 and 29 years old [7], with the aim of
eliminating epidemic meningitis as a public health problem.
Before 2010, repeated epidemics have been reported in the African meningitis belt
with weekly incidence reaching up to 100 cases per 100,000 population [8]. Group A
meningococcus accounted for an estimated 80% of all cases of meningitis [9]. Since the
introduction of MenAfriVac, the proportion of serogroup A cases has declined remarkably
[10–12].
The aim of this thesis is to develop and apply mathematical models to investigate the
epidemiology of meningococcal carriage and disease and predict the impact of further
vaccination with MenAfriVac.
1.2 Outline of the thesis
This thesis is organised as follows:
2 Introduction
• Chapter 2 provides a description of the epidemiology of meningococcal meningitis
around the world and more specifically in the African meningitis belt before and
after the introduction of MenAfriVac, followed by a discussion on the usefulness
of mathematical models in guiding public health action and the models related to
meningococcal meningitis that are developed up to now.
• Chapter 3 presents the development of a meningitis transmission dynamic model.
The model is then applied to investigate the impact of various immunisation
strategies with MenAfriVac in Burkina Faso. The strategies are compared to a
scenario in which there is no long-term immunisation schedule.
• Chapter 4 presents a comparison of my model with a previously published model,
triggered by observed differences in their results.
• Chapter 5 presents the work undertaken as part of the Vaccine Impact Modelling
Consortium (VIMC). The model presented in Chapter 3 is adapted to meet the
requirements set by VIMC and is used to provide estimates on disease burden in
the 26 countries of the African meningitis belt.
• Chapter 6 presents my work on simulating alternative vaccination strategies
targeting school-aged children instead of infants for routine immunisation. Key
assumptions about the duration of vaccine-induced immunity are revisited based
on newly available data. The model from Chapter 5 is used to provide estimates
on disease burden in Chad under a range of different assumptions regarding the
duration of protection. The potential impact of an additional mass immunisation
campaign using the novel pentavalent vaccine on Neisseria meningitidis serogroup
A is also explored.
• Chapter 7 concludes this thesis with a discussion on the implications of my
findings on vaccine policy. The key limitations and weaknesses are summarised,
followed by a discussion on areas of future work.
The definition of the age range when I refer to the terms infants, children, adolescents






Young adults 20-29 years
1.3 Publications
• The work in Chapter 3 has been published as the following paper (attached at the
end of this thesis in Appendix B):
A. Karachaliou, A. J. K. Conlan, M-P. Préziosi, and C. L. Trotter. Modeling
long-term vaccination strategies with MenAfriVac in the African meningitis belt.
Clinical Infectious Diseases, 61(Suppl 5):S594–600, Nov 2015.
I was the lead author of this paper and I developed the code and analysed all
the results. I also wrote the first draft of the manuscript. Dr Andrew Conlan
contributed to this paper by providing technical advice and guidance. Dr Marie-
Pierre Preziosi provided consultation and data on vaccine coverage. Dr Caroline
Trotter was the principal investigator.
• I used the model from Chapter 3 to produce estimates for a cost-of-illness study
published (attached at the end of this thesis in Appendix B) as follows:
A. Colombini, C. L. Trotter, Y. Madrid, A. Karachaliou, and M-P. Préziosi.
Costs of Neisseria meningitidis group A disease and economic impact of vaccination





Meningitis is a severe infection of the meninges, the membranes surrounding the brain
[2]. Meningococcal meningitis is a bacterial form of meningitis, caused by the bacteria
Neisseria meningitidis, also referred to as meningococcus. N. meningitidis, first recognised
in 1805, only affects humans and is a major cause of bacterial meningitis worldwide.
While recognised as an important cause of disease, the typical habitat of meningococcus
is the human nasopharynx and acquisition of the bacterium in most cases leads to a
harmless colonisation [13].
Strains of N. meningitidis are classified into distinct serogroups on the basis of the
chemical composition of their capsule. There are 12 serogroups, 6 of which, namely, A, B,
C, W, X and Y, are the primary cause of disease in most parts of the world [14]. Some
meningococci do not possess the genes encoding a capsule; these are known as capsule
null (cnl). The capsule enhances the survival of the organism during the invasion of the
bloodstream [15] while the absence of a capsule is believed to allow the bacterium to
evade the human’s immune response while in the carrier state [16]. Meningococci can
also control the expression of the capsule through phase variation. Invasive disease is a
rare outcome of colonisation by a capsule-deficient strain; the first reported fatal case of
meningococcal disease caused by a cnl strain was in 2005 [17].
2.2 Epidemiology of carriage
The meningococcus is transmitted from human to human through the exchange of
respiratory secretions during very close contact [13]. The reported prevalence of carriage
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is in the range 1%-30% [18, 19] and varies greatly by age, sex and region [20]. Studies
have shown that common risk factors associated with high prevalence of carriage are
smoking, crowding in pubs or universities, intimate kissing and preceding viral infections
[21–23]. In industrialised countries, a systematic review of carriage prevalence showed
that carriage is rare in infants and young children, rises to a peak in late teen years and
then gradually declines in older age groups [20]. As most studies are point prevalence
studies rather than longitudinal, the duration of carriage is not very well defined in
any setting. An episode of carriage may be transient or last for a few months before
it is cleared [24, 25]. Different patterns of carriage have been described in the African
meningitis belt [26], as described in more detail below.
2.3 Epidemiology of disease
Meningococcal disease incidence differs geographically. Many countries, including most
high-income countries, suffer from endemic meningococcal disease with low incidence [4].
Most cases are sporadic, with occasional small clusters of epidemiologically linked cases
occurring in higher education establishments. Occasionally, a country, or regions within
a country, may experience ’hyperendemic periods’ of elevated incidence of more than 10
cases per 100,000 population annually. New Zealand experienced such a ’hyperendemic
period’ between 1996 and 2003, with annual incidence consistently above 13 cases per
100,000 population [4]. Large-scale mobilisation of troops during World War II resulted
in a large number of cases and deaths in the United States but outbreaks have been rare
since [27, 28]. The annual pilgrimage in Mecca attracts a vast number of people from all
over the world all year. In 1987, a virulent meningococcal outbreak was spread globally
by a group of pilgrims returning to their home town [22].
In certain regions of the world, epidemics of disease occur periodically but irregularly.
The scale of these epidemics is entirely different from hyper-endemic disease. The epidemic
threshold defined by the World Health Organisation (WHO) is a weekly incidence of
10 cases per 100,000 (usually at a district level) and over the course of an epidemic
season, cumulative incidence can be well in excess of 100 cases per 100,000 population.
Most frequently recurring epidemics have been observed in the semi-arid area of sub-
Saharan Africa with attack rates in the range of 100-800 cases per 100,000 population [4].
Repeated epidemics have also been reported in India and China over the last century,
but China has lost the epidemic cyclic activity since the widespread use of meningococcal
polysaccharide serogroup A vaccines in the 1970s [29].
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For reasons not fully understood, the overall attack rates across developed countries
have decreased substantially over the last decades. It is believed that population immunity
to the strains currently circulating as well as changes in the prevalence of behavioural
risk factors have contributed to the decline of the incidence [30]. In the United States
and Europe, over the last 40 years, the estimated weekly incidence is around 1-3 cases
per 100,000 population and small periodic outbreaks characterise the disease [4]. Why
there are such different patterns of disease in different areas of the world and over time
is not clear, certain differences in the predominant strains may be more important as are
environmental factors and socioeconomic status.
Patterns of disease differ greatly to patterns of carriage. There is higher incidence
observed in children under the age of five with a smaller secondary peak in teenagers [19].
Although meningococcal meningitis is primarily a disease of children and young adults,
epidemic outbreaks, especially in sub-Saharan Africa, tend to involve adolescents and
young adults. Disease outbreaks are also sensitive to seasonal effects. In most countries,
infections occur in annual seasonal cycles.
2.4 African meningitis belt
Countries in sub-Saharan Africa suffer from frequent epidemics of meningococcal disease.
The first proven outbreak of meningococcal meningitis in Africa was recorded at the
beginning of the 20th century in northern Nigeria and it is argued by Greenwood [8] that
the meningococcus was brought to West Africa by pilgrims or followers of the Mahdi on
their return home.
In 1963, Lapeyssonnie defined the meningitis belt, as the region in sub-Saharan Africa
where the rates of incidence of meningitis are the highest worldwide. In his description,
there was no clear definition of the belt’s location nor were there any clear borders. The
most recent definition of the belt came in 2002 by Molesworth et al. who used reports
of meningitis epidemics from the last two decades of the 20th century [31]. It is now
generally accepted that the African meningitis belt spans all the way from Ethiopia
to Senegal [8]. Twenty six countries lie, either entirely or partially, in the "expanded
meningitis belt". The total population of these countries exceeds 750 million, while more
than 400 million of these individuals are considered to be at high risk.
Recurrent epidemics of meningococcal disease have been reported throughout the
African meningitis belt since the description of the disease [8]. Broutin et al. [32], using
wavelet analysis, showed that the frequency of the epidemics in the countries of the
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meningitis belt is every 8-12 years and that although huge epidemics may affect several
countries at the same time, the epidemic cycle is not synchronised across countries. The
weekly incidence rates during epidemics can reach up to 100 per 100,000 population
in individual communities [8, 33]. According to WHO, the number and intensity of
epidemics have been increasing since the late 1970s affecting the lives of hundreds of
thousands of people [34]. The largest epidemic took place in 1996-1997, resulting in
250,000 cases and 25,000 deaths. The number of cases of suspected meningitis over time
in Chad is shown in Figure 2.1, illustrating the variation in disease over time.
Fig. 2.1 Time series showing the number of suspected cases of meningitis in Chad
1940-2012. Figure: Daugla et al. [10].
Meningitis in Africa is highly seasonal. During the dry season between December to
June, dust winds and cold nights lead to upper respiratory tract infections and result
in an increased risk of meningococcal disease. The number of cases drops every year
with the onset of the rains. There are recurrent multiannual epidemic waves on a large
national scale. Large epidemics may span 2 or more dry seasons, with very few cases
during the intermediate rainy seasons [8, 32, 33]. During non-epidemic years, even during
the dry season, the number of cases is considerably lower than the number of cases during
epidemic years. Over the last decade, several studies have been conducted trying to
investigate the relationship between the climate and the incidence of meningitis [35–37].
All the studies conclude that dust may have a significant impact on the meningitis season.
It is not clear, however, whether climatic variation affects the meningococcus directly.
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One hypothesis trying to explain climate impact on disease incidence is an increase
in the invasion rate (i.e. the rate at which carriers develop invasive disease) due to
damage of the pharyngeal mucosa caused by high dust loads. Additionally, close contacts
of individuals who take refuge from the strong winds in closed spaces can contribute
to a higher transmission rate. Finally, the immune system can be vulnerable due to
co-occurrence of viral respiratory infections, which can facilitate transmission and/or
invasion of disease [38, 39].
In 2003, Molesworth et al. developed the first forecasting spatial model which predicts
the probability of a future meningitis epidemic in areas of the African meningitis belt [40].
The model was used to derive a risk map of epidemic meningitis and they identified low
humidity to be the most important factor associated with the occurrence of epidemics in
sub-Saharan Africa.
2.4.1 Description of epidemiology of meningitis across the African
meningitis belt
Seasonal attack rates can reach up to 800 cases per 100,000 at the district level [41].
Neisseria meningitidis serogroup A (NmA) is responsible for the majority of epidemics
across the African belt [9, 42]. Lingani et al. [12] published a study recently reporting
that there were more than 340,000 suspected and confirmed cases of meningitis due
to NmA in ten countries of the African belt over ten years. There was a peak in the
incidence rate of around 25 per 100,000 population in 2009 due to a large epidemic of
NmA. The case fatality was around 10%, comparable to developed countries, while it was
lowest during the epidemic year 2009. A study looking at the case-fatality ratio (CFR)
of bacterial meningitis in the African meningitis belt has shown that CFR was lower
for serogroup A (5.5%) than for other serogroups (12%) [43]. Therefore, the low case
fatality reported in 2009 may reflect the high proportion of cases due to NmA (77%).
Another explanation could be that reporting was weaker during the epidemic season.
There appears to be no association between case fatality and age or sex [44].
Age distribution of cases varies between epidemic years and different countries but
children 1-14 years of age account for around 75% of all cases while under five-year-olds
account for 40% [18, 45]. Meningitis is rare amongst individuals aged more than 30 years.
In 1999, Campagne et al. [46] conducted an extensive study looking at the epidemiology
of meningitis in Niamey, Niger between 1981 and 1996. They reported a mean annual
incidence of 101 cases per 100,000 population and they found a similar age distribution
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between epidemic and non-epidemic years. This is probably still the best descriptive
study of meningitis epidemiology in the belt.
Carriage prevalence can reach more than 10% of the population during an epidemic
[47]. Contrary to the age distribution of meningitis cases, carriage prevalence is higher
for individuals 5-30 years old than for infants. A number of carriers older than 30 years
are also observed during epidemics. Meningococcal carriage in the African belt is not
very well understood. A systematic review published in 2007 [18] showed that overall
carriage prevalence of meningococci was in the range of 3.5%-35%. A large recent study in
Burkina Faso [48] set a baseline carriage of NmA of 0.39%. The MenAfriCar consortium
conducted 20 standardised surveys in seven countries across the African meningitis belt
at approximately the same time [26]. Their findings confirm the results of previous
studies undertaken at different sites, different times and with different techniques. They
concluded that meningococcal carriage in the African belt is both complex and highly
dynamic both in terms of prevalence of carriage and meningococcal genogroup.
The socioeconomic implications of epidemic meningitis are alarming. Most countries
are struggling to respond appropriately to the needs of control and prevention of the
disease. During the epidemic period 2006-2007 in Burkina Faso, the total national costs
exceeded 9 million US$. That is, around 2% of the country’s annual national health
spending [49].
2.4.2 Immunisation
Until recently, the epidemics were controlled by mass vaccination with polysaccharide
vaccines. Two epidemic thresholds are defined by WHO to guide the different actions
needed depending on the phase of the epidemics. The alert threshold is set to be 3
cases per 100,000 individuals in districts where the total population is more than 30,000.
When the alert threshold is passed, investigation is launched and the countries check
their preparedness for an epidemic. In the case in which a neighbouring area is suffering
from an epidemic, vaccination starts. When the epidemic threshold, 10 cases per 100,000
population, is passed, the emergence of an epidemic is confirmed, the people are informed
and mass vaccination of targeted age groups begins. A single dose of the polysaccharide
vaccine induces a rapid response of antibodies in more than 85% of individuals above the
age of four years and protection lasts for at least one year. A modelling study published
in 2014 showed that reactive campaigns with polysaccharide vaccine could reduce the
number of cases by as much as 50% at a local level provided that they are conducted
early [50]. Although a good antibody response is observed, the vaccine fails to reduce the
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carriage prevalence amongst vaccinated individuals [51]. Response is poorer in infants
and protection is short; hence, routine immunisation is not recommended. The costs
associated with this strategy are enormous. During an epidemic year, the cost for the
reactive vaccination campaigns can exceed 8 million US$ [49].
Meningitis Vaccine Project (MVP)
In May 2001, the Bill and Melinda Gates Foundation announced a global health grant in
support of the collaboration between the World Health Organisation (WHO) and the
Program for Appropriate Technology in Health (PATH) [52]. The Meningitis Vaccine
Project (MVP) was a ten-year project with the elimination of NmA from the African
meningitis belt as its ultimate goal. To achieve their goal, MVP was responsible for
developing, licensing and introducing a tailor-made vaccine for use in Africa [53–55].
Existing effective conjugate vaccines can cost over $50 per dose. The meningitis belt
is made up of some of the poorest countries in the world that cannot afford to pay more
than one percent of that amount. Cost was the primary constraint to the introduction of
a new conjugate vaccine. For that reason, a cheaper solution needed to be found. MVP
partnered with the Serum Institute of India Ltd, who agreed to develop a vaccine at a
target cost of $0.40 per dose [5, 6].
MenAfriVac
MVP developed a serogroup A meningococcal polysaccharide-tetanus toxoid protein
conjugate vaccine (MenAfriVac or PsA-TT). The combination of meningitis bacteria
polysaccharide capsule with a carrier protein is far more potent than the polysaccharide
vaccines that were used previously.
Trials began in 2005 in India and Africa and the vaccine was found to be safe
and highly immunogenic [56]. Besides being very effective, MenAfriVac has one more
significant advantage. Most vaccines require to follow the so-called cold chain [57]. That
is, they need to be stored cool from the point of storage all the way to delivery in the
field. This is a considerable challenge in the heat of the African countries. MenAfriVac
is licensed to be used in Controlled Temperature Chain (CTC) [58] and can last for up
to four days without refrigeration. This provides enough time for people living in remote
areas to reach the vaccination stations.
In December 2010, Burkina Faso was the first country to introduce MenAfriVac via
a national mass immunisation campaign [7]. The campaign targeted individuals 1-29
12 Background
years old, which is approximately 70% of the population of the country. More than 11
million individuals were given one dose of MenAfriVac in a period of 10 days. The mass
campaign achieved very high coverage reaching more than 95%. Two more countries,
Mali and Niger, initiated their mass immunisation campaigns in the year 2010. The
campaigns were implemented in 2 phases and were completed in 2011. The vaccine is
being rolled out across the 26 nations of the African meningitis belt over the course of
several years (Figure 2.2). By 2020, MenAfriVac is expected to offer protection to the
entire population of the African meningitis belt. The coverage is consistently high across
all countries that have implemented the mass immunisation campaigns [59–62]
Fig. 2.2 The MenAfriVac is being rolled out across the 26 countries of the African
meningitis belt. Image taken from www.path.org.
2.4.3 Impact of MenAfriVac
The initial mass immunisation in Chad was completed in two phases. The first phase, in
which 20% of the 1-29 year olds received one vaccine dose, took place in 2011. The rest of
the target population was vaccinated the following year, in 2012. More than 1.8 million
people received the MenAfriVac in 10 days in 2011. There was a 94% difference in the
incidence levels between vaccinated and non-vaccinated regions and despite enhanced
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surveillance, no cases of NmA were reported in the vaccinated regions. Only 1 carrier was
identified after vaccination in a rural area with a carriage prevalence of 0.75% (32/4278
individuals) two months before the campaigns took place [10]. There was a 98% decrease
in the prevalence of NmA carriage in all age groups. Niger introduced MenAfriVac in
2010 and the disappearance of serogroup A meningococcus was noted in 2011 [11]. In
addition to the dramatic decline of NmA cases, at the time of writing, prevalence of
carriage remains at very low levels following MenAfriVac vaccination [26, 12, 63–66].
Apart from the great success of the vaccine in eliminating NmA, studies have shown
that MenAfriVac has also boosted tetanus immunity and it is possible that it can have
an impact on the incidence of neonatal tetanus in sub-Saharan Africa [67, 68].
Before mass immunisation, serogroup A predominated, but C, W, X and Y were
all present [9]. Outbreaks in Burkina Faso in 2012 and Nigeria in 2013-2014 caused by
serogroups W and C respectively suggest that increased surveillance is needed along
with consideration of immunisation with multivalent conjugate vaccines rather than for
Neisseria meningitidis group A alone [69, 70].
2.4.4 Immunity after vaccination
Assessment of the safety and immunogenicity of the vaccine has shown a 4-fold increase
in serum bactericidal antibody (SBA) titers in 96% of the 601 subjects that took part
in clinical trials in Mali and Gambia [71]. Studies conducted in the first years after
MenAfriVac introduction showed more than 90% of vaccinated individuals maintaining
high antibody titers against NmA [72]. Four years after vaccination, 90% of the subjects
are still considered protected against NmA [73].
As years go by and new data are being collected, scientists begin to assess the
duration of vaccine-induced protection. Tapia et al. in 2015 estimated that a single dose
administrated to children aged less than two years provides protection against NmA for
up to five years [74]. A more recent study shows that older age is associated with better
antibody persistence and hence protection lasts longer when children receive a dose at the
age of five years or older compared to being vaccinated when they are less than 5 years
old [75]. More specifically, data from two randomised trials were used and analysed. The
first trial included children aged between 12 and 23 months while the second randomised
trial included participants aged 2-19 years. Immunogenicity was assessed with a serum
bactericidal antibody (SBA) assay as well with MenA-specific immunoglobulin G (IgG)
enzyme-linked immunosorbent assay (ELISA). The study aims to make predictions about
vaccine efficacy in the next 20 years. Twenty years after primary vaccination, vaccine
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efficacy is predicted to be 70% among people aged between 2-29 years compared to
52% in those in the 12-23 months age group. The authors of the paper translated these
findings to a half-life of antibody persistence of 7.4 years for the younger age group and
16.5 years for the older participants, when measured by SBA titers. When measured by
ELISA, the half-life was 4.5 and 6.3, respectively. According to this new study, ten years
of duration of protection may be an underestimate and the true duration is potentially
much longer. Another study, however, after conducting surveys in 2013 and 2016 in
Burkina Faso, suggested that protection is shorter [76].
2.5 Using mathematical models to guide public health
action
The mathematical modelling of human diseases dates back to the beginning of the 20th
century, when the first compartmental model was developed [77]. Technology has since
advanced and has allowed the management of complex models and abundant sources of
data. Computational models have become an essential tool for vaccine policy makers
and they play an essential role in guiding public health actions.
The pioneer of the world’s first vaccine was Edward Jenner in 1796 [78]. Jenner
developed a vaccine to fight smallpox. The eradication of smallpox and the decline in
incidences of other vaccine-preventable diseases such as polio and measles are testimonies
to the effectiveness of vaccine interventions. The evaluation of public health programmes
is not always possible with controlled trials. An evaluation, however, is essential to ensure
that the expected benefits will happen using the most cost-effective means [79].
Mathematical modelling is a powerful tool to investigate the impact of a wide range
of vaccination strategies on the epidemic patterns before they are implemented. The
predictive scope of an epidemic model allows us to make projections of the incidence and
prevalence of disease in both the vaccinated and unvaccinated population. Estimates of
the impact of a vaccine on disease burden can then be used in cost-effectiveness models
to assess the value for money that vaccination strategies offer in comparison to other
potential health spending options. Cost-effectiveness studies are becoming a vital part of
decision making process for many organisations, such as Gavi, the Vaccine Alliance and
the Bill and Melinda Gates Foundation when considering the funding of new public health
interventions. More specifically, Gavi builds the Vaccine Investment Case (VIS) based
on the assessment of the potential impact of new vaccines generated by mathematical
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models. This assessment takes place every five years and enables evidence-based decisions
about future vaccine investments.
2.5.1 Models related to meningococcal infection
A number of meningococcal transmission models have been developed to date. Trotter
et al. [19] developed a model attempting to estimate the forces of infection and risk of
disease given infection for serogroups B and C using data from the late 1980s and early
1990s. The same group of researchers in 2005 published their work on the dynamic model
of meningococcal carriage and the impact of serogroup C vaccination [80]. A few years
later, in 2013, when a new vaccine against meningococcal disease was licensed in the EU,
Christensen et al. [81] used two mathematical models to study its potential impact: a
cohort model and a transmission dynamic model.
Any mathematical model attempting to specifically examine NmA transmission in
the African meningitis belt should be able to capture the unique epidemiology the disease
exhibits in that region. There are sporadic, unpredictable epidemics of different sizes and
magnitudes occurring every 8-12 years taking place only during dry seasons. Irving et al.
[82] developed a range of simple deterministic compartmental models of meningococcal
disease and carriage to examine the importance of population immunity against the
acquisition of the bacteria and also to explore how seasonality in transmission rates
affected the model dynamics. Seasonal forcing and different assumptions regarding
immunity were incorporated into the simple models. Irving et al. concluded that waning
immunity and an increase in the risk of acquisition of carriage could play an important
role in the occurrence of repeated epidemics at irregular intervals. A systematic review
and meta-analysis of studies performed in 2015 suggested that seasonal changes in the
rate of progression to disease should be taken into consideration in mathematical models
of NmA transmission [83].
In 2013, Tartof et al. [84] developed an age-structured mathematical model of NmA
transmission and used it to evaluate the impact of different vaccination strategies.
Seasonality together with stochasticity were incorporated into their model. Despite the
limited data and lack of model fit, their model was able to reproduce realistic patterns
of the disease. This was the first mathematical model that supported the decision
making about a long-term vaccination strategy in the countries introducing MenAfriVac.
According to Tartof et al. the most effective long-term plan is to have periodic mass
campaigns taking place every five years targeting children between the ages of 1 and 5
years. Jackson et al. revisited this model in 2018 [85] and used more recent published
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studies to estimate parameters. In addition to updating parameter values, they examined
the effect of key structural assumptions. Both models, the original [84] and the updated
[85], suggest that a long-term immunisation strategy is essential in maintaining low levels
of disease transmission.
Yaesoubi et al. [86] developed a stochastic compartmental model to investigate the
cost-effectiveness of using a novel conjugate vaccine which would target more serogroups
instead of just group A. The impact of alternative strategies involving the new vaccine are
compared to the current strategy with MenAfriVac. Despite the limitations of the model
and the uncertainty around assumptions made, they conclude that further immunisation
with the novel vaccine will be cost-effective and will also lead to even more cases of
meningitis averted.
Chapter 3
A mathematical model of
meningococcal disease in Africa
3.1 Introduction
In this chapter, I extend the transmission models of Irving et al. [82] by addressing
some of the limitations (including the assumption of homogeneous mixing, lack of age
structure and the wide parameter space considered) and I incorporate vaccination. I will
discuss how I formulate a model and utilise recently available NmA/MenAfriVac specific
parameters. I will then apply the model to investigate appropriate vaccination schemes
for the sustained use of MenAfriVac.
3.2 SCIRS model
This section introduces Irving et al.’s model version of SCIRSCI [82] that I am going to
extend later. From the four structures Irving et al. explored, this one best describes the
observed epidemiology of Neisseria meningitidis A in the African meningitis belt. We can
think of the population being divided into four distinct compartments which represent
their health status with respect to meningitis infection. An individual can be susceptible
to infection (S), carrier of NmA (C), case of invasive meningococcal meningitis (I), or
have temporary immunity from previous infection (R). Individuals carrying the bacteria
show no signs of invasive disease but are infectious.
People are being born in the susceptible compartment. When there is contact between
a susceptible and an infected individual, either a carrier or a case of invasive disease, the












Fig. 3.1 Flow diagram of the SCIRS compartmental model. Individuals are divided into
susceptibles (S), carriers (C), infected with meningitis (I) and recovered with temporary
immunity (R). The arrows indicate possible movement to and from each compartment.
β is the transmission rate. Carriers recover at a rate α or may develop invasive disease
at a rate a. Infected individuals recover at a rate ρ. Temporary immunity wanes at a
rate φ. b and µ are the birth and mortality rates, respectively.
susceptible may become a carrier. Once in the carriage state, one can either develop
invasive disease or recover and have temporary immunity before they are moved back to
the susceptible compartment. There is only movement to the recovered state for infected
individuals. From each compartment there is a natural death rate µ. Since during
epidemics only a small proportion of people develop invasive disease, and mortality rate
is only 10%, deaths from disease are negligible compared with deaths from other/natural
causes and, therefore, I altered the published model and assume that disease-induced
death rate (γ) is equal to zero. The flow diagram of the simple SCIRS model can be seen
in Figure 3.1 and a list of parameter names with their description is given in Table 3.1.
The SCIRS model is defined by the set of differential equations:
dS
dt
= bN − βS (C + I)
N
+ φR − µS
dC
dt
= βS (C + I)
N
− (a + α + µ)S
dI
dt
= aC − (ρ + µ)I
dR
dt
= αC + ρI − (φ + µ)R,
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Parameter name Description
b Birth rate
µ Natural death rate
β Transmission rate
φ Rate of loss of immunity
α Rate of loss of colonisation
a Rate at which carriers develop disease
ρ Recovery rate
Table 3.1 Parameter names and meanings used in this chapter.
where N = S+C+I+R. The total population N can be normalised to 1, so that S, C,
I and R are fractions of the total population. The rescaled system is:
dS
dt
= b − βS(C + I) + φR − µS
dC
dt
= βS(C + I) − (a + α + µ)S
dI
dt
= aC − (ρ + µ)I
dR
dt
= αC + ρI − (φ + µ)R,
3.3 Derivation of the age-structured model for Burk-
ina Faso
The vaccination campaigns with MenAfriVac target all individuals from 1 to 29 years
of age, as discussed in section 2.4.2. In order to explore the effects of vaccination that
targets specific age groups, an age structure needed to be added to the model described
in the previous section [82].
I split the population into 19 age groups: 0 to <3 months, 3 to <9 months, 9 to <12
months, 1-4 years, 5-9 years, and 5-year age groups to age 80 years subsequently. This age
grouping was chosen because there is high observed incidence in infants and toddlers and
high carriage prevalence among children and young adults. Furthermore, the vaccination
strategies explored in this chapter are mainly focused on the immunisation of infants
and children.
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The countries of the meningitis belt have rapidly growing populations, with a median
age of 17 years in Burkina Faso [87]. The demographic part of this model is intended
to correspond to the structure of the population of such a country. Annual fluctuations
in the birth and death rates are not included since that would lead to a much more
complicated model. Moreover, it would not be possible to know whether the observed
features of meningococcal meningitis are due to epidemiological reasons (e.g levels of
humidity) or annual demographic changes. The model presented here is developed for
the population of Burkina Faso, a typical country in the region and entirely within the
meningitis belt, and the demographic data used in simulations were chosen for 2011 or
the closest available year.
The population growth rate for 2011 was estimated by the US Census Bureau as
3.09% per year [88]. The age-specific mortality rates were taken from the WHO’s Global
Health Observatory [89]. It is also assumed that all individuals die by the age of 80 and
thus, the mortality rate of the age group 75-79 years is taken to be 0.2/year. In order to
derive the age-structured demographic model of Burkina Faso, a method from Hethcote
[90] was adapted by Irving. Full details of the method are in Tom Irving’s PhD thesis
and can also be found in Appendix A in this thesis. The age distribution used is shown

























Fig. 3.2 Barplot showing the actual (red, taken from [88]) and simulated (blue) number
of people in each age group. The data is for Burkina Faso for the year 2011.
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The population distribution is taken to be stationary, that is, although the number
of people in each age group increases exponentially, the proportion of the population in
each age group remains constant.
The complete age-structured SCIRS model is given by the following system of coupled
ordinary differential equations:
for j = 2, . . . , 19
dS1
dt
= (K1 + d1 + q)P1 + φR1 − λ1S1 − (K1 + d1 + q)S1 (3.1)
dSj
dt
= Kj−1Sj−1 + φRj − λjSj − (Kj + dj + q)Sj (3.2)
dC1
dt
= −(a + α)C1 + λ1S1 − (K1 + d1 + q)C1 (3.3)
dCj
dt
= Kj−1Cj−1 − (a + α)Cj (3.4)
dI1
dt
= aC1 − ρI1 − (K1 + d1 + q)I1 (3.5)
dIj
dt
= Kj−1Ij−1 + aCj − ρIj − (Kj + dj + q)Ij (3.6)
dR1
dt
= ρI1 + αC1 − φR1 − (K1 + d1 + q)R1 (3.7)
dRj
dt
= Kj−1Rj−1 + ρIj + αCj − φRj − (Kj + dj + q)Rj (3.8)




β(zj, zk)(Ik + Ck) (3.9)
The form of the matrix of contact rates between people in age group j and age group k
β(zj, zk) and the role of the stochastic term θ are discussed in Section 3.3.1 and 3.3.5,
respectively. Seasonality is also implemented in the model and is be discussed in Section
3.3.2.
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Parameter Parameter Name Value Unit Source
Size of the first age group P1 0.01 proportion Census reports
Mortality rate d Age-specific
(0.001-0.2)
year−1 Census reports
Recovery rate from disease ρ 52 year−1 [3]
Rate of loss of carriage α 12 year−1 [25]
Transmission rate β0 10.5 year−1 Estimate
Rate at which carriers fall ill a Age-specific
(0.002-0.155)
year−1 [83],age-specific parameters estimated
Rate of loss of immunity φ 0.0839 year−1 Estimate, based on [82]
Seasonal forcing of transmission rate ϵβ 0.6 - Estimate, based on [82]
Seasonal forcing of invasion rate ϵα 0.6 - Estimate, based on [82]
Annual growth rate q 0.0309 year−1 Census reports
Rate of progression between age groups K Age-specific
(0-3.94)
year−1 Estimated using µ and q
Table 3.2 Model parameter names and values used for the model simulations. A range is
given inside brackets for the age-specific parameters. Exact values can be found in
Appendix A.
3.3.1 Mixing of population
The WAIFW (Who Acquires Infection From Whom) matrix is a central parameter in every
age-structured epidemiological model. The WAIFW matrices describe the age-specific
contact rates, β(zi, zj), between individuals within and between different age groups.
Several different WAIFW matrices were used and compared in preliminary analysis
(following Tom Irving’s PhD thesis, University of Bristol 2013). However, none of the
matrices used by Irving were able to reproduce the observed age profiles of MenA carriage
and disease in the African meningitis belt. In all the model simulations, the prevalence
of carriage in young children and people aged more than 30 years was unrealistically
high. As shown in Figure 3.3, carriage prevalence peaks in children and young adults
while it drops in older ages. Unlike the observed patterns of carriage, 75% of all MenA
cases are seen in children under the age of 15 years, while more than 40% of cases are in
children younger than five years old [46].
A variation of the preferential mixing pattern is shown in Figure 3.4. People are
assumed to interact more with people close to their age (b2). Higher contact rates are
assumed among children > 5 years and teenagers to account for sibling contacts and
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Fig. 3.3 Prevalence of serogroup A (dark grey) and serogroup Y (light grey) meningococcal
carriage by age groups in the general population during a localized epidemic due to
meningococcal serogroup A in western Burkina Faso, 2006. Error bars are 95% confidence
intervals. Image from Mueller et al. [47].
school contacts (b3). Also, since some of the risk factors of meningococcal disease is
cigarette smoking and attendance in bars and clubs, high contacts are also assumed
among people 15-30 years (b4). The level of contact between all other age groups, b1, is
the lowest. For simplicity, it is assumed throughout that b2 = 2b1, b3 = 4b1 and b4 = 6b1.
I used the contact matrix shown in Figure 3.4 and I numerically solved equations
(3.1)-(3.8) for different lengths of immunity, φ using the R package version 3.1.0, using
the package deSolve. The range of φ explored was 5-12.5 years. As initial conditions, I
assumed that 1% of the population is in the carriage state, 70% of the population are in
the recovered compartments and the rest are assumed to be susceptible. I set the model
to run for a period of 50 years, following a 20-year burn-in period, and record the age
distribution of carriers and people infected with meningitis during one epidemic year.
This was done in order to check that the model is able to reproduce realistic patterns of
the age profile of carriage and disease.
Figure 3.5 shows the predicted age distribution of carriers (left) and disease (right) for
three different values for φ. The results indicate that the profile of the age-distribution
of carriage is a good visual fit as carriage is highest in teenagers. However, the predicted
age profile of disease is not realistic. The proportion of cases in people over the age of
24 A mathematical model of meningococcal disease in Africa
30 years is higher than expected. Natural immunity develops with age from repeated
carriage episodes [19]. For that reason, the use of an age-dependent rate at which carriers
fall ill (case: carrier ratio, a) is clearly important. I deal with this by varying the value
of a as a function of age (see Table 3.2, exact values given in Appendix A)
Fig. 3.4 Adapted WAIFW matrix. The boxes represent the contact levels between age
groups. Darker areas represent higher contact rates. It is assumed that b2 = 2b1, b3 = 4b1
and b4 = 6b1.
3.3.2 Seasonality
Seasonality is a key feature of the epidemiology of MenA in the African meningitis
belt. Every year from December to June, during the dry season, meningococcal disease
incidence peaks and only dies out with the onset of the rains. Any mathematical model
aiming to study the dynamics of meningitis infection in Africa should therefore incorporate
seasonality in some way.
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Fig. 3.5 Age profiles of carriage and disease simulated using the adapted WAIFW matrix.
Left panel: Predicted carriage prevalence by age during an epidemic peak for three
different values for the duration of temporary immunity. Right panel: Age distribution
of cases during an epidemic peak for three different values for the duration of temporary
immunity.
In this model, a sinusoidal term is used to capture the effects of seasonal change [82].
The transmission rate between people in the ith and jth age classes is defined as follows:
β(zi, zj) = β0(zi, zj)(1 + ϵβcos(2πt))
where ϵβ scales the magnitude of the flunctualtion and β0 is the baseline parameter
value. Further, it is assumed that the seasonal variation in serogroup A meningococcal
meningitis between the dry and the rainy season is driven by seasonal change in the ratio
of clinical cases to carriers [83]. For that reason, the invasion rate is also replaced with a
sinusoidal term as follows:
a(z) = a0(z)(1 + ϵacos(2πt))
where ϵa scales the magnitude of the fluctuation and a0 is the baseline parameter value.
3.3.3 Determination of parameters
Many model parameters are readily available in census reports and the scientific literature
for most populations. Fertility and natural mortality rates are typically provided via
recorded figures in census reports. Demographic rates and age distributions do not vary
drastically when comparing less developed countries.
26 A mathematical model of meningococcal disease in Africa
There are many parameters, however, that are not readily available in literature, such
as effective contact rate (β) and rates at which carriers develop invasive disease (a). These
rates, along with the number of individuals in each epidemiological stage, determine the
age-specific force of infection and therefore, the horizontal spread of infection. Irving et al.
[82] explored a wide range of values for the duration of natural immunity, φ, ranging from
6 months to 25 years. Their work showed that longer periods of immunity led to longer
inter-epidemic periods similar to the observed epidemiology of Neisseria meningitidis
group A in Bourkina Faso. For this reason, a range of 5 to 12.5 years is considered for
the duration of natural immunity following a period of carriage or disease (1/φ) in this
model.
The number of unknown parameters makes it difficult to fix the rates at specific
values, since the value of some rates affect the values of other unknown rates. The ABC
(Approximate Bayesian Computation) method was used in an attempt to estimate some
of the parameter values [91]. I attempted to fit parameters to the annual incidence of
cases from Chad between 1930 and 2011. Although no clear estimates where given from
the method, a strong correlation between the transmission rate and the duration of
colonization was observed. This provided reassurance that the method was working to
an extent, but was likely limited by the paucity of information within our chosen metric
(i.e. annual meningitis incidence). These results from the ABC also gave good agreement
with a not very large Basic Reproduction Number.
The baseline parameter values used for the numerical simulations of the model used
throughout this chapter and the sources from which they were extracted are shown in
Table 3.2.
3.3.4 Basic Reproduction Number (R0)
I estimated the basic reproduction number by calculating the largest eigenvalue of the
next-generation matrix [92]. That is, a matrix with elements gij = κSibij, where gij is
equal to the number of secondary infections in group i produced by an infective in group
j, κ is the average duration of infectiousness (1/α), Si is the number of susceptibles in
the ith age class and bij is the transmission rate between age classes i and j. Since both
the transmission rate and the duration of infectiousness are unknown parameters, R0
was calculated for a number of parameter sets which reproduce ‘realistic’ results. It was
found that the likely average value of R0 is in the range 1.55 – 1.80.
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3.3.5 Incorporating stochasticity into the model
Other factors that are not captured in the mechanics of this model may also be important
and it is possible that there is variability in the parameters due to some unpredictable
force. For example, the transmission rate may be modified by climatic conditions such as
fluctuations in temperature or humidity; this may vary from year to year and so not be
captured by the sinusoidal seasonal fluctuations. Such variability may be independent of
carriage/disease prevalence or the number of susceptibles. For these reasons, I considered
it important that stochasticity is taken into account and incorporated into the model.
One modelling technique to introduce noise is to consider the governing parameter, i.e.





β(zj, zk)(Ik + Ck)
where β(zj, zk) is the contact rate between people in the jth and kth age classes and
θ is a number drawn randomly from a uniform distribution of 0.8 to 1.2.
The use of such a stochastic term is necessary to reproduce irregular epidemics if the
duration of carriage is taken to be one month, in line with the only published estimate of
the duration of NmA carriage [25].
3.3.6 Numerical simulations
Solving equations (3.1)-(3.8), using the parameters shown in Table 3.2 and setting initial
conditions as discribed in Section 3.3.1, we get the proportion of individuals in each of
the four compartments (susceptible, carrier, infected, recovered) at any time t.
To compare the model results with the known data on the number of cases recorded,
I need to calculate the incidence of infection. I do this by aggregating the number of new
infections over a one year time step. One typical model run is shown in Figure 3.6. The
model can describe the typical annual incidence of meningitis in the pre vaccine era, with
irregular epidemics of varying size. During epidemic years the incidence can exceed 100
cases per 100,000 individuals, compared to very low incidence levels between epidemics.
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Fig. 3.6 Typical model results showing the annual incidence over a period of 50 years.
3.4 Vaccination
Based on their immunisation status with MenAfriVac, people are further divided into
vaccinated and unvaccinated compartments. A schematic of the infection and vaccination
processes can be seen in Figure 3.7. Note that births and deaths are not shown in
the diagram but are included in the model. People are being born in the susceptible
compartment and leave each compartment according to an age-dependent mortality rate.
Individuals enter the equivalent vaccinated compartments according the vaccination
coverage (v(z, t)). Those in the vaccinated susceptible compartment are assumed to have
some protection against aquiring NmA carriage (called vaccine efficacy against carriage,
δ). A proportion of carriers (σ) is assumed to clear infection upon vaccination and enter
directly the vaccinated immune state, while those who fail to clear carriage, are assumed
to have some protection against developing invasive disease (called vaccine efficacy against
disease, ξ). Vaccinated carriers who fail to recover immediately are assumed to recover
at the same rate as unvaccinated individuals. Vaccinated individuals are assumed to
revert to their equivalent unvaccinated compartment at a constant rate (w), due to the
possible vaccine’s failure to provide life-long protection.
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Fig. 3.7 Flow diagram of the SCIRS model with vaccination. Susceptible individuals
become carriers at age and time dependent force of infection (λ(z, t)) which is reduced
by the vaccine efficacy against carriage (δ) for vaccinated people. Similarly, the age and
time dependent rate at which carriers develop disease (a(z, t)) is reduced by the vaccine
efficacy against disease (ξ). Carriers and diseased individuals recover at a rate α and ρ,
respectively. Temporary immunity wanes at a rate φ, while vaccine induced protection
wanes at a rate w. Individuals are being transferred to the vaccinated compartments
at a rate ν and σ is the proportion of carriers who loose carriage immediately upon
vaccination.
The complete age-structured model with vaccination is given by the following system
of coupled ordinary differential equations:
for j = 2, . . . , 19
dS1
dt
= (K1 + d1 + q)P1 + φR1 − λ1S1 − (K1 + d1 + q)S1 (3.10)
dSj
dt
= (1 − γj−1)Kj−1Sj−1 + φRj − λjSj − (Kj + dj + q)Sj + wSVj (3.11)
dSVj
dt
= Kj−1SVj−1 + γj−1Kj−1Sj−1 + φRVj − (1 − δ)λjSVj−
(Kj − dj + q)SVj − wSVj (3.12)
dC1
dt
= −(a + α)C1 + λ1S1 − (K1 + d1 + q)C1, (3.13)
dCj
dt
= (1 − γj−1)Kj−1Cj−1 − (a + α)Cj + λjSj + wCVj (3.14)
dCVj
dt
= Kj−1CVj−1 + γj−1Kj−1Cj−1 − ((1 − ξ)a + α)CVj−1+
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(1 − δ)λjSVj − (Kj + dj + q)SVj − wCVj (3.15)
dI1
dt
= aC1 − ρI1 − (K1 + d1 + q)I1 (3.16)
dIj
dt
= Kj−1Ij−1 + aCj − ρIj − (Kj + dj + q)Ij (3.17)
dIVj
dt
= Kj−1Ij−1 + (1 − ξ)aCVj − ρIVj − (Kj + dj + q)IVj (3.18)
dR1
dt
= ρI1 + αC1 − φR1 − (K1 + d1 + q)R1 (3.19)
dRj
dt
= (1 − γj−1)Kj−1Rj−1 + ρIj + αCj − φRj − (Kj + dj + q)Rj + wRVj (3.20)
dRVj
dt
= Kj−1RVj−1 + γj−1Rj−1 + ρIVj + αCVj − φRVj−
(Kj + dj + q)RVj − wRVj, (3.21)
where γ is the rate of routine vaccination, w is the rate of loss of vaccine induced
protection, and δ and ξ are the vaccine efficacy against carriage and disease, respectively.
The values of the parameters characterising disease are taken to be the same as in Table
3.2, while Table 3.3 includes the values of the vaccine associated parameters under the
base case scenario as well as the full range explored in the sensitivity analysis.
Parameter Name Value Range Unit Source
Vaccine efficacy against carriage δ 0.9 0.6-0.9 Proportion [10]
Vaccine efficacy against disease ξ 0.9 0.6-0.9 Proportion [10]
Carriage clearance upon vaccination σ 0.9 0-1 Proportion -
Waning of vaccine protection w 0.1 years−1 -
Vaccine coverage for initial
mass campaign 0.95 Proportion [59, 62]
Vaccine coverage for additional
mass campaigns 0.8 0.6-0.8 Proportion -
Vaccine coverage for routine EPI ν 0.8 0.5-0.8 Proportion -
Table 3.3 Vaccine associated parameters under the base case scenario. Range explored in
a sensitivity analysis
When this work was conducted and published, there had been no studies assessing
the duration of protection induced by MenAfriVac. An average of 10 years duration of
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protection was chosen as the baseline parameter value, consistent with findings from
unpublished Meningitis Vaccine Project (MVP) trials which is further explored in a
sensitivity analysis in Chapter 6. Similarly, due to limited data at the time, the range
for routine vaccination was taken from typical Expanded Programme on Immunisation
(EPI) coverage in meningitis belt countries.
3.4.1 Vaccination strategies
I considered a range of long-term vaccination strategies and compared them to a scenario
without any vaccination and with only an initial mass vaccination campaign of 1-29
year olds. I simulated the introduction of MenAfriVac into the Expanded Programme
on Immunisation (EPI), which is routine immunisation of infants less than 12 months
old. Vaccination through EPI takes place when a child reach a specified target age. In
addition to routine immunisation of infants, I also simulated periodic mass vaccination
campaigns, targeting people born since the last mass campaign; either 1-4 year olds
every 4 years or 1-9 year olds every 9 years. Finally, I simulated a combination strategy
whereby MenAfriVac was introduced into EPI five years after the initial campaigns had
taken place, with a catch-up campaign of 1-4 year olds. The catch-up campaign intends
to target the children who were either not born at the time of the introduction or they
were too young to be immunised then.
The full range of vaccination strategies considered are summarised in Table 3.4.
3.4.2 Model implementation
The model was coded and run using the R software version 3.1.0 [94], using the package
deSolve to perform the numerical integration of differential equations. The time step
was 1 day. For each simulation, I ran the model for a 20-year burn-in period before
implementing the initial mass vaccination campaign in year 0. The model was then run
for a further 40 years; all results are reported for this 40-year period. For each vaccination
strategy, the average of 300 simulations was taken; this was based on a comparison of
between 100 and 500 simulations that showed very small marginal differences between
300 and 500 simulations.
In the model, the initial campaign targeting 1-29 year olds is assumed to be a discrete
time event at one point in time, and was implemented by transferring the individuals in
the targeted age groups (4th, 5th, 6th, 7th, 8th and 9th) to their corresponding vaccinated
compartments at time t = tv. In a similar way, periodic mass immunisations were also
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Vaccine Strategy Introduction Long-term
A. Initial campaign only Mass immunisationof 1-29 year olds None
B. Periodic campaigns Mass immunisationof 1-29 year olds
1. Periodic mass immunisation
of 1-4 year olds every 4 years;
2. Periodic mass immunisation
of 1-9 year olds every 9 years
C. Routine EPI Mass immunisationof 1-29 year olds
Routine EPI months,
5 years after introduction
D. Combination Mass immunisationof 1-29 year olds
Routine EPI, 5 years after introduction
plus 1-4 year old catch-up
Table 3.4 Full range of vaccination strategies considered in the model runs
treated as discrete events and were implemented by transferring individuals from the
fourth unvaccinated age group (1-4 years) to the corresponding vaccinated age group
every five years. Routine immunization was implemented continuously as individuals
reached the target age for the EPI. The narrow age groups in <1-year-olds allowed
routine vaccination to be implemented at different ages.
3.4.3 Results
Following initial mass vaccination of 1-29 year olds at high uptake, disease control was
excellent in the short term. With no subsequent immunisation, the model predicted a
strong resurgence in disease incidence approximately 15 years after vaccine introduction,
assuming an average of 10 years of protection by vaccination.
In the absence of any vaccination, the model predicted an average annual incidence of
24.5 cases per 100,000 population. After primary vaccination, incidence remains very low,
<1/100,000 for approximately 15 years, followed by a rapid increase in disease incidence
with a peak of 79 cases per 100,000 population, before it declines again to an equilibrium
of 24.5 cases per 100,000 population. The trajectories of 300 model runs are plotted
together with the mean in Figure 3.8, where a rapid increase in disease incidence can be
clearly seen in all simulation runs.
Of the long-term immunization strategies considered, all were effective in maintaining
control of disease as they all resulted in a lower average annual incidence compared to a
scenario with only the initial mass campaign taking place. The predicted average annual
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Fig. 3.8 Results from 300 simulations of the initial mass immunization of 1- to 29-year-olds
(implemented in year 0). The black dashed line depicts the mean annual incidence.
incidence for the different scenarios can be seen in Table 3.5. There was considerable
overlap in the distribution of results (Figure 3.9), but routine EPI immunization at 9
months of age (strategy C) resulted in lower average annual incidence than regular mass
campaigns of 1 to 4-year-olds (strategy B) under base case assumptions. Note here that
as strategy B in all the following figures, I will be referring to periodic mass campaigns
of 1-4 year olds every 4 years. Strategy C was superior to strategy B provided that EPI
coverage was above approximately 60%. The strategy with the lowest overall average
annual incidence and longest time to resurgence was introduction into EPI at 9 months,
5 years after the initial mass campaigns, with a catch-up targeting unvaccinated children
aged 1–4 years (strategy D). All the results are summarised in Table 3.5.
All long-term strategies resulted in disease incidence of less than 10 cases per 100,000
population. The periodic mass vaccination of 1 to 4 year olds every five years and the
periodic mass vaccination of 1-9 year olds every 10 years following the primary campaign,
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both resulted in an average annual incidence of around 7 cases per 100,000 population
across the 40-year period. The two strategies were very close to each other, however, the
mass vaccination of 1 to 9 year olds resulted in greater herd immunity, at the expense
of toddlers between 1 and 4 years of age. In Figure 3.10, the strong resurgence in the
absence of any long term strategy is highlighted. The strategy with the longest time to
the next peak is the ’combination’ strategy (i.e the black line in Figure 3.10).
Fig. 3.9 Box plot to show the median, interquartile range, and full range of the predicted
annual incidence per 100 000 for different immunization strategies in the 40 years following
vaccine introduction from 300 model simulations. Strategy B refers to vaccination of 1-4
year olds every 4 years from Table 3.4.
.
Assuming that 80% coverage could be achieved by both EPI and periodic mass
campaigns, routine EPI vaccination was better than periodic mass vaccination campaigns
(Figure 3.10). In fact, it appeared that EPI was superior to mass campaigns unless EPI
coverage was very low (less than around 60%).
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A. Initial campaign only
B. Periodic campaigns
C. Routine EPI 
D. Combination
Fig. 3.10 Comparison of immunisation strategies under consideration. Different colour
lines represent the mean annual incidence over a 40 year period after vaccination (imple-











EPI at 9m and
1-4y
Catch-up
<1 40.32 27.71 8.77 13.52 7.50
1-4 37.38 25.82 4.43 7.15 3.80
5-9 42.54 28.76 6.92 10.00 5.91
10-14 38.61 26.82 8.71 11.48 7.43
15-19 32.14 23.05 9.96 12.10 8.51
20-24 19.18 14.06 7.05 8.26 6.07
25-29 11.20 8.36 4.36 5.10 3.80
30+ 3.18 2.35 1.07 1.30 0.94
All 24.45 17.06 5.31 7.12 4.56
Table 3.5 Estimated average annual Neisseria meningitidis group A incidence per
100,000 by age group in the 40 years following vaccine introduction under different
immunization strategies. Averaged across 300 simulation runs.
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3.4.4 Sensitivity analysis
I investigated the effect of changing some key model parameters and assumptions. In
the absence of any long-term immunization, assuming a shorter duration of protection
resulted in disease incidence increasing more quickly; with 5 years of vaccine protection,
the resurgence occurred after around 10 years.
Increasing the age of routine vaccination, from 0 to 3 to 9 to 12 months, I observed
only marginal differences (see Figure 3.11), with overall disease incidence decreasing
when immunising at older ages. However, there were more cases in infants as the age
at routine immunisation increased (see Table 3.6). To allow for comparison, I assumed
a fixed coverage of 80% for routine immunisation across all scenarios. When averaged
across 300 simulations, when MenAfriVac was given routinely at the age of 3 months,
the model predicts an average annual incidence of 5.43 cases per 100,000 population per
year in all ages and 4.67 cases per 100,000 individuals in infants, compared with the base
case of immunization at 9 months (average annual incidence of 5.31 cases/100,000 across
all ages and 8.77 cases/100,000 in infants). Immunizing within EPI at 12 months of age
results in an average annual incidence of 5.18 cases per 100,000 population, but 10.53
cases per 100,000 in infants.







<1 2.99 4.67 8.77 10.53
1-4 5.15 4.85 4.43 4.16
5-9 7.82 7.44 6.92 6.58
10-14 9.63 9.23 8.71 8.34
15-19 10.79 10.41 9.96 9.58
20-24 7.54 7.31 7.05 6.81
25-29 4.64 4.50 4.36 4.24
30+ 1.13 1.10 1.07 1.04
All 5.59 5.43 5.31 5.18
Table 3.6 Average annual incidence per 100,000 people by age group for routine
vaccination at different ages and coverage of 80%. Averaged across 300 simulation runs.
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EPI at 3m 
 EPI at 9m
EPI at 12m
Fig. 3.11 Results from 300 simulations of the initial mass immunization of 1- to 29-year-
olds (implemented in year 0) and routine EPI at birth, 3 months, 9 months or 12 months
of age. The lines represent the mean across the 300 simulation runs. Coverage for routine
EPI is assumed to be 80%.
As expected, as EPI coverage increased, the incidence of disease decreased. For
every 10% increase, the average annual incidence decreases by approximately 1 case
per 100,000 population per year. The time to the first peak is also longer when higher
coverage is assumed. Results of routine immunization at 12 months of age under different
assumptions for the coverage is shown in Figure 3.12.
The vaccine effectiveness against carriage and disease is not known. In the base case,
I assumed that MenAfriVac offered a 90% protection against both disease and carriage.
The model results were insensitive to changes in the assumption of vaccine effectiveness
against disease (ξ) when vaccine effectiveness against carriage (δ) was high (90%). This
can be explained because in this situation, carriage acquisitions were rare and therefore,
few people were at risk of disease downstream. Because it is unclear whether the vaccine
can clear an episode of carriage, I also investigated the sensitivity of the results to changes
in clearance upon vaccination. In the base case, I assumed that 90% of the carriers
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recover immediately after vaccination; when this proportion changed to 10%, I found
that the results were insensitive to the change.
























EPI at 12m 80% coverage
EPI at 12m 70% coverage 
 EPI at 12m 60%coverage
EPI at 12m 50% coverage
Fig. 3.12 Results from 300 simulations of the initial mass immunization of 1- to 29-year-
olds (implemented in year 0) and routine EPI at different coverage levels. Lines represent
the mean across simmulation runs.
One key parameter of the model which is not known is the duration of natural
immunity after an episode of colonisation or disease. The assumption made under the
base case scenario was that individuals are immune for an average of 12 years after they
have cleared infection. When this was lowered to 7 years, keeping all other parameters
fixed, the incidence of disease under all scenarios was higher. However, the relative
ranking of each strategy did not change.
The sensitivity of the results to changes in the model structure were also investigated.
In the base case, the stochastic term is a random number drawn annually. When I changed
this to weekly, a wider range of numbers was necessary for the model to produce irregular
epidemics. However, the results from the "noisy" model in which the transmission rate
varied stochastically each week were very similar to the results presented here.
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3.5 Discussion
I developed a model of NmA transmission and disease that was able to describe the
epidemiology observed in the African meningitis belt. I simulated the impact of the
initial mass vaccination campaigns of 1-29-year-olds and predicted a period of very
low incidence for at least ten years, even when assuming a relatively short duration
of protection. The indirect effects of the vaccine were crucial in maintaining this low
incidence post-introduction; I considered a high degree of protection against carriage,
consistent with the observed data [63, 10]. Following this honeymoon period, the model
predicted a strong resurgence in disease incidence if there was no long-term immunisation
strategy. Of the long-term strategies I investigated, a combination strategy of routine EPI
vaccination after five years together with a catch-up campaign targeting children aged 1-4
years who were born after the initial campaigns was the most effective, although there
was considerable overlap in the distribution of results for different strategies. Routine EPI
alone appeared to be more effective than periodic mass campaigns, unless EPI coverage
was less than approximately 60%.
These findings suggest, first, that it is essential to implement a long-term strategy for
the continued use of MenAfriVac. It is not sufficient for the vaccine only to be used in a
large one-off campaign, as this may result in catastrophic resurgences in disease 10-20
years after vaccine introduction. All of the long-term strategies considered were effective
in maintaining disease control, although for all strategies incidence was predicted to
rise over the long-term as population immunity from the initial campaign waned. The
inclusion of MenAfriVac into the routine EPI as a single dose at nine months of age
has the apparent advantage of using and likely strengthening existing infrastructure.
The option to conduct periodic campaigns may, however, provide better disease control
for those countries with very poor routine EPI uptake. The combination strategy of
introduction into routine EPI with a one-off catch-up campaign targeting those born
since the initial campaign was the most effective and also the most equitable option.
My work has several strengths and limitations. I based my model structure on
extensive previous work that used a range of deterministic models, to explore the
importance of seasonality and immunity following colonisation [82]. I extended these
models to incorporate age structure and vaccination and included a stochastic term so
that the extent of seasonal forcing varied from year to year, to capture the effect of
external forces (including, e.g. dust or humidity conditions). I parameterised the model
using appropriate published and unpublished data specific to African populations as far
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as possible. Although Burkina Faso and the rest of the sub-Saharan countries have got
an increasing annual growth rate, the use of a fixed rate in this instant is justified since I
am only considering 40 years post-vaccination. For a longer time horizon, more realistic
demographic parameters are essential to capture all demographic changes and their
potential effect on the model results. Some model parameters were unknown including
the transmission rate and duration of natural immunity. Here, I used a variety of methods
to estimate a reasonable range and possible parameter combinations, ensuring that the
model produced realistic results by comparing the model predictions to evidence on
carriage prevalence by age, disease incidence by age, total annual incidence, seasonality,
and periodicity. Further investigation of formal fitting methods such as Approximate
Bayesian Computation is warranted, and more information on a range of parameters
would be desirable, including age-specific contact patterns. Quantifying the duration of
natural immunity following infections is particularly difficult; estimation is hampered
by co-dependence with other parameters, and empirical measurement is problematic,
not least because of the lack of an absolute correlate of protection [95]. I performed
sensitivity analyses to investigate parameter uncertainty and showed that my findings
were robust.
My conclusions are different from another model of MenAfriVac, which found that
mass campaigns were superior to routine EPI. This is probably largely because the
duration of protection assumed by Tartof et al. was much higher (essentially life-long)
for children immunised in campaigns than through EPI [84], whereas I assumed that
protection in 1-to-4-year-olds would be similar to those immunised at the age of 9 months,
based on recent data from the MVP’s MenAfriVac trials. Tartof et al. also used a
different model structure, a larger time-step, non-continuous ageing, a smaller number of
simulations, and higher frequency (weekly) and amplitude (0-0.75) of stochastic forcing.
I chose a more parsimonious model structure that did not consider variable levels of
protection against colonisation and disease, as there was little evidence to inform such a
structure and its parameterisation. I explored the effect of other structural changes in my
model, including the implementation of stochasticity as weekly variation in transmission
rates, but this had minor impact on the model predictions and did not change my
conclusions on the relative merits of each immunisation strategy.
The burden of disease predicted by the model for the first 26 years after introduction
with MenAfriVac was used in a cost-of-illness study which showed that preventive
immunisation with MenAfriVac would be significantly cost saving for Burkina Faso,
compared with reactive, emergency mass vaccination campaigns [96].
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Following its introduction in 2010, MenAfriVac has been remarkably successful in
controlling NmA disease. This success will not be maintained without a long-term
immunisation strategy. The early adopting countries will need to consider imminently
how best to sustain population protection against NmA, and findings from mathematical





mathematical model of MenAfriVac
impact
4.1 Introduction
A mathematical model can be used to provide predictions, the validity of which relies
on the underlying assumptions of the model [97]. "All models are wrong, but some are
useful" is a famous quote by the British statistician George E. P. Box. A model is a mere
approximation of reality. When developing a disease transmission model, one is forced
to make assumptions regarding the inputs (i.e. the model parameters) as well as the
structure of the model. Each assumption, however, is a source of uncertainty around
the model outputs. The robustness of a model’s results against assumptions around
the inputs can be examined with sensitivity analysis [98, 99]. One way to examine the
validity of a model and the trustworthiness of its predictions is by comparing it with
other models. Model comparison is a common practice among researchers [100–103]. If
two or more models using different mechanisms to describe disease transmission yield
similar results, we gain some confidence in the predictions produced. However, different
models may lead to similar observed patterns in the absence of vaccination but may
fail to do so when intervention is added [97]. This can be due to different mechanisms
governing the models. It can be beneficial, therefore, to have more than one model to
address policy makers questions.
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Up to the time of writing, two mathematical models have been published to support
decision making about long-term vaccination strategies with MenAfriVac in the African
meningitis belt. The first paper to be published was by Tartof et al. in 2013 [84]
followed by the model presented in Chapter 3 which was published in 2015 [104]. The
two models were developed independently and both aim to investigate the impact of
different immunisation strategies with MenAfriVac. Both models considered the same
selection of immunisation strategies as those were of interest to WHO and CDC at the
time. Both are stochastic transmission models that can reproduce key features of the
epidemiology of NmA in the African meningitis belt. But while the models use similar
values for specific parameters, the models also differ in potentially important ways,
including differences both in parameter values and in model structure. In consequence,
the models make different predictions regarding the relative benefits of different NmA
vaccination strategies. For that reason, I wanted to compare the two models and determine
which assumptions influence these differences in predictions. By doing so, I hope to
resolve/interpret differences in policy-relevant outcomes, identify areas for improvement
and address important knowledge gaps.
4.2 Model Desrciption
4.2.1 Tartof et al. model
Model structure
The population is divided into different states based on age, level of protection (None,
Low, High) and meningitis infection status (Susceptible, Carrier, Diseased). Individuals
in the high protection state are assumed to have a very high level of immunity to becoming
colonised, and if colonised, they cannot become diseased.
Individuals in the low protection state are assumed to have relatively low immunity to
colonisation but still high protection against disease. The no protection state represents
individuals with no immunity to colonisation or disease (Figure 4.1). It is further assumed
that vaccination with MenAfriVac is equivalent to natural infection in inducing immunity
to future colonisation and disease.
Implementation
The population is divided into 361 age groups by month of age with individuals 30 years
and older treated as one homogeneous age group using census data to determine the age
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distribution of Burkina Faso in 2010. The ageing process is discrete and individuals move
from one age group to the next each month, while newborns enter the model at age a=0.
Seasonality is incorporated into the model by having two different Who Acquires
Infection From Whom (WAIFW) matrices. One for the dry season, which runs from
November through April, and one for the rainy season. Similarly, the rate at which
colonised individuals develop invasive disease is higher during dry season compared to a
lower value in the rainy season.
Fig. 4.1 Model diagram in Tartof et al. [84]. Individuals are born into the no protection,
susceptible state with time- and age- dependent birth rate µ(t,a) and die from all model
states with time-dependent death rate ν(t). Susceptible individuals become colonized at
time- and age- dependent force of infection λ(t,a), which is reduced by immunity due to
low (αL) or high (αH) protection levels. Colonized individuals develop invasive disease at
age-dependent rate σ(a), which is reduced by low (βL) or high (βH) protective immunity.
Diseased individuals recover to the high protection, susceptible state at recovery rate
ρD, low protection colonized individuals recover from colonization to the high protection,
susceptible state at recovery rate ρC , and no protection colonized individuals recover
from colonization to the low protection, susceptible state at recovery rate ρC . Protection
wanes from high to low and from low to none, at age-dependent rate ωH(a) and ωL(a),
respectively. Susceptible individuals with no or low protection are vaccinated at time-
and age- dependent rate γ(t,a), where vaccination induces high protection.
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The transmission rate is multiplied by a stochastic term added to allow cyclic but
irregular epidemics similar to observed epidemic patterns. The stochastic term φ is
calculated as:
φ = 1 + 0.75cos(θπ)
where θ is a random number drawn from the uniform distribution (0,1) 1.
The model is governed by a set of stochastic difference equations that were numerically
solved using a time step of one calendar week. All computations were implemented using
SAS version 9.2.
4.2.2 Karachaliou et al. model
Model structure
This is a compartmental model that divides the population based on their infectious
status. Individuals are assigned to one of the following states: (a) susceptible, (b) carrier
of NmA, (c) disease due to NmA and (d) recovered and immune (Figure 3.7).
Implementation
The population is divided into 19 age groups, 0 to <3 months, 3 to <9 months, 9 to <12
months, 1-4 years, 5-9 years, and 5-year age groups to age 80 years subsequently, with
continuous ageing between age groups. The proportion of the population in each age
group remains constant over time.
Seasonality is implemented through seasonal forcing of the transmission rate and the
rate at which carriers develop invasive disease using a sinusoidal function.
Stochasticity was introduced with annual variations in the transmission rates, drawn
from the uniform distribution (0.8-1.2).
Vaccination was implemented in different ways according to the strategy used. Mass
vaccination campaigns occurred as a discrete event at one point in time, whereas routine
immunisation was implemented continuously as individuals reached the target age. It is
assumed that the risk of transmission and the risk of developing invasive disease is lower
among vaccinated individuals.
The model is governed by a set of stochastic differential equations that were numerically
solved in R using the lsoda function in package deSolve [94] with a time step of one
1This is not what is reported in the paper (see section 4.4.1)
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day. Further details on the model structure and initial conditions used can be found in
Chapter 3.
4.2.3 Vaccination strategies
The two models explored the relative effectiveness of a range of different vaccination
strategies and compared them to a scenario without any vaccination and with only the
initial mass campaign of 1-29 year olds. The strategies that both models considered were
routine immunisation at 9 months of age as well as periodic mass campaigns of 1-4 year
olds every 5 years.
4.2.4 Model predictions
In the base case scenario, both models suggest that introduction of MenAfriVac in the
Expanded Programme on Immunisation (EPI) and follow-up mass campaigns would
reduce the incidence of invasive disease compared to no long-term vaccination.
(a) Karachaliou et al. (b) Tartof et al.
Fig. 4.2 Boxplot to show the median, interquartile range and full range of the predicted
annual incidence for different immunisation strategies. (A) Initial mass campaign only,
(B) Routine EPI at 9 months, (C) Periodic campaigns of 1-4 year olds every 5 years.
Left panel: Results from Karachaliou et al. model. Right panel: Figure produced using
Tartof et al. model and parameter values as in the published paper.
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The results produced by the two models can be seen in Fig 4.2. The Tartof model
[84] suggests that periodic campaigns of 1-4 year olds would prevent the most cases
of all strategies considered. They report a mean of 1.6 cases per 100,000 per year if
periodic campaigns take place every 5 years, compared to a mean rate of 7.3/100,000
per year if MenAfriVac is introduced into EPI 5 years after the initial mass campaign.
On the contrary, our model suggests that although there was considerable overlap in the
distribution of results, routine EPI immunisation at 9 months resulted in lower mean
annual incidence than periodic mass campaigns of 1-4 year olds. Note here that the
strategy D from Chapter 3 is not shown here as this strategy was not explored by Tartof
et al. and thus, there could be no direct comparison.
4.3 Similarities and differences
4.3.1 Similarities
Both models are age-structured, stochastic models. An episode of colonisation or disease
offers complete protection against future colonisation for a certain period of time.
4.3.2 Differences
The ageing process is different in the two models. Tartof et al. use discrete ageing by
moving individuals from one age group to the next every month, whereas I implemented
continuous ageing between age groups.
The duration of vaccine protection in the two models are not directly comparable.
My model assumed an average duration of vaccine protection of 10 years regardless of
the age at vaccination. In the other model, a dose of the vaccine is equivalent to natural
infection, therefore, when individuals are vaccinated in ages older than 10 years, the
protection is lifelong. Vaccination of children between 2 and 10 years of age also leads to
an average of 25 years duration of protection. The exact parameter values can be found
in Table 1 of their paper.
A summary of the differences between the two models can be seen in Table 4.1.
4.4 Comparison process
To begin the comparison process, it was more convenient for me to have two working
models that were coded in the same programming language so that they can easily be
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modified. Since the Tartof model was coded in SAS, I decided to recode their paper into
R, which is a free software. Another reason for choosing to use the same programming
language to implement the two models was to reduce sources of variation, such as using
different solvers. Further, independent implementation of a model can identify any
possible coding errors.
My initial aim was to replicate the results presented in the paper so that I am
confident that the code is the same as the one used by the other team. I sourced all the
information and the parameter values from the paper. My initial attempt to reproduce
the results was unsuccessful. The average annual incidence my code was estimating was
far lower than the average yearly incidence in the paper.
4.4.1 Errors in code/paper
After communicating with the authors, I discovered that two of the key parameters -the
transmission rate and the rate at which carriers develop invasive disease- were not scaled
appropriately when reported in the paper. The rates provided in the article are weekly
rates and not annual as stated. Using the correct values, however, did not improve my
model predictions. I was still unable to reproduce the results in the initial published
study.
My next step was to request for the source code from the authors. I then discovered
some more discrepancies between the information in the paper and the code that was
actually used to produce the results.
• In the paper, the stochastic term is described as a random number between 0 and
0.75. The stochastic term actually used was drawn from a U-shaped distribution
with range (0.25-1.75).
• The duration of disease was assumed to be 10 days, compared to 7 days listed in
the paper.
• The rate of waning of immunity depends on age, and it is lower for individuals
older than 2 years of age, compared to 3 years listed in the paper.
Changing the duration of disease and the age-specific rate of waning did not have a great
effect on the dynamics, but the imprecise stochastic term was influential.
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4.4.2 Implementation issues
The main issue that prevented me from correctly reproducing the results in Tartof et al.
was the way periodic campaigns were implemented. The periodic campaigns targeting
1-4 year-olds every five years were implemented monthly over the course of a whole year
instead of occurring as a discrete event at one point in time. This implementation was
wrong as it does not correspond to reality and resulted in the vaccination of an additional
age cohort. The initial mass campaign in 2010 was completed in only ten days [7]. It
would be reasonable to assume that the periodic campaigns would take place in a similar
way and not once a month over a period of one year.
Another difference between the papers is the period for which the average annual
incidence is calculated. Tartof et al. included the year 2010 in their calculations even
though initial mass campaign took place in December 2010. I estimated the average
annual incidence for the first 40 years after the initial campaigns.
Lastly, I noticed that although dry season runs from December through May (6
months), the rate at which carriers develop disease takes a higher value during seven
months of the year. This was ambiguous in the paper and it is not clear whether it was
intentional or another coding error.
A summary of all the implementation issues is given in Table 4.2. The results
presented in the Tartof model are therefore not consistent with the model shown in the
paper. This finding led to a correction to the original paper in 2017 [105].
Reported in paper What was actually done
Annual rates Weekly rates
Stochastic term (0 - 0.75) Stochastic term (0.25 - 1.75)
Duration of disease 7 days Duration of disease 10 days
Age group 3 - 10 years of age Age group 2 - 10 years of age
High invasion rate period 6 months High invasion rate period 7 months
Table 4.2 Summary of errors in reporting in Tartof et al..
After taking into consideration of all the issues shown in Table 4.2, I was finally able
to reproduce the results in the paper (Figure 4.3).
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All this work provided a corrected Tartof model to use for the model comparison.
Altering the implementation of the periodic campaigns, as shown in Figure 4.4, if
campaigns of 1 to 4 year olds take place in one week only every five years, as expected,
the estimated average annual incidence is higher.
Comparing again the benefits of routine immunisation at nine months and periodic
campaigns targeting children 1 to 4 years of age, it is shown in Figure 4.5 that there is
considerable overlap in the distribution of results. However, if we simply look at the
median values across 100 model runs, the argument that periodic campaigns are more













































































Fig. 4.3 Boxplot to show the median, interquartile range and full range of the average
annual incidence from 100 simulation runs with discrete ageing based on my implemen-
tation of Tartof model in R. Red marks indicate the mean values which can be found
in Table 2 of their paper and blue circles represented the mean from the simulations.
Strategies from top to bottom and left to right: No vaccination, A, B and C.








































Fig. 4.4 Boxplot to show the median, interquartile range and full range of the average
annual incidence from 100 model runs of the Tartof et al. model for periodic campaigns
(strategy C) over a course of a year every 5 years compared to periodic campaigns taking








































Fig. 4.5 Boxplot to show the median, interquartile range and full range of the average
annual incidence from 100 model runs for periodic campaigns every 5 years (strategy C)
compared to EPI at 9 months (strategy B).
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4.4.3 Continuous model
To aid the model comparison, I decided to re-implement the Tartof model using differential
equations and continuous ageing. Using the same simulation/integration routine allows
me to explore differences in structure only.
I divided the population into 33 age groups: 0 to <6 months, 6 to <9 months, 9
to <12 months, and one year age groups to age 30. Similarly to the discrete model,
individuals who are 30 years and older are treated as one homogeneous age group. The
parameters were set to exactly the same values as in the discrete model. The time step
was one day. The methodology to derive the age-structured model is described in Chapter
3 and more details can be found in Appendix A.
The difference equations were re-written as a set of differential equations to implement
continuous ageing between age groups:
for j = 2, . . . , 33
dNS1
dt
= (K1 + d1 + q)P1 − (K1 + d1 + q)NS1 + wL1LS1 − λ1NS1 − foNS1
dNSj
dt
= Kj−1NSj−1 − (Kj + dj + q)NSj + wLj LSj − λjNSj − foNSj
dLS1
dt
= ρCNC1 − (K1 + d1 + q)LS1 − wL1LS1 − λ1(1 − aL)LS1 + wH1HS1 − foLS1
dLSj
dt
= Kj−1LSj−1 + ρcNCj − (Kj + dj + q)LSj − wLj LSj − λj(1 − aL)LSj + wHj HSj − foLSj
dHS1
dt
= ρCLC1 + ρCHC1 + ρDD1 − λ1(1 − aH)HS1 − wH1HS1 − (K1 + d1 + q)HS1 − foHS1
dHSj
dt
= Kj−1HSj−1 + ρCLCj + ρCHCj + ρDDj − λj(1 − aH)HSj − wHj HSj
− (Kj + dj + q)HSj − foHSj
dNC1
dt
= λ1NS1 − ρCNC1 − σ1NC1 − (K1 + d1 + q)NC1 + foNS1
dNCj
dt
= Kj−1NCj−1 + λjNSj − ρCNCj − σjNCj − (Kj + dj + q)NCj + foNSj
dLC1
dt
= λ1(1 − aL)LS1 − ρCLC1 − σ1(1 − βL)LC1 − (K1 + d1 + q)LC1 + foLS1
dLCj
dt
= Kj−1LCj−1 + λj(1 − aL)LSj − ρCLCj − σj(1 − βL)LCj − (Kj + dj + q)LCj + foLSj
dHC1
dt
= λ1(1 − aH)HS1 − ρCHC1 − σ1(1 − βH)HC1 − (K1 + d1 + q)HC1 + foHS1
dHCj
dt
= Kj−1HCj−1 + λj(1 − aH)HSj − ρCHCj − σj(1 − βH)HCj − (Kj + dj + q)HCj + foHSj
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dD1
dt
= σ1(1 − βL)LC1 + σ1(1 − βH)HC1 + σ1NC1 − ρDD1 − (K1 + d1 + q)D1
dDj
dt
= Kj−1Dj−1 + σj(1 − βL)LCj + σj(1 − βH)HCj + σjNCj − ρDDj − (Kj + dj + q)Dj
Parameter name Description Value
K Rate at which people move between age groups 0-3.98/year
d Mortality rate 0.01302-0.02/year
q Country’s growth rate 0.0308/year
λ Force of infection -
fo External force of infection 0.0005/year
wL Waning of low protection to none 0.04-0.4/year
wH Waning of high protection to low 0.025-0.877/year
aL Immunity of low protection against colonisation 0.25
aH Immunity of high protection against colonisation 0.75
σ Rate at which carriers develop disease 0.089-0.098/year
βL Immunity of low protection against disease 0.9
βH Immunity of high protection against disease 1
ρC Rate of recovery from colonisation 12.175/year
ρD Rate of recovery from disease 36.5249/year
Table 4.3 Description and values of parameters in Tartof model with continuous ageing.
A range is given for age-dependent values.
A list of parameter names and their description is given in Table 4.3. The mortality
rate is assumed to be the same for the first 32 age groups and is set to 0.02/year
for the last age group to ensure that all individuals die by the age of 80 years. For
each simulation, I ran the model for a 20-year burn-in period before implementing the
initial mass vaccination campaign. In the absence of vaccination as well as if only the
initial large-scale vaccination campaign takes place, as shown in the top panel in Figure
4.6, the differential equations and the difference equations models produce very similar
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results across all ages. Continuous and discrete ageing yield very similar results when
MenAfriVac is introduced into EPI at nine months of age. The estimated average annual
incidence though, as shown in bottom panel in Figure 4.6, is higher in the continuous
model.
Fig. 4.6 Boxplot to show the median, interquartile range and full range of the average
annual incidence under different ageing processes and immunisation strategies. From 100
simulation runs for the time period 2010-2050.
Comparing again EPI and periodic campaigns for the continuous model, as shown
in Figure 4.7, the model suggests that routine EPI at 9 months is more effective than
periodic campaigns. This agrees with the results from my model presented in Table 3.5.
The main difference in the results of the two models which triggered this comparison study
initially was that Tartof et al. suggested that routine EPI was less effective than periodic
campaigns. From this work, I found that the ageing process seems to be influential in
predicting the relative impact of the two vaccination strategies compared.


























































Fig. 4.7 Boxplot to show the median, interquartile range and full range of the average
annual incidence for the routine EPI and periodic campaigns for continuous and discrete
ageing processes.
4.4.4 From discrete to continuous model
Each choice between difference and differential equations has its advantages and dis-
advantages in the modelling process. Continuous models are obtained using the same
principles as corresponding discrete models. An important question is whether discrete
and continuous models are consistent in the sense that they give the same solutions or
solutions with the same qualitative features [92]. Since time discretisation can cause
problems when numerically solving differential equations, I decided to examine how a
different step size would affect the results of the discrete model. To explore that, I
removed the stochastic term and reduced the time step from one calendar week to one
day. The results are shown in Table 4.4. In the absence of vaccination and when only the
mass vaccination campaign takes place, the model seems to have ’converged’, since the
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results with a step size of one week are similar to those based on a one-day step size. The
fact that the model predicts higher incidence for a smaller step size when considering
long-term immunisation strategies suggests that the time step of one calendar week may
















<1 74.44 77.00 60.17 62.25 12.49 13.09 12.59 13.68
1-4 66.47 68.22 53.32 54.83 5.06 5.18 8.94 9.79
5-9 66.04 65.94 56.12 56.24 7.71 7.88 6.47 6.80
10-14 41.61 41.20 37.30 36.69 11.24 11.81 6.90 7.36
15-19 25.97 25.37 19.69 19.32 14.59 14.83 8.09 8.66
20-24 10.34 9.96 7.89 7.62 6.21 6.36 5.81 6.12
25-29 8.58 8.28 6.48 6.31 5.75 5.64 5.34 5.56
30+ 6.73 6.58 6.30 6.20 4.97 5.14 4.50 4.71
All 34.99 35.16 29.15 29.33 7.66 7.89 6.67 7.11
Table 4.4 Numerical solution of discrete Tartof model using a time step of 1 calendar
week and 1 day.
Just changing from discrete to continuous time, leaving the model structure and
parameters unchanged can yield a different Reproduction number (R0). I believe that
this is the reason for the discrepancy between the results of the difference and differential
equations systems but have not pursued further technical analysis of this issue.
4.5 Discussion
Two models have been published to date looking at the effect of a number of immunisation
strategies with MenAfriVac in the African meningitis belt. The two models exhibit several
differences, including the model structure, and they make different predictions regarding
the relative benefits of the immunisation strategies they considered. I decided to start
a model comparison process in an effort to identify which features of the models are
responsible for the observed differences in their predictions.
Initially, I believed that the different assumption for the duration of immunity after
vaccination was the driver of the observed differences in model predictions. However,
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in the process, I discovered that Tartof et al. had implemented the periodic campaigns
differently. The different implementation was the reason their model predicted that
periodic campaigns were more effective than incorporating MenAfriVac into the routine
EPI schedule. When I altered the way follow-up campaigns were implemented, although
periodic campaigns resulted in lower average annual incidence than EPI, there was
considerable overlap in the distribution of results. This finding was communicated back
to the authors and that resulted in them publishing a correction to the original paper
[105].
When I implemented the same model with continuous ageing, the model predicted
that EPI was superior to periodic campaigns. That is, the results from my model and the
model developed by Tartof et al. followed the same pattern. This indicated that the key
feature responsible for the observed differences in the two models’ predictions is the choice
of the ageing process. When numerically solving difference and differential equations,
there is always an error in the approximations. An additional error is introduced when
converting a set of difference equations to a set of differential equations. It is challenging
to quantify these accumulated errors.
This model comparison exercise has been useful in allowing me to examine differences
in both the reported and code based predictions of NmA vaccine impact. Some issues
can be easily resolved, such as the implementation of periodic mass campaigns. Other
issues, such as decisions on ageing processes, are more challenging, but nevertheless could
still be influencing model predictions. When measuring vaccine impact, guidelines from







The Vaccine Impact Modelling Consortium (VIMC) [106] was established in 2016 for
a period of five years. The aim of the Consortium is to coordinate the work of several
research groups modelling the impact of vaccination programmes that are supported
by Gavi [107]. The reason behind the coordination of all modelling activities into a
Consortium is to harmonise the assumptions made by the different modelling groups
working around the globe to ensure the best possible quality of the estimates produced
by the teams. A secretariat based at Imperial College London coordinates the work being
carried out by the Consortium members. It consists of a management group as well as
administrative, scientific and technical teams.
The Consortium will work on aggregating estimates from a portfolio of ten vaccine-
preventable diseases and further advancing the research agenda in the field of vaccine
impact modelling. Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation
are funding the Consortium and plan to use the data generated by its members to
monitor their progress towards the Decade of Vaccines targets and inform potential
future investments and vaccine scale-up opportunities.
I will outline the changes necessary to fit within VIMC guidelines and the new results
and outputs that were obtained.
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5.2 Montagu
Working with all the participating modelling groups, the secretariat has developed a
web-based delivery platform, called Montagu. All the members of the VIMC can interact
with Montagu through different portals. Modellers can have easy access to the latest
demographic and coverage data to ensure consistency between the groups, while funders
can quickly access the estimates and browse through several reports generated by the
secretariat.
Each time an input parameter, such as the coverage data, is updated, Montagu starts
a new ’touchstone’ which enables strict version control. This feature provides an easy
way to trace back the input data that were fed into the models generating specific burden
estimate sets.
Through the modellers’ contribution portal, the modelling groups, apart from coverage
data and life tables, can also download burden estimate templates which guide them to
produce the right type of output. The completed template with the estimates can be
uploaded into the platform at the end of the modelling round.
5.3 Description of deliverables
There are rounds of modelling taking place every odd-numbered year. The most recent
modelling round took place in December 2017. All modellers were asked to provide
estimates of disease burden in terms of number of cases, deaths, and Disability Adjusted
Life Years (DALYs) stratified by country, age and year for the 96 Gavi-supported and
Decade of Vaccines countries. The burden should be reported by calendar year, and
stratified by age into annual age cohorts. Estimates for a number of vaccination coverage
scenarios, including various routine and campaign strategies were requested, shown in
Table 5.1.
More specifically, for NmA, the disease-specific ranges to be explored are shown
in Table 5.2. MenAfriVac is being administrated in the 26 countries of the African
meningitis belt. The time horizon is set to be from the introduction of the vaccine in
2010 until 2100. Not all countries introduce MenAfriVac in the same year though. All
introductory campaigns take place during the period 2010-2020 as illustrated in Figure
5.1. In Figure 5.1 we can see that the introductory campaign in 8 countries, namely
Mali, Niger, Cameroon, Chad, Nigeria, Senegal, Sudan and Ethiopia, took place across
more than one year. This is due to the campaign being completed in phases targeting
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Scenario Schedule
No vaccination -
Campaign 1 dose for 1-29 year olds in introductory campaigns1 dose for over 1 year olds in catch-up campaigns
Campaign & routine
1 dose for 1-29 year olds in introductory campaigns
1 dose for over 1 year olds in catch-up campaigns
1 dose in routine programme given at 12 months of age
Table 5.1 Immunisation strategies requested from Gavi to provide estimates for during
the modelling round in 2017.
different parts of the country in each phase. Although Gavi require impact estimates to
2030, the time horizon is extended to 2100 in order to capture the lifetime burden of any
vaccinated cohorts, allowing for generation of burden by year of vaccination estimates.
Due to the stochastic nature of the model, 200 model runs were required by the VIMC
secretariat. The full amount of age and year stratified data generated from the stochastic




Age range Time horizon Vaccination strategy




Table 5.2 MenA-specific ranges and scenarios to be considered for the generation of
vaccine impact estimates for round 2017.
5.4 Incidence by country
In order to meet the deliverables above, I needed to modify the model from Chapter
3. I recognise that there is diversity in the incidence of meningitis in the countries of
the African meningitis belt. For some countries there are also rather poor data, e.g
only 9 were considered to have consistent high quality data in a recent epidemiological
assessment of the impact of MenAfriVac to date [108]. Rather than parameterise 26
different models, I felt it was more appropriate to classify countries into categories, based
on the incidence levels, which would define the transmission dynamic parameters of the
model.

































Fig. 5.1 Year of MenAfriVac introduction in the 26 countries of the African meningitis
belt.
Not all countries lie entirely in the African meningitis belt. The belt consists of
seven countries in their entirety and parts of other countries, where only a fraction of
their population is considered to be at high risk of meningococcal meningitis according
to WHO. The proportion of the population assumed to be at risk in each country is
illustrated in Figure 5.2 and is as follows:
• 7 countries (100% population at risk)
– Burkina Faso, Chad, Ethiopia, Gambia, Mali, Niger, Sudan
• Nigeria (70% population at risk)
• South Sudan (50% population at risk)
• 12 countries (20% population at risk)
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Fig. 5.2 Map showing the proportion of people considered to be at risk of meningococcal
meningitis in the countries of the African meningitis belt. Three letter code is used
for the names of countries. BDI - Burundi, BEN - Benin, BFA - Burkina Faso, CAF -
Central African Republic, CIV - Cote d’Ivoire, CMR - Cameroon, COD - Democratic
Republic of the Congo, ERI - Eritrea, ETH - Ethiopia, GHA - Ghana, GIN - Guinea,
GMB - Gambia, GNB - Guinea-Bissau, KEN - Kenya, MLI - Mali, MRT - Mauritania,
NER - Niger, NGA - Nigeria, RWA - Rwanda, SDN - Sudan, SEN - Senegal, SSD - South
Sudan, TCD - Chad, TGO - Togo, TZA - Tanzania, UGA - Uganda.
– Benin, Cameroon, Democratic Republic of the Congo, Ghana, Guinea, Guinea-
Bissau, Rwanda, Mauritania, Senegal, Burundi, Cote d’Ivoire, Togo
• 5 countries (10% population at risk)
– Central African Republic, Eritrea, Kenya, Tanzania, Uganda
In the MenA Investment Case written in 2008 (Marie-Pierre Preziosi, personal
communication, October 20, 2015), the 26 countries were classified as follows:
• Core countries (N=7)
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– Burkina Faso, Ethiopia, Mali, Niger, Sudan, 26 northern states of Nigeria
• Bordering countries with hyperendemic zones (N=12)
– Benin, Cameroon, Central African Republic, Cote d’Ivoire, Democratic Re-
public of the Congo, The Gambia, Ghana, Kenya, Togo, Senegal, Uganda and
the remaining states of Nigeria
• Other at-risk countries without hyperendemic zones (N=7)
– Burundi, Eritrea, Guinea, Guinea-Bissau, Mauritania, Rwanda and Tanzania
I examined the available historic reports [31] and more recent surveillance data [12]
to investigate whether the categories defined in the investment case were suitable for the
modelling purposes, or whether an updated classification was more appropriate.
Based on these data, summarised in Table 5.3, it is clear that Burkina Faso and
Niger have the highest incidence, with frequent large outbreaks. The incidence during an
outbreak in these countries exceeds 400 cases per 100,000 population. For other countries
included in the ’core’ category above, such as Mali and Chad, these data suggest that
the average annual incidence is substantially lower than for Burkina Faso and Niger.
Some countries have very little reported data making it difficult to categorise them
solely based on the incidence. Therefore, I decided to classify them using additional
information on their geographical position and year of MenAfriVac introduction, into
High-Medium-Low incidence categories. Countries that are located near the two high
incidence nations and which introduced MenAfriVac before the year 2015, were assigned
in the medium incidence category, with all the rest assigned in the low incidence category.
Looking at the reported annual incidence of the countries for the periods 1980-1999
and 2005-2010, in Table 5.3, the countries with a median annual incidence of more than
5 cases per 100,000 population and frequent large outbreaks are assigned to the ’Medium’
category. The ’Low’ category consists of countries with lower reported annual rates of
disease as well as smaller and less frequent epidemics. This categorisation was discussed
and agreed with WHO colleagues in July 2017.












Benin 4.28 (2.7-11.6) 4.12 11 (6-57) Low
Burkina Faso 83.11 (13.1-188.4) 56.88 48 (9-438) High
Chad 14.18 (1.2-48.4) 13.27 18 (0-150) Medium
Cote d’Ivoire 3.14 (0.5-5.8) 3.35 1 (0-6) Low
Ghana 2.31 (1.1-4.6) 1.98 6 (0-108) Medium
Mali 5.78 (1.6-10.8) 5.31 15 (3-119) Medium
Niger 29.73 (1.6-85.8) 21.37 53 (16-490) High
Nigeria 8.34 (0.4-36.1) 3.56 5 (1-98) Medium
Togo 8.03 (2.5-12.2) 7.13 8 (1-77) Medium
Mauritania - - 4 (0-14) Low
Cameroon - - 17 (1-224) Medium
Central African
Republic
- - 16 (0-48) Low
Eritrea - - 0 (0-0) Low
Ethiopia - - 1 (0-104) Medium
Gambia - - 7 (4-165) Medium
Guinea - - 3 (0-17) Low
Guinea-Bissau - - 2 (0-133) Low
Senegal - - 3 (0-53) Low
Sudan - - 3 (1-140) Medium
Democratic Republic
of the Congo
- - 2 (0-6) Low
Burundi - - 1 (0-49) Low
Kenya - - 4 (0-15) Low
Rwanda - - 3 (0-28) Low
Uganda - - 5 (0-18) Low
Tanzania - - 2 (0-19) Low
Table 5.3 The average and median incidence for countries of the African meningitis belt
taken from [31, 12]. All numbers are cases per 100,000 population per annum.
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5.5 Methods
In order to meet the requirements set by the VIMC, some changes needed to be made to
the model developed and presented in Chapter 3. I changed the model from having broad
age groups into annual age cohorts. Originally, it was assumed that the age distribution
was stationary, that is that the proportion of people in each age group did not change
over time. To achieve that, I had assumed that the country’s annual growth rate was
constant each year. For this modelling round I used country- and year-specific birth
rates to parameterise the models. All vaccine-associated parameters are the same as in
Chapter 3. Different values for the contact parameters are used to run the simulations
for the countries in the three incidence categories. These values are shown in Table 5.4
and were chosen so that model simulations resulted in an average of 45-50 cases per
100,000 people in the ’High’ category countries, 20-25 cases per 100,000 population in
the ’Medium’ category countries and no more than 5 cases per 100,000 population in









Table 5.4 Values for the transmission rate parameters used in the model simulations.
5.5.1 Initial conditions
I divided the population into a hundred discrete age groups based on their age. That is,
the first age group consists of individuals who were just born plus all individuals who
have not had their first birthday yet. The second age group consists of individuals who
are between one and two years of age and so on. All individuals within a particular age
group are assumed to be equal with respect to their mortality rates. A newborn enters
the first age class upon birth and progresses to the next age class at a rate κ.
Initially, I assumed that the growth rate of each country in the year 2010 is equal to
zero. The ageing process in a population that has zero growth rate is described by the
following equations:
BN − κN1 − µ1N1 = 0; i = 1
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κNi−1 − κNi − µiNi = 0; 2 ≤ i ≤ L − 1
κNL−1 − µLNL = 0; i = L
where N is the total population, Nj is the population size in age group j, µ is the
age-specific death rate, κ is the rate of ageing and B is the birth rate. The model was run
using a daily time step and therefore κ is equal to 1/365. Rearranging, we can calculate
the age-specific mortality rates for the year 2010 using values for the population size and












; i = L
I set 1% of the population in the carrier state and used the above death rates in
order to run the model for a burn-in period of 50 years while the population remained
constant. The model was subsequently run for the time period 2010-2100 with initial
conditions the state of the system at the end of the 50-year burn-in period and the year-
and age-specific birth and mortality rates taken from UNPOP.
5.5.2 Vaccination coverage
Projections of demand and vaccination coverage for the 2010-2100 time horizon were
provided by Gavi. For routine immunisation there was a 1% annual increment in coverage
with a 90% cap. The lowest bound of coverage was 5.9% in Togo during the first year of
the country’s introduction of MenAfriVac into the routine vaccination programme. Four
countries with very low observed incidence of meningococcal meningitis, namely Burundi,
Kenya, Rwanda and Tanzania, are not planning to introduce MenAfriVac into routine
immunisation.
Not all countries are assumed to be at high risk of meningitis as I discussed in section
5.4. To calculate the coverage for the introductory mass campaign, I started by dividing
the number of individuals targeted by the total number of people in the targeted age
groups in the year of vaccination. This gave me the proportion of the population targeted
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for vaccination. I then multiplied that proportion with the reported coverage, to get the
final coverage which I used in the model.
Most countries also plan to have a catch-up campaign in the same year as the
introduction of MenAfriVac into their routine immunisation schedule, targeting children
who were either born after the initial campaigns or were too young to be immunised
then. The 100% coverage rate provided by Gavi for this mini vaccination campaign
was sub-national immunisation coverage. That is, only children from the proportion of
the country considered to be at risk (see Section 5.4) are eligible for vaccination. For
countries that lie entirely in the African meningitis belt, such as Burkina Faso and Niger,
this means 100% coverage, while for countries with 20% or 10% of their population
considered to be at risk, the coverage is 20% and 10% respectively. Eritrea and Central
African Republic completed the mass campaign and started the routine immunisation of
infants in the same year and therefore there is no catch-up campaign
Even though campaigns may be taking place at a sub-national level, after communi-
cation with WHO, it was determined that routine immunisation should be modelled so
that it is introduced nationwide in all countries.
Table 5.5 shows the vaccination schedule for all the 26 African nations. Gavi coverage
estimates for the initial mass campaign might differ from the proportion of population at
risk shown in Figure 5.2.
5.5.3 Calculation of DALYS
The disability-adjusted life year (DALY) is a measure of the burden of disease [109].
It is commonly used by researchers who wish to compare populations and diseases as
it quantifies the burden of disease from mortality and morbidity. One DALY can be
considered as the loss of one year of full health.
DALYs are calculated as the sum of two components: the Years of Life Lost (YLL)
and Years Lost due to Disability (YLD).
DALY = Y LL + Y LD (5.1)
The YLL represents the years lost due to early death caused by a disease. It is calculated
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where Da is the number of deaths at age a and La is the standard life expectancy
at age of death in years. Deaths due to NmA are not explicitly included in the model
dynamics. The model reports the number of cases and I applied a 10% case-fatality ratio
to the total case estimates. Life expectancy tables were provided by Gavi.
Not all cases of meningococcal meningitis result in death. While some patients survive
and continue their lives in full health, disease may also lead to life-long sequelae. The
severity of a disease is represented by a factor known as the Disability Weight (DW). The
DW can take any value between 0 and 1, where 0 represents full health and 1 represents
death. The probability of getting meningitis sequelae is 7.2% and the disability weight
(DW) associated with bacterial meningitis is 0.26 [110].




[0.072 ∗ (Ia − Da) ∗ DW ∗ La] (5.3)
where Ia and Da are the number of incident cases and deaths at age a, respectively,
DW is the disability weight which measures how much the disease affects the survivors
and La is the life expectancy at age a.
5.6 Results
5.6.1 Cohort size
Initially, I performed a self-consistency check on demography. The population structure
in the countries of the African meningitis belt, as can be observed in Figure 5.3, is
expected to change in the next 80 years. Using data provided by Gavi, when aggregated
across all 26 countries, the median age of the population is expected to increase from
16.4 in 2010 to 33.5 in 2100.
By using country and year specific birth and mortality rates, the model was able
to produce demographic figures comparable to those provided by Gavi in the Montagu
platform, which were taken from UNPOP. The left panel in Figure 5.4 shows the number
of people in each age group over the period 2010-2100 provided in Montagu (unpop),
the middle panel represents the cohort size calculated by the model (model) and the
right panel represents the absolute difference between the two, calculated as model -
unpop population. The small positive values in the right panel indicate that the model





















Fig. 5.3 Evolution of age distribution of the 26 countries of the African meningitis belt
for the time period 2010-2100.
of UNPOP projections includes migration and it is not simply births minus deaths which
is essentially what happens in the model. For that reason, there will be some expected
differences between simulated and UNPOP projections.
5.6.2 Fully vaccinated persons (FVPs)
The number of fully vaccinated persons is calculated by multiplying the percentage
coverage achieved for each immunisation strategy times the target population. The left
panel in Figure 5.5 represents the number of vaccinated individuals in a scenario in which
only the initial campaigns take place. All the campaigns take place between 2010 and
2019 with some countries completing the introductory mass campaign over 2 or more
years (Table 5.5). The right panel represents the number of fully vaccinated persons when
routine immunisation is added to the schedule. The number of vaccinated individuals
through routine immunisation increases over time due to increasing birth cohorts.












































Fig. 5.4 Comparison between actual and simulated population, aggregated across the 26
countries between 2010 and 2100.
campaign campaign & routine
















Fig. 5.5 Fully Vaccinated Persons (FVPs) by scenario and by year of vaccination. Aggre-
gated across all countries.
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The proportion of the population in the vaccinated compartments over time and by
country based on simulation is shown in Figures 5.6 and 5.7.
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Fig. 5.6 Proportion of people in the vaccinated compartments when only the campaigns
take place. Three letter code is used for the names of countries. BDI - Burundi, BEN -
Benin, BFA - Burkina Faso, CAF - Central African Republic, CIV - Cote d’Ivoire, CMR
- Cameroon, COD - Democratic Republic of the Congo, ERI - Eritrea, ETH - Ethiopia,
GHA - Ghana, GIN - Guinea, GMB - Gambia, GNB - Guinea-Bissau, KEN - Kenya,
MLI - Mali, MRT - Mauritania, NER - Niger, NGA - Nigeria, RWA - Rwanda, SDN -
Sudan, SEN - Senegal, SSD - South Sudan, TCD - Chad, TGO - Togo, TZA - Tanzania,
UGA - Uganda.
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Fig. 5.7 Proportion of people in the vaccinated compartments when both campaign and
routine immunisation take place. Three letter code is used for the names of countries.
BDI - Burundi, BEN - Benin, BFA - Burkina Faso, CAF - Central African Republic,
CIV - Cote d’Ivoire, CMR - Cameroon, COD - Democratic Republic of the Congo,
ERI - Eritrea, ETH - Ethiopia, GHA - Ghana, GIN - Guinea, GMB - Gambia, GNB
- Guinea-Bissau, KEN - Kenya, MLI - Mali, MRT - Mauritania, NER - Niger, NGA
- Nigeria, RWA - Rwanda, SDN - Sudan, SEN - Senegal, SSD - South Sudan, TCD -
Chad, TGO - Togo, TZA - Tanzania, UGA - Uganda. Note that coverage for routine
immunisation is set to 0% for BDI, KEN, RWA and TZA.
5.6.3 Disease burden
The total burden of serogroup A Neisseria meningitidis disease in the African meningitis
belt in terms of cases is illustrated in Figure 5.8. The graph shows the average of 200
stochastic model runs and a 95% confidence interval around the mean. The colours
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red, blue and green represent countries that are assigned in the high, medium and low
category, respectively. Overall, as expected, the model predicts a decline in the number
of cases and deaths in the presence of vaccination. The number of deaths is not shown
but since they are calculated outside the model by taking a proportion of the cases, the
patterns for each outcome are identical, although the scale differs.
No vaccination Campaign Campaign & routine

























Fig. 5.8 Predicted disease burden across all countries. The solid lines represent the
average of 200 simulation runs and the shaded areas show the 95% confidence interval.
Different colours represent countries in different incidence categories.
Looking at the left panel in Figure 5.8, in the absence of vaccination, the model
predicted an increase in the number of cases for the first 60 years with the number of
cases starting to drop after the year 2075. Of the total number of cases, 62% are among
people in countries which are classified as medium incidence countries, as opposed to
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7.7% in the low incidence countries which are predicted to be free of NmA after 2075. In
the early years, the vast majority of cases are predicted in the nine medium-incidence
countries. However, as 2100 approaches, the number of cases is more equally distributed
between high and medium incidence nations. Plotting the disease incidence over time as
opposed to the absolute number of cases, Figure 5.9 shows a constant decline in disease
incidence even in the absence of vaccination which explains the drop in the number of
cases we can see in Figure 5.8
No vaccination Campaign Campaign & routine



























Fig. 5.9 Predicted disease incidence across all countries. The solid lines represent the
average of 200 simulation runs and the shaded areas show the 95% confidence interval.
Different colours represent countries in different incidence categories.
When only the campaigns take place, middle panel in Figure 5.8, the number of cases
drops to very low numbers for around 10 years. The drop is not sharp due to the fact that
not all countries immunise their population in the same year. The two high incidence
countries, Burkina Faso and Niger, introduced MenAfriVac in 2010, and a resurgence
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in those countries is observed which peaks in 2023. An overall increase in the number
of cases is predicted around the period 2030-2050, before it starts following the same
pattern as the "No vaccination" scenario until 2100.
The far right panel in Figure 5.8 represents the burden of MenA in terms of cases when
both campaign and routine immunisation take place. The number of cases is predicted to
decrease dramatically if countries introduce MenAfriVac into their routine immunisation
schedule. Most cases are seen in the two high-incidence countries, compared to very low
level of disease burden in the fifteen low incidence countries.
The country-specific projections of disease burden in the "No vaccination", "Campaign"
and "Campaign & routine" scenarios are shown in Figures 5.10, 5.11 and 5.12, respectively.
We can see a continuous increase in the number of cases in the two high incidence countries
in the absence of vaccination, whereas the model predicts very low levels of disease and
even elimination after 50 to 60 years in the low incidence countries.
The total number of cases predicted across all 26 countries of the belt can be seen in
Fig 5.13. The aggregation of the results by age and over time is shown in Figure 5.14.
The model predicts very few cases in people older than 30 years old in the absence of any
vaccination. The highest number of cases is in infants less than one year of age. Looking
at the central panel of Figure 5.14 though, we can see that the mean age of infection
increases if infants are being routinely immunised. The changes in the age distribution of
predicted cases by decades for each scenario can also be seen in Figure 5.15. An increase
in the mean age of infection is noted over the years as the population ages even without
vaccination.
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Fig. 5.10 Number of cases predicted for each of the 26 countries of the African meningitis
belt in the absence of vaccination. Solid red line represent the mean across 200 simulation
runs and shaded are shows the 95% confidence interval. Three letter code is used for the
names of countries. BDI - Burundi, BEN - Benin, BFA - Burkina Faso, CAF - Central
African Republic, CIV - Cote d’Ivoire, CMR - Cameroon, COD - Democratic Republic
of the Congo, ERI - Eritrea, ETH - Ethiopia, GHA - Ghana, GIN - Guinea, GMB -
Gambia, GNB - Guinea-Bissau, KEN - Kenya, MLI - Mali, MRT - Mauritania, NER -
Niger, NGA - Nigeria, RWA - Rwanda, SDN - Sudan, SEN - Senegal, SSD - South Sudan,
TCD - Chad, TGO - Togo, TZA - Tanzania, UGA - Uganda.
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Fig. 5.11 Number of cases predicted for each of the 26 countries of the African meningitis
belt if only the campaigns take place. Solid red line represent the mean across 200
simulation runs and shaded are shows the 95% confidence interval. Three letter code is
used for the names of countries. BDI - Burundi, BEN - Benin, BFA - Burkina Faso, CAF
- Central African Republic, CIV - Cote d’Ivoire, CMR - Cameroon, COD - Democratic
Republic of the Congo, ERI - Eritrea, ETH - Ethiopia, GHA - Ghana, GIN - Guinea,
GMB - Gambia, GNB - Guinea-Bissau, KEN - Kenya, MLI - Mali, MRT - Mauritania,
NER - Niger, NGA - Nigeria, RWA - Rwanda, SDN - Sudan, SEN - Senegal, SSD - South
Sudan, TCD - Chad, TGO - Togo, TZA - Tanzania, UGA - Uganda.
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Fig. 5.12 Number of cases predicted for each of the 26 countries of the African meningitis
belt if campaigns and routine immunisation take place. Solid red line represent the mean
across 200 simulation runs and shaded are shows the 95% confidence interval. Three
letter code is used for the names of countries. BDI - Burundi, BEN - Benin, BFA -
Burkina Faso, CAF - Central African Republic, CIV - Cote d’Ivoire, CMR - Cameroon,
COD - Democratic Republic of the Congo, ERI - Eritrea, ETH - Ethiopia, GHA - Ghana,
GIN - Guinea, GMB - Gambia, GNB - Guinea-Bissau, KEN - Kenya, MLI - Mali, MRT -
Mauritania, NER - Niger, NGA - Nigeria, RWA - Rwanda, SDN - Sudan, SEN - Senegal,
SSD - South Sudan, TCD - Chad, TGO - Togo, TZA - Tanzania, UGA - Uganda. Note
that there is no routine vaccination in BDI, KEN, RWA and TZA (see Table 5.5).
5.6 Results 83
No vaccination Campaign Campaign & routine






















Fig. 5.13 Mean number of cases (red line) by scenario from 200 simulation runs. The
grey area identifies the 95% prediction intervals for the predicted values.








































Fig. 5.14 Aggregated (all countries and all years) age distribution by outcome. Averaged
across 200 simulation runs.





































Fig. 5.15 Age distribution of cases across scenario for the time period 2010-2100 divided
by decades. Aggregated results across all 26 countries. Average from 200 simulation runs.
The total number of cases, deaths and DALYs for each scenario across all ages and
years can be seen in Figure 5.16. If no vaccination takes place, the model predicted a total
of 12,532,741 cases across the 26 countries, with 30% of those being in high incidence
countries and around 60% in medium incidence countries, compared to 10,817,428 if only
the campaigns take place and 3,194,322 cases if MenAfriVac is also introduced into EPI.
This difference in the number of cases and deaths translates to more than 60 million
DALYs being averted if countries begin to routinely immunise infants some period after
the introductory mass campaigns. The numbers used to create Figure 5.16 can be found
in Table 5.6.
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Scenario Category Variable Value
Campaign High deaths 363,436
Campaign & routine High deaths 187,373
No vaccination High deaths 380,306
Campaign Low deaths 62,896
Campaign & routine Low deaths 28,850
No vaccination Low deaths 96,950
Campaign Medium deaths 655,411
Campaign & routine Medium deaths 103,209
No vaccination Medium deaths 776,019
Campaign High cases 3,634,361
Campaign & routine High cases 1,873,726
No vaccination High cases 3,803,056
Campaign Low cases 628,961
Campaign & routine Low cases 288,503
No vaccination Low cases 969,499
Campaign Medium cases 6,554,105
Campaign & routine Medium cases 1,032,093
No vaccination Medium cases 7,760,185
Campaign High DALYs 27,201,378
Campaign & routine High DALYs 13,060,327
No vaccination High DALYs 28,372,243
Campaign Low DALYs 4,445,185
Campaign & routine Low DALYs 2,040,673
No vaccination Low DALYs 6,754,314
Campaign Medium DALYs 45,870,473
Campaign & routine Medium DALYs 6,665,070
No vaccination Medium DALYs 53,771,984
Table 5.6 Total burden of disease in terms of cases, deaths and DALYs across all ages
between 2010 and 2100 for the three scenarios. Average across 200 simulation runs.
























































































Fig. 5.16 Total burden of disease in terms of cases, deaths and DALYs across all ages by
scenario and by category over the period 2010-2100. Average across 200 simulation runs.
5.6.4 Countries with different immunisation schedules
Each country’s immunisation schedule has a different impact on the predicted disease
burden. Figure 5.17 illustrates the predicted number of cases by scenario in four countries
with a different vaccination schedule.
Burkina Faso is one of the two countries in the high-incidence category and as can be
seen in Figure 5.17a, a large number of cases is predicted even after the introduction
of the vaccine into EPI. This is due to the high levels of transmission in the country.
However, the number of cases drop sharply right after the introductory campaign. This
sharp drop cannot be seen in the results for Nigeria (Figure 5.17b) due to the fact that
the initial campaign takes place over a period of four years instead of just one.
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Uganda (Figure 5.17c) and Kenya (Figure 5.17d) are both countries assigned in the
low-incidence category. Their main difference is that Uganda is planning to have national
routine immunisation while MenAfriVac will be administered through just the initial
mass vaccination campaign in Kenya. This lack of routine immunisation results in the
number of cases being above zero for approximately 40 years after the introduction of
the vaccine compared to zero predicted cases in Uganda.
No vaccination Campaign Campaign & routine
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Fig. 5.17 Predicted total mean number of cases (blue line) by scenario in four countries
of the African meningitis belt: (a) Burkina Faso, (b) Nigeria, (c) Uganda, (d) Kenya.
The grey area identifies the 95% prediction intervals for the predicted values.
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5.7 Modelling only the population at risk
The results presented so far in this chapter were generated by running the simulation on
the whole population of each country. This is a sensible approach for countries which lie
entirely in the meningitis belt. However, as discussed in section 5.4, not all countries are
considered to be entirely at risk. For the majority of the countries, disease is affecting
only people living in certain parts of the country which is reflected in the proportion
targeted for the campaigns in Table 5.5. Here, I run the simulation on only the population
assumed to be at risk. To achieve this, I assigned all the areas at risk of the partially
in the belt countries in the medium incidence category as defined in the methods. The
vaccination coverage was scaled according to the proportion of the population at risk
and the proportion of the population targeted in Table 5.5. For example, if proportion
targeted was greater or equal to the proportion at risk, I assumed 100% vaccination
coverage for the target age group. If proportion targeted was lower than the proportion
at risk, the coverage was calculated by diving the number of people targeted by the total
number of eligible for vaccination people in the at risk area. I further assumed that
routine vaccination takes place only in the parts of the country at risk and is not nation
wide as happens in reality.
A comparison of the two approaches is presented in Figure 5.18. Both approaches lead
to similar patterns when vaccination occurs with vaccination at the national level leading
to smaller in size peak if only the campaigns take place. Modelling only the population
at risk, the model predicts a very sharp drop in the number of cases immediately after
the initial mass vaccination campaign of 1 to 29 year olds.
In the years after the initial campaign more people are being born and the proportion
of people susceptible increases. This increase in the number of susceptible individuals
eventually leads to a sharp peak in the number of cases as seen in the previous chapters.
On the contrary, the peak is not as large if we assume that vaccination takes place
nationally. In this case, 20% vaccination coverage translates to 20% of the population
randomly selected for vaccination leaving the rest 80% unprotected. This in turn leads
to a slower replenishment of susceptible individuals in the country’s total population.
Choosing to use one approach over the other depends on the policy question one
wants to address. By modelling only the population at risk, I had to disregard a large
number of vaccine doses provided to the countries. In the majority of the cases, the
proportion targeted was larger than the proportion at risk, see Table 5.5. Also, the
nation wide routine vaccination was not taken into account since I assumed that only
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Fig. 5.18 Comparison of predicted disease incidence over the time period 2010-2100 across
all 26 countries if simulation runs over the entire country and if it runs only on the
population at risk. Average of 200 simulation runs.
children at the age of 12 months who live in the areas inside the meningitis belt receive
the vaccine.
5.8 Discussion
To meet the requirements set by the VIMC secretariat, I adapted my initial model,
presented in Chapter 3, and I used annual age cohorts instead of 5-year age groups which
I had initially used. Furthermore, I used country and year specific birth and mortality
rates which resulted in a realistic evolution of the age distribution, compared to the initial
stationary age distribution. The stationary age distribution was a fair assumption to
make as the model was run for a relatively short time horizon, i.e. 40 years. A stationary
distribution though, is not a realistic assumption, and especially for low-income countries
such as the countries of the belt. Demographic structure in less developed countries is
changing. Life expectancy increases over the years while fertility declines and this leads
to older populations. When the model was run for a 90-year period, this change in the
90 Vaccine Impact Modelling Consortium
demographic structure resulted in a decline in the predicted annual disease incidence
in each country. While the number of cases increases initially, due to the population
growth, the incidence drops. This occurs because the proportion of the population in the
high risk age groups declines over time as the population becomes older. Subsequently,
transmission of disease is reduced because the mixing of the population changes.
Data on historic disease incidence for the majority of the countries is very limited
or non-existent and therefore, a decision was made to classify the countries into differ-
ent categories. After consultation with WHO, I divided the countries based on their
geographical location and the available historic data into High-Medium-Low disease
incidence countries. According to WHO, most countries were only partially targeted for
the introductory mass campaigns. In the coverage sets provided by the secretariat, the
coverage for the mini catch-up campaigns was assumed to be the same as the fraction
of the population in each country that is considered to be at risk of meningococcal
meningitis. However, for a number of countries, such as Guinea-Bissau and Central
African Republic, the coverage achieved during the initial mass campaigns is surprisingly
high and it is not clear why this is the case. Although for some countries the mass
campaigns take place at a sub-national scale, routine immunisation is assumed to occur
nationwide.
The model was run for the time horizon 2010-2100 and recorded the number of cases
deaths and DALYs by year, age and country under three immunisation scenarios. The
results for the scenario in which routine immunisation together with a mini catch-up
campaign following the introductory campaign targeting 1-29 year olds were compared
with the results under a no vaccination scenario and a scenario in which only the
campaigns take place. When aggregated across all countries, the model predicted that
the use of MenAfriVac in the long-term will prevent more than 9 million cases until the
year 2100.
The fact that NmA cases are not eliminated even after routine vaccination of babies
suggests that this immunisation strategy may not be the most effective in the long
run. Assuming that vaccine protection lasts for an average of 10 years, most vaccinated
children will lose protection while they are still in the high risk age groups. Additionally,
recent data also suggest that protection wanes faster in individuals vaccinated at a
very young age. Thus, it is worth exploring alternative immunisation strategies such as
targeting school children for routine vaccination.
The results of this work were consistent with the results from the initial model, that
suggested that unless MenAfriVac is introduced into routine immunisation, there will
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be a strong resurgence in disease incidence after a honeymoon period following the
initial mass campaigns. This resurgence cannot be seen clearly in the aggregated results
because countries introduce MenAfriVac at different times and over the course of ten
years. However, looking at the results for each country individually, one can see the effect
which the vaccine has on their population. For countries in the Low incidence group, the
number of cases drops to very low numbers even with no vaccination. This is caused
solely by the shift in the age distribution of the population over time.
One of the limitations of this work is that it is not possible to validate the model
predictions. Vaccination started in 2010 and that translates to only eight years of data
from Burkina Faso. All data from studies looking at MenAfriVac impact support an
extended period of very low incidence immediately after the mass campaigns [108, 63,
73, 111].
In the Investment Case submitted by WHO in 2008, the vaccine impact estimates
were based on models that used data from one population-based study in Niger. The
vaccine impact for a ten year period was estimated for only seven countries assuming
that they all have the same levels of incidence. The model was static and assumed that
there was one epidemic every ten years. According to published studies, Niger, together
with Burkina Faso, has very high levels of incidence compared to the rest of the countries
of the belt. For that reason, by assuming that all countries have the same high incidence
rates, the impact presented in the Investment Cases was most likely an overestimation of
the true impact. This model was initially used by Gavi to estimate MenAfriVac impact.
Our model is thus an improvement in several respects since it is a dynamic transmission
model which uses country-specific demography.
Understanding that every mathematical model has its strengths and limitations, the
secretariat sub-contracts two modelling groups to develop models for the same disease and
they are asked to produce the same output. Having two models for the same disease can
offer a better view on the uncertainty around the model structure and the assumptions
made during the simulation runs by the modellers (see Chapter 4).
This exercise supports the huge investment in MenAfriVac as it shows that the
potential benefits of MenAfriVac immunisation in reducing mortality and morbidity
across the African meningitis belt are tremendous. Nonetheless, it is important to
emphasize the effect of protecting newborn cohorts after the initial campaigns have
been completed. The routine immunisation of children with MenAfriVac might make it




strategies and understanding the
role of duration of vaccine
protection
6.1 Introduction
Considerable reductions in meningitis incidence have been observed following the intro-
duction of MenAfriVac. A study published in 2017 shows a 99% decline in the number
of confirmed group A cases in fully vaccinated populations [108]. However, the work
presented in the previous chapters suggests that routine immunisation of babies under
the age of 12 months may not be the optimum long-term strategy. This is due to waning
of protection by the teenage years, when there is still heightened risk of meningitis.
Additionally, recent studies show that vaccination later in childhood offers higher levels
of antibodies that persist for longer [75].
It is not uncommon for a country to change its immunisation schedule based on new
data and the continued monitoring of the situation. For example, the MenC vaccination
schedule in the UK has changed several times since its introduction in 1999 [112]. The
MenC vaccine was initially administered to babies in 3 doses at the ages of 2, 3, and 4
months. Then, in 2006, it changed to two doses at the age of 3 and 4 months followed
by a booster dose at 12 months. To maintain high levels of herd immunity, a further
booster dose targeting teenagers aged 13-15 years was introduced in 2013. In 2015, the
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Joint Committee on Vaccination and Immunisation recommended that the infant dose
at three months should be dropped [113], so that the current schedule is one dose at 12
months followed by a booster dose at 13-15 years.
When making recommendations about a vaccine schedule, the aim is to provide the
best possible protection to the population through the smallest number of vaccine doses
given at most effective times.
In this chapter I explore how the optimal vaccination strategy may change in the long
term. Specifically, I consider four scenarios that could be plausible alternative strategies
to the current.
6.2 Demographic model
I used the existing model, presented in Chapter 3 and adapted in Chapter 5, which
reproduces the country-specific epidemiology of NmA in the pre-vaccination era, to
project the burden of disease under a number of alternative vaccination schedules in the
years after MenAfriVac introduction. Demographic data for Chad were used to estimate
parameters for the model. The total population of Chad is expected to increase a 4-fold
according to UNPOP during the time period 2010 - 2060, as plotted in Figure 6.1 which
shows the change in the number of total population size (Left panel in Figure 6.1) as
well as the change in relevant age groups over time (Right panel in Figure 6.1). In the



























































































Fig. 6.1 Changes in the population of Chad during the time period 2010-2060. Left panel:
Total change in population size. Right panel: Evolution of age distribution over time.
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Epidemics of MenA in Chad in the pre-vaccine era occurred every 8-12 years as
previously described in Figure 2.1, which is representative of the epidemiology of NmA
in the African meningitis belt. The introduction of MenAfriVac in that country was
completed in two phases during 2011 and 2012. People between 1 and 29 years of age
in three regions, consisting of 20% of the total population of 1-29 year olds in Chad,
were targeted during the initial phase in 2011 while vaccination of individuals of the
same age group in the rest of the country followed one year later. Figure 6.2 shows
the dramatic effect of vaccination on the annual incidence of suspected and laboratory
confirmed cases of bacterial meningitis per 100,000 in Chad. Note that the incidence
in Figure 6.2 represents all Neisseria meningitidis serogroups and not only serogroup A





































Fig. 6.2 Annual incidence of suspected and confirmed cases of bacterial meningitis per
100,000 in Chad. Year of completion of MenAfriVac initial mass vaccination campaign
indicated by dotted line. Data taken from WHO weekly meningitis reports [1].
For simplicity in the model, I assumed that 50% of those aged between 1 and 29
years of age were targeted in 2011 while the remaining 50% received the vaccine in 2012.
In 2012, those that had not been vaccinated and turned 30 were no longer eligible and
children under 12 months of age in 2011 became available for selection.
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6.3 Immunisation schedules assessed
The scenarios outlined below were elucidated through informal discussions with colleagues
at WHO, PATH and CDC to be of interest. Children and young adults are the people in
the highest risk age groups, as seen in Figure 3.3, and this is why routine immunisation
at 5 and 10 years were chosen as possible alternative strategies. All routine programmes
are assumed to start taking place either 5 or 10 years after the second phase of the initial
mass campaign of 1-29 year olds in 2012. The mass campaigns in 2011 and 2012 are
modelled as discrete time events taking place at one point in time.
Strategy EPI@12m (current strategy)
Start of routine immunisation at 12 months in 2017 together with a mini catch-up
campaign of children aged between 1 and 6 years.
Strategy EPI@5y
Routine immunisation of children when they reach the age of 5 years starting in 2017
(i.e five years after the introduction of MenAfriVac). This five-year delay allows children
to reach the target age group for routine vaccination without having received a vaccine
dose at an earlier age through the initial mass campaign.
Strategy EPI@10y
Routine vaccination targets children when they become 10 years old which is assumed to
start ten years after the completion of the initial campaign (i.e in 2022). No catch-up
campaign is assumed to take place during the period 2012-2022.
Strategy Booster
Starting in 2017, children receive two doses of MenAfriVac. The first one at the age of
12 months followed by a booster dose at the age of 5 years.
Strategy Switch
This scenario aims to reflect what would happen if the current schedule was changed and
routine vaccination started targeting 5 year olds instead of children at the age of one.
In a real life scenario, one would not expect the switch to happen instantaneously and
thus I assumed that for a period of 5 years children are given two doses. One at the age
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of 12 months and a booster dose at the age of 5 years. After this intermediate period
I assume that the dose at 12 months is dropped and only 5 year olds are targeted for
routine vaccination.
6.3.1 Duration of protection
Once the model is developed, the identification of the most effective scenario is not trivial.
Examination of vaccine associated parameters can alter the conclusions regarding the
best long-term strategy. An important vaccine parameter is the duration of protection
offered by MenAfriVac. All the model runs presented in the previous chapters were done
under the assumption that vaccine induced protection lasts for an average of ten years.
To account for the uncertainty around the duration of protection, I ran the model
under four different scenarios:
• 5 years duration of protection for all ages.
• 10 years duration of protection for all ages.
• 20 years duration of protection for all ages.
• 5 years duration of protection for <5 year olds and 10 years duration of protection
for children >=5 years.
6.3.2 Model modification
A model modification was necessary in order to simulate an age-dependent duration of
protection. I added four new compartments to the existing model, namely SE, CE, IE,
RE. These four states represent the susceptible, carriers, diseased and recovered/immune
who receive vaccination at an early age. A list of all the compartments in the model and
their definitions is provided in Table 6.1.
Children vaccinated up to the age of five years, get transferred to those compartments
while children who are targeted after they have had their fifth birthday are moved to the
SV, CV, RV compartments accordingly. For example, during the initial mass campaign,
children in the age groups 1 to 2 year, 2 to 3 years, 3 to 4 years, 4 to 5 years are transferred
to the early vaccination compartments (SE, CE, RE) while individuals between 5 and
29 years of age are moved to the vaccinated compartments (SV, CV, RV). Note that
there is no movement to the IV or IE compartment upon vaccination as I assume that
individuals with meningitis do not receive a vaccine dose. Individuals in the vaccinated
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Compartment name Definition
S Susceptible individuals not vaccinated
C Carriers of NmA not vaccinated
I Individuals with invasive disease not vaccinated
R Immune after colonisation or disease not vaccinated
SE Susceptible individuals vaccinated with MenAfriVacbefore the age of 5 years
CE Carriers of NmA vaccinated with MenAfriVacbefore the age of 5 years
IE Diseased individuals vaccinatedbefore the age of 5 years
RE Immune after colonisation or disease vaccinatedbefore the age of 5 years
SV Susceptible individuals vaccinated with MenAfriVacafter the age of 5 years
CV Carriers of NmA vaccinated with MenAfriVacafter the age of 5 years
IV Diseased individuals vaccinatedafter the age of 5 years
RV Immune after colonisation or disease vaccinatedafter the age of 5 years
Table 6.1 List of the model compartments and their definitions.
states (SE/SV, CE/CV, IE/IV, RE/RV) revert to the equivalent unvaccinated S, C, I, R
states at the age-specific rate depending on the strategy implemented.





β(zj, zk)(Ik + Ck + IVk + CVk + IEk + CEk)
where θ is the stochastic term which changes annually and β(zj, zk) is the transmission
rate between age groups j and k.
The system of differential equations used to simulate each vaccination scenario can
be found in Appendix C.
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6.3.3 Vaccination coverage
According to Gavi’s operational forecast, the coverage in Chad for routine immunisation
of infants starts at 75% in 2017 and continues with annual increments of 1% until it
reaches the 90% mark. It is then assumed to stay constant for the remaining years. This
coverage has been used to generate the results in Chapter 5. However, determining what
the coverage would be if the target age of routine immunisation is 5 or 10 years is not
straightforward since there is no vaccine currently being administered at these ages in
African countries. I explored the impact of vaccination assuming a high coverage of 80%
and a low coverage of 50%.
6.3.4 Measuring vaccine impact
The model is run for the time period 2010-2060 using a daily time step. For each model
run, the number of cases by age is calculated per year. The average number of cases
and the percentage of cases prevented by each of the strategies is calculated over 200
simulation runs per strategy. To account for the uncertainty due to the stochastic nature
of the model, a 95% confidence interval of the mean is also calculated using the t.test
function in R.
To allow for a comparison between the different strategies, the model was set to keep
track of the time to resurgence, median age of infection and the age distribution of cases
for each strategy and for each assumption regarding both the duration of protection and
vaccine coverage. As resurgence I defined the time it takes for the incidence to reach 100
cases.
When comparing vaccination strategies it is important to understand the potential
benefits of each strategy. The number of cases predicted is a measure but it is often not
enough alone. Another helpful measure which illustrates the impact of vaccination on
the population is the number of people needed to vaccinate (NNV) to prevent one case.
NNV as a measure of efficiency has been widely used in the literature [114]. In this case,
NNV is defined as the total number of doses administered divided by the total number of
cases prevented under each vaccination strategy over the time period under consideration.
The total number of doses given for each scenario was calculated by multiplying the total
number of people targeted with the assumed age-specific vaccine uptake. The number of
cases prevented for each scenario is calculated as # cases with no vaccination - # cases
predicted for each scenario.
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6.4 Results
6.4.1 Baseline Scenario (EPI@12m)
Results in this section are in the baseline scenario assuming a mean duration of protection
of 10 years and 80% vaccine uptake for children routinely immunised over the age of 12
months. The numerical results for the different strategies are shown in Table 6.2. The
results in this section are also presented graphically in the following sections which focus on
the comparison of the strategies. The model results suggest that in the baseline scenario,
routine vaccination aimed at school children is not better than routine immunisation of
one year old children. However, switching the age at vaccination from 12 months to 5
years is the single dose strategy with the lowest average number of cases predicted. The
strategy which leads to the largest number of cases averted is the Booster strategy with
a 79.3 (95% CI: 78.7-79.8) predicted overall reduction.
6.4.2 Number of vaccinated individuals
The immunisation schedules under consideration may all start with the same introductory
mass campaign, but the target population for routine immunisation is different. This
leads to differences in the number of people predicted by the model to be in the vaccinated
states and therefore assumed to be protected against carriage and disease. The time-series
plot in Figure 6.3 shows the proportion of people in the vaccinated compartments over
the 50 year time horizon between 2010 and 2060. All strategies start with the same
number of immunised individuals but over time, this changes according to the schedule
and the target population. Longer duration of protection results in a greater proportion
of people in the vaccinated states as they stay there for longer periods. Vaccinated
individuals start appearing in 2011 during the first phase of the MenAfriVac introduction
which is completed the following year. The secondary peak which can be seen in Figure
6.3 in the year 2017 represents the mini-catch-up campaign which takes place at the start
of the routine immunisation of 1 year olds.
6.4.3 Time to resurgence
Figure 6.4 shows the average number of cases predicted during the 50-year period
across the different schedules as well as the different assumptions about the duration of
protection. The scenario in which there is no further vaccination after the mass campaign
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5 years variable duration
10 years 20 years

































Fig. 6.3 Proportion of population vaccinated over time for each vaccination strategy and
for each assumed duration of vaccine protection.
cases are predicted in the year prior to MenAfriVac introduction. This number drops
to 662 (95% CI: 472-852) cases in 2011, the year in which half of the population aged
between 1 and 29 years receive a vaccine dose.
The model also predicts that when the assumed duration is other than 20 years for all
ages, a resurgence always follows the initial mass campaigns. The size of the peak as well
as the year of resurgence both depend on the schedule and the duration of protection. No
cases are predicted for at least 50 years if duration of immunity provided by the vaccine
is assumed to last for an average of 20 years.
Also, the longer the duration of protection, the longer the predicted honeymoon
period is. This can be better seen in Figure 6.5 which shows the total number of cases
plotted against the year of resurgence for each scenario and for the different assumptions
regarding the duration of protection and coverage. Note that the year shown in Figure
6.5 is not the year of the peak but the year in which the number of cases starts to increase
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Fig. 6.4 Average disease incidence across the different vaccination scenarios and across
the different assumptions regarding the duration of vaccine induced protection. Assumed
coverage for schoolchildren vaccination is 80%. Shaded areas represent the 95% confidence
intervals.
following the zero incidence years as a result of the introductory campaign. Also, since
the model does not predict a resurgence when vaccine induced protection is assumed to
last for an average of twenty years, the results for 20 years duration of protection are not
shown in Figure 6.5.
If we assume that the duration of protection is five years regardless of the age at
vaccination, the model predicts that the number of cases will start increasing only ten
years after the introduction of MenAfriVac, compared to 20 years of honeymoon period
when duration of protection is 10 years. However, routine immunisation at 12 months
with a booster dose at 5 years is the strategy with the lowest number of cases predicted.
Earlier resurgence does not necessarily translate to a larger number of total cases. For
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Fig. 6.5 Total number of cases plotted against the year of resurgence across all scenarios
and all assumptions regarding duration of protection and coverage. Each strategy is
represented with a different colour and each assumption about the duration of protection
is represented with a different symbol shape. Symbols not filled with colour represent
the low coverage scenario, that is 50%, while symbols filled with colour represent the
high coverage, i.e 80%. Note that 20 years duration of protection is not shown. Error
bars show the 95% confidence interval.
example, we can look at routine vaccination at either 12 months or 5 years when antibody
response is short lived when children are targeted at the age of 12 months. In both cases,
meningococcal cases start reappearing in 2028 but routine EPI at 5 years results in a
total of 98,194 (95% CI: 96,303-100,086) cases while EPI at 12 months in 151,990 (95%
CI: 149,829-154,151) cases.
6.4.4 Burden of disease
As one might expect, the scenario in which children who are routinely immunised at
the age of 12 months and receive a booster dose on their fifth birthday, results in the
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least number of cases across all different assumptions regarding the duration of antibody
persistence.
Taking into consideration only the single-dose schedules, as can be seen in Figure 6.6,
the model results suggest that if the duration of protection is assumed to be the same for
everyone regardless of at what age an individual is targeted, routine immunisation at 12
months of age is no better than routine immunisation at older ages. There is considerable
overlap in the results but strategy Switch is the strategy with the lowest average number






































































































































































Fig. 6.6 Box plot showing the median, interquartile range, and full range of the predicted
total number of cases for different immunisation strategies in the time period 2010-2060
from 200 simulation runs.
However, looking at the last panel on the right in Figure 6.6, assuming that vaccination
of 1 year olds offers a shorter duration of protection compared to vaccination at older
ages, the predicted number of cases is lower when children at the age of 5 or 10 are
targeted for routine immunisation compared to children who are 12 months old. The
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results for routine EPI at 5 years, 10 years and Switch strategy, all look very similar with
no significant difference in the means (p-value=0.607). This is due to the mini catch-up
campaign, which is present only in the Switch strategy, offering short lived protection
as it targets young children with short lived antibody responses. The effect of the mini
campaign on the results is explored in section 6.4.
Routine vaccination at older ages leaves a lot of children under the age of five
unprotected and as a result, a large number of cases are predicted in that age group,
as can be seen in Figure 6.7. Similarly, more cases in children older than five years
are observed when routine EPI targets one year olds. This is due to waning of vaccine
protection and it can be better seen in the two bottom panels of Figure 6.7, where the
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Fig. 6.7 Box plot showing the median, interquartile range, and full range of the total
number of cases by age group from 200 simulation runs.
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Vaccination programmes raise the average age of infection since young children are
protected against disease. According to Figure 6.8, the strategy with the highest median
age of infection and the lowest number of total cases is the 2-dose strategy which includes
one dose at 12 months of age as well as a booster dose at a later age, when assuming the
duration of vaccine induced immunity is 10 years for all ages.
Routine immunisation at ten years is associated with the lowest median age of
infection due to the large number of unprotected children under the age of ten. It is clear
from Figure 6.8 that the strategy with the highest median age of infection is the routine
immunisation targeting children on their first birthday, with or without a booster dose
when they turn 5 years of age.
Fig. 6.8 Median age of disease plotted against the total number of cases across all scenarios
and all assumptions regarding duration of protection and coverage. Each strategy is
represented with a different colour and each assumption about the duration of protection
is represented with a different symbol shape. Symbols not filled with colour represent
the low coverage scenario, that is 50%, while symbols filled with colour represent the
high coverage, i.e 80%.
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6.4.5 Numbers needed to vaccinate
The initial mass campaign is common for all the scenarios I considered in this chapter.
Assuming 100% coverage, which is consistent with the data, the number of doses given
during the two phases of the campaign was 8,914,813. This was calculated by taking
the number of people aged between 1 and 29 years in Chad in 2011. Note that vaccine
wastage is not included in these calculations. When averaged across 200 simulation runs,
the model predicts a total of 260,758 cases in the absence of any vaccination during the
period 2011-2060. The number of doses together with the number of cases prevented for
each scenario are given in Table 6.3. The number of doses given is not affected by the
duration of vaccine protection but the number of cases predicted by the model is.
Fig. 6.9 Number of doses administered plotted against the proportion of cases prevented
across all scenarios and all assumptions regarding duration of protection and coverage.
Each strategy is represented with a different colour and each assumption about the
duration of protection is represented with a different symbol shape. Symbols not filled
with colour represent the low coverage scenario, that is 50%, while symbols filled with
colour represent the high coverage, i.e 80%.
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An efficient strategy would be the one that prevents the most cases of MenA using as
few vaccine doses as possible.
Assuming that MenAfriVac offers long protection that lasts for an average of 20 years,
all strategies can be considered effective due to the small number of doses needed to
prevent one case. On the other hand, if vaccine induced protection is five years for all
ages, a large number of doses is required per case prevented while the total number of
cases prevented is not the highest either.
Strategy Coverage Duration of protection # of doses(in millions) Cases Cases prevented NNV
EPI@12m estimate 10 years 42.03 86,366 174,392 243 (240-247)
EPI@5y 80% 10 years 33.87 87,622 173,136 198 (195-200)
EPI@5y 50% 10 years 24.51 131,153 129,605 193 (189-198)
EPI@10y 80% 10 years 30.02 87,175 173,583 175 (172-177)
EPI@10y 50% 10 years 22.10 136,277 124,481 182 (178-186)
Switch 80% & estimate 10 years 39.96 77,344 183,414 220 (217-223)
Switch 50% & estimate 10 years 31.37 113,281 147,477 216 (212-219)
Booster 80% & estimate 10 years 63.88 54,092 206,666 311 (307-315)
Booster 50% & estimate 10 years 54.52 69,539 191,219 287 (284-291)
EPI@12m estimate 5 years 42.03 164,537 96,221 450 (438-461)
EPI@5y 80% 5 years 33.87 165,412 95,346 367 (358-377)
EPI@5y 50% 5 years 24.51 188,672 72,086 364 (348-380)
EPI@10y 80% 5 years 30.02 166,190 94,568 329 (320-338)
EPI@10y 50% 5 years 22.10 189,069 71,688 331 (317-344)
Switch 80% & estimate 5 years 39.96 158,594 102,164 401 (392-409)
Switch 50% & estimate 5 years 31.37 179,533 81,225 403 (390-416)
Booster 80% & estimate 5 years 63.88 135,926 124,832 520 (510-530)
Booster 50% & estimate 5 years 54.52 148,420 112,338 498 (486-509)
EPI@12m estimate variable 42.03 148,459 112,299 382 (374-390)
EPI@5y 80% variable 33.87 94,663 166,095 206 (203-209)
EPI@5y 50% variable 24.51 137,679 123,079 204 (199-208)
EPI@10y 80% variable 30.02 96,285 164,473 185 (182-188)
EPI@10y 50% variable 22.10 143,272 117,486 193 (189-197)
Switch 80% & estimate variable 39.96 95,564 165,194 245 (241-249)
Switch 50% & estimate variable 31.37 131,166 129,592 247 (242-252)
Booster 80% & estimate variable 63.88 72,097 188,661 341 (337-345)
Booster 50% & estimate variable 54.52 102,207 158,551 348 (343-353)
EPI@12m estimate 20 years 42.03 658 260,100 162 (160-164)
EPI@5y 80% 20 years 33.87 658 260,100 131 (130-132)
EPI@5y 50% 20 years 24.51 53,500 207,258 119 (118-121)
EPI@10y 80% 20 years 30.02 716 260,042 116 (115-117)
EPI@10y 50% 20 years 22.10 66,580 194,178 115 (113-116)
Switch 80% & estimate 20 years 39.96 658 260,100 155 (153-156)
Switch 50% & estimate 20 years 31.37 1,034 259,724 121 (120-123)
Booster 80% & estimate 20 years 63.88 658 260,100 247 (244-250)
Booster 50% & estimate 20 years 54.52 658 260,100 211 (209-213)
Table 6.3 Number of doses given, number of cases predicted and prevented and number
of doses needed to prevent one case (NNV) under each immunisation strategy for the
time period 2011-2060. Averaged across 200 simulation runs. 95% confidence intervals
for NNV are provided in brackets. The word "estimate" under the coverage column
represents the coverage estimate provided by Gavi which was described in Section 6.3.3.
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6.5 Alternative contact matrices
So far throughout this thesis, the same contact matrix has been used in all the analyses
and no sensitivity analysis on WAIFW matrices has been explored. Here, I attempt to
explore the effects of using two alternative contact matrices on the model outputs. More
specifically, I assume homogeneous mixing and assortative mixing, the structure of which
can be seen in Figure 6.10. Homogeneous mixing assumes a constant transmission rate
independent of age, while by assortative mixing I assume that individuals have higher
contact rates between people of a similar age. More specifically, I assume that the contact
rate between people with an age difference of five years is two times higher that the
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Fig. 6.10 Reperesentation of "who acquires infection from whom" (WAIFW) matrices
for each mixing pattern. a) Homogeneous mixing. b) Assortative mixing. Black colour
indicates twice as high contact rate between people with a five years age difference as
with the rest of the population.
As an initial comparison of the consequences of using a different contact matrix, the
model was run without seasonal forcing. For each WAIFW matrix, I ran the unforced
model for 1,000 different values of the transmission parameter β drawn from a uniform
distribution on the range (1,100) while keeping all other parameters fixed, and calculated
the steady state (S∗,C∗,I∗,R∗). To ensure that the same effective values of β were used,
as β ranged from 1 to 100, the steady state value of I∗ was recorded. Then for each
contact structure, the value of β was found for each the value of I∗ was closest to the value
of I∗ calculated using the adapted WAIFW matrix. The value used for the homogeneous
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mixing was β = 18 and for the assortative mixing was β1 = 13.5 and β2 = 27. The
absolute differences in the values of the endemic steady state of the homogeneous and
assortative mixing with the adapted matrix can be seen in Table 6.4.
S∗ C∗ I∗ R∗
Homogeneous mixing -0.0025 4.63e-05 1.707e-07 0.0025
Assortative mixing -0.0013 1.817e-05 3.865e-07 0.0012
Table 6.4 Absolute amount by which the endemic fixed point of the unforced model with
the adapted WAIFW matrix are smaller than those of the other mixing assumptions.
The model was subsequently run using the chosen transmission parameters for 200
values for the stochastic parameter for each mixing assumption using demographic data
from Chad as discussed in section 6.2. For each run, the age-specific carriage prevalence





























































Fig. 6.11 Box plot showing the median, interquartile range and full range of the age-
specific carriage prevalence during an epidemic peak for different mixing assumptions
from 200 simulation runs.
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For the homogeneous and assortative mixing pattern, carriage prevalence is highest
among younger ages. This is in contrast to data suggesting that carriage prevalence
peaks amongst individuals between 10 and 12 years of age, while it is not very high in
children under the age of 5 years (Figure 3.3).
Time series of disease incidence with and without vaccination for each of the different
contact patterns are seen in Figure 6.12. The results and the different predictions can be
explained intuitively in the following way. The indirect effect of routine immunisation
of one year old children is to raise the average age of infection. The adapted WAIFW
matrix used so far in this thesis assumes that contact is higher among people aged
between 15 and 30 years. Routine vaccination with an average duration of protection of
10 years means that susceptibility increases in the age group with the highest contacts
thus leading to a stronger resurgence than would be predicted with either homogeneous
or assortative mixing.
Campaign and routine Campaigns only No vaccination


























Fig. 6.12 Average disease incidence across the different vaccination scenarios and across
the different assumptions regarding the contact pattern. Averaged across 200 simulation
runs. Shaded areas represent the 95% confidence intervals. The campaign and routine
scenario refers to the strategy EPI@12m.
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6.6 Infant vs school children vaccination
The actual immunisation strategy used in Chad included two campaigns. One introductory
mass campaign of 1 to 29 year olds completed in two phases in 2011-2012 and one catch-up
campaign targeting children between the ages of 1 and 6 years at the start of routine EPI
in 2017. The two campaigns offer very high levels of herd protection making it difficult
to detect the direct effects of routine immunisation. To allow for comparison between
immunising at different ages, I decided to consider a hypothetical scenario in which there
are no campaigns, but instead, MenAfriVac is only routinely given to children aged 12
months, 5 years or 10 years.
To account for the fact that the vaccination of infants may provide a relatively
short-term immune response compared to vaccination of older children, I investigated
the effects of assuming five years of protection for EPI at 12 months.
I ran the model for a period of 50 years starting in 2010 using the demographic
parameters of Chad and I considered the scenarios outlined in Table 6.5. The word
"estimate" under the coverage column in Table 6.5 represents the coverage estimate
provided by Gavi which was described in the methods.
Scenario Start year End year Coverage Duration of protection
EPI at 12 months 2010 2060 estimate 10 years
EPI at 12 months 2010 2060 80% 10 years
EPI at 12 months 2010 2060 estimate 5 years
EPI at 12 months 2010 2060 80% 5 years
EPI at 5 years 2010 2060 80% 10 years
EPI at 5 years 2010 2060 50% 10 years
EPI at 10 years 2010 2060 80% 10 years
EPI at 10 years 2010 2060 50% 10 years
Table 6.5 Complete set of scenarios explored assuming absence of any campaigns.
The results of the comparison of the strategies mentioned above can be seen in Figure
6.13. The numbers which can be seen above the boxplots indicate the values used for the
coverage assumed and also the duration of vaccine induced protection. In the absence
of an initial mass campaign, although there is considerable overlap between the results,
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routine EPI at 10 years is the strategy which leads to the least number of cases, averaged
across 200 simulation runs, when coverage is set at 80%.
Assuming that vaccination at 12 months offers protection for only five years, the light
blue and light green boxplots in Figure 6.13 indicate that routine EPI at 5 years with
only 50% coverage would lead to fewer total number of cases compared to routine EPI at
12 months. This translates to the first strategy being more efficient as it prevents more


























































Fig. 6.13 Estimates of the average number of cases predicted in a scenario with no
campaigns and routine EPI targeting different ages during the time period 2010-2060.
Lighter shades indicate lower coverage. Exact values used for the coverage and duration
of protection can be seen above each boxplot.
According to the computer simulations, routine EPI at older ages is more effective in
reducing the overall number of cases predicted, however, this is done at the expense of
pre-school children. More cases in the under five age group are predicted when routine
immunisation is aimed at 5 or 10 year olds (Table 6.6).







Age of cases in years Total
0-4 5-9 10-29 30+
No vaccination - - 63.3 63.8 121.9 11.9 260.8
EPI at 12 months estimate 10 17.3 21.1 77.4 8 123.9
EPI at 12 months 80 10 20.9 24.7 82.7 8.4 136.7
EPI at 12 months estimate 5 28.5 39.7 109.7 10.3 188.1
EPI at 12 months 80 5 31.7 42 110.9 10.4 195
EPI at 5 years 80 10 34.6 12.6 64.8 7.5 119.5
EPI at 5 years 50 10 45 26.9 86 9.1 167
EPI at 10 years 80 10 30.7 30.4 43 6.7 110.8
EPI at 10 years 50 10 44.1 44.2 71.3 9 168.6
Table 6.6 Computer simulations of age-specific number of cases. Averaged across 200
simulation runs. The numbers of cases are reported in thousands.
6.7 Pentavalent vaccine
Although there has been more than a 99% decline in the number of confirmed Neisseria
meningitidis A cases among countries that have been fully vaccinated with MenAfriVac,
the disease incidence caused by non-A serogroup has increased with an incidence rate
ratio of around 2.5 before and after vaccination [108]. In 2013, Neisseria meningitidis
serogroup C started emerging in Nigeria [69] and is responsible for 8,000 cases and
500 deaths in Niger during the first semester of 2015 [115]. A new pentavalent vaccine
targeting serogroups A, C, Y, W and X is currently in phase 1 clinical trial [116] and
is expected to be available for use by 2022 [117]. Similarly to MenAfriVac, the new
vaccine will be introduced to the population through a mass campaign followed by
infant’s routine immunisation. Work on the design of a new carriage study is ongoing
and the age group targeted for the initial campaign is yet to be determined, although
Gavi considered targeting 1 to 29 year olds or children aged between 5 and 14 years in
its Vaccine Investment Strategy. However, it is worth exploring the potential benefits
and effects on NmA of an additional mass campaign of 1 to 29 year olds taking place a
decade after the first one.
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Fig. 6.14 Comparison of current strategy and vaccination with pentavalent.(a) Number
of people in the vaccinated states over time. (b) Predicted average number of cases per
year from 200 simulation runs. Shaded area identify the 95% confidence interval.
Computer simulations suggest that a mass campaign in 2022 with the new pentavalent
vaccine will prevent a further 35,500 cases assuming that the current strategy continues
unchanged until 2060 and children at the age of 12 months are routinely immunised.
The greatest effect will be in children under the age of ten years, as the number of
cases predicted in that age group will be halved, as shown in Table 6.7. The additional
campaign will further delay the time to resurgence by 15 years (Figure 6.14b). Note that
in Figure 6.14a the two lines initially overlap as vaccination with the pentavalent vaccine
is assumed to take place in 2022.





























Table 6.7 Estimates of age-specific number of cases. Averaged across 200 simulation runs.
95% confidence interval around the mean is given in the brackets.
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6.8 Discussion
The resurgence of meningococcal disease predicted by the model in the previous chapters
has raised doubts about whether targeting infants for routine vaccination is the best way
forward in reducing disease burden in the African meningitis belt. The idea that the
immunisation of school-age children may result in better herd protection is supported
by new studies [75, 76], indicating that protection lasts longer in individuals receiving
MenAfriVac after the age of five years. I used the existing model to assess the impact of
a set of new vaccination strategies and compared them to the actual strategy followed by
the African countries since 2015.
Assuming that the duration of vaccine induced protection is shorter than 20 years,
model results suggest that meningococcal disease cannot be eliminated within the first
50 years after initial vaccination by the current or the new strategies explored. The most
extensive vaccination strategy (the booster strategy) leads to a 79.3% (95% CI: 78.7-79.8)
overall reduction. On the contrary, provided that high antibody levels persist for an
average of 20 years, all strategies, including the current, result in a possible elimination
of MenA cases since there are no predicted cases until at least 2060.
Computer simulations indicate that in the absence of any immunisation campaigns,
routine vaccination of 10 year olds would lead to the smallest average number of cases.
However, including the campaigns, in the case of determining which strategy leads to the
least number of cases, if we assume that the duration of protection is the same regardless
of the age at vaccination, no single-dose strategy was superior to the rest, as there was
considerable overlap in the results and there were no significant differences in their mean
values. This is due to the mini catch-up campaign which is part of only the current
strategy and not the other two (EPI at 5 or 10 years). The main difference in the results
comparing the strategies is in the age distribution of cases. Reductions in the number of
cases in one age group results in a rise of cases in another age group. Routine vaccination
at 12 months offers better protection in young children, whereas vaccination at older
ages reduces disease burden in adolescents and young adults. In the light of new data, if
vaccine protection is short-lived in children under the age of 2 years, the model suggests
that it would be wiser to change the target age of routine immunisation from 12 months
to 5 years.
Based on the number needed to vaccinate (NNV), routine EPI at 10 years is consis-
tently the most effective strategy across all different assumptions about the duration of
vaccine protection. This is due to the small number of doses administered, calculated
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based on the population demography of Chad. The strategy associated with the highest
NNV is the addition of a booster dose. This is not surprising since the number of doses
is almost double that of the rest of the strategies. NNV is widely used in the scientific
literature. The nature of the disease (endemic, epidemic, high/low R0) as well as the way
NNV is calculated can produce biased results [118] and for this reason caution should be
taken when interpreting results or comparing NNVs with other diseases in the scientific
literature. However, the highest NNV value of 485 produced by the computer results if
a booster dose of MenAfriVac is given to five-year-old children is far superior to NNV
2800-3700 estimated by Trotter et al. [119] when evaluating the response thresholds for
reactive vaccination campaigns.
This is the first model to explore the potential benefits of targeting schoolchildren
for routine immunisation with MenAfriVac. As in all mathematical models, there is a
limitation in the uncertainty of the model structure and certain key model parameters. In
this study, I expanded the model I first developed in 2015 and presented in Chapter 3 and
used it to explore a range of new vaccination strategies. The results from this study were
generated using demographic data from Chad, a country lying entirely in the meningitis
belt and which suffered from epidemics every 8 to 12 years before the introduction
of MenAfriVac in 2011. A number of key parameters, such as the transmission rate
and the duration of natural immunity remain unknown and therefore I kept them the
same allowing for a more direct comparison with the original study. As in all age-
structured mathematical models, the mixing patterns are very important and especially
when exploring vaccination strategies that target specific age groups. An exploration
of alternative contact patterns showed that prediction of resurgence is sensitive to the
WAIFW matrix assumed. The results assuming homogeneous and assortative mixing,
however, are not realistic as they do not fit with known patterns of carriage. The carriage
prevalence produced by the model using the adapted WAIFW matrix is consistent with
contact studies in Africa, in which highest intensity of contacts is observed in 5-15
year-olds [120].
The overall conclusion of this study is that none of the strategies explored is superior
in all respects. This is especially true when vaccine induced protection is the same for all
ages. Vaccinating infants offers protection to young children and raises the median age of
infection. However, the NNV to prevent one case is higher than the NNV to prevent one
case when EPI targets 10 year-olds. Leaving children up to the age of ten unprotected,
however, results in more cases in younger ages and less in older age groups. A possible
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change in the current immunisation schedule would have to be based on the prioritisation
of all the above factors.
Since the start of immunisation with MenAfriVac, there is an increased disease
incidence caused by serogroups other than serogroup A. A new pentavalent vaccine is
being developed and has completed phase I trials [116] with the expectation of licensure
in the next three years [117]. I performed computer simulations as an initial attempt to
estimate the potential benefits of an additional mass campaign of 1-29 year olds on NmA
only. The results suggest that such a campaign would have a positive effect especially
on the number of cases in the younger ages. In order to truly estimate the impact of
introducing this new pentavalent vaccine in an already vaccinated population, a more
robust study including a multi-serogroup model should be performed. This will involve a
number of new unknown parameters and further increase the complexity of the model
structure. Data on age-specific contact parameters would be desirable as well as data on
age and serogroup specific case/carrier ratio. Yaesoubi et al. [86] developed a transmission
dynamic model to investigate the cost-effectiveness of alternative vaccination strategies
using the novel multivalent vaccine. All non-A serogroups were pooled into one group
and the scenarios they explored included the replacement of MenAfriVac in the EPI and
either the use of the novel vaccine in reactive campaigns or catch-up campaigns similar
to the introduction of MenAfriVac. The age groups they considered for the campaigns
were 1-29 years and 1-18 years. Yaesoubi et al. concluded that the inclusion of a catch-up
campaign using the pentavalent vaccine is cost-efective and it will also contribute to a
further reduction of meningococcal disease burden.
Despite the limitations of this study and the uncertainty surrounding the introduction
of the pentavalent vaccine in the countries of the African meningitis belt, this analysis
and conclusions drawn can be used in the future by policy makers to support a possible
change in the current immunisation schedule. This change can either be the addition of
a booster dose at a later age or simply the age of the primary dose. Additional work on





7.1 Implications of my research
The plethora of options when designing a new public health intervention makes a
mathematical model a powerful tool for policy makers. Its ability to make predictions
about the progress of infectious diseases allows the evaluation of a wide range of scenarios
that would be otherwise impractical to test in clinical trials. These predictions can be
used to determine the best possible public health action.
Before the development of MenAfriVac, the approach for battling epidemics of
meningitis in the African meningitis belt was based on the use of polysaccharide vaccines
in reactive campaigns. The success of a reactive campaign however, depends on the
early detection of an emerging epidemic as well as the rapid arrival of the vaccine to
the affected areas. This tends to make reactive responses very inefficient. A conjugate
vaccine, like MenAfriVac, could be used in a preventive campaign more efficiently and
with greater success. My research was motivated by the challenges of investigating
potential long-term immunisation strategies with the new conjugate vaccine, MenAfriVac
to achieve its maximum potential.
Building on previous work [82], I developed an age-structured transmission dynamic
model able to describe the epidemiology of NmA in countries of the African meningitis
belt. I considered several different immunisation strategies including the use of the
vaccine solely in an one-off introductory mass campaign of 1 to 29 year olds and showed
that the absence of any long-term vaccination plan could lead to a catastrophic resurgence
of disease.
This result provides the main public health conclusion of this thesis, which is that
failure to introduce MenAfriVac into the countries’ routine immunisation schedule could
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have disastrous consequences. The Expanded Programme on Immunisation (EPI) in
Africa has been continuously improving since its initiation around 40 years ago [121] and
the addition of MenAfriVac to the schedule can only strengthen the current infrastructure
and save even more lives in the high risk areas, as the demand for MenAfriVac may
also drive up measles vaccination coverage. Additionally, MenAfriVac gives an excellent
tetanus boost [68]. Despite the model not being systematically fitted to data, its
predictions were well perceived by WHO’s experts. The results of the model presented
in Chapter 3, accompanied by a cost-of-illness study [96], formed the basis of WHO’s
recommendation concerning the use of MenAfriVac in the African meningitis belt. It
was recommended that countries should introduce the vaccine into routine childhood
immunisation schedule together with a mini catch-up campaign after completing the
initial campaign of 1 to 29 year olds. Up to the time of writing, the majority of the
countries have adopted the recommended strategy.
Continuous monitoring of the situation and updating model parameters as new data
become available may lead to possible future changes in the vaccination strategy, especially
if vaccine-induced immunity is proved to be short-lived for children vaccinated before
the age of two years. The work in Chapter 6 highlighted the effect of the assumptions
regarding the duration of vaccine protection on the model-derived predictions. Assuming
that duration of immunity provided by MenAfriVac varies depending on the age at
vaccination, I showed the potential benefits of either targeting older children for routine
vaccination or adding a booster dose to the current schedule. The caveat of adding a
booster dose is that it will be a more costly intervention, however, it may be the optimal
way to maintain longer-term protection levels.
The use of a model, however, is not limited to the guidance of a new intervention or
the aid with the planning for the response to an emerging disease. The work for VIMC in
Chapter 5 showed how a model can be used to estimate disease burden and assist funders
in monitoring the progress of meeting their set goals. I was asked to provide estimates
on vaccine impact for each of the 26 countries of the African meningitis belt. These
estimates, generated every other year, are used by Gavi and the Bill and Melinda Gates
Foundation to support decision making on future investments as well as to evaluate their
existing vaccination programmes. The number of cases due to meningococcal meningitis
account for only a small fraction of the total number of cases caused by other more
common vaccine-preventable diseases, like measles, in the African nations. The estimates
generated within VIMC are used in cost-of-illness studies which provide information
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about the efficiency of a vaccination policy. These estimates are also used to monitor
Gavi’s progress towards the Decades of Vaccine (DoV) targets.
The VIMC consists of modellers as well as public health representatives. This
strengthens the connection between the two fields which is vital in communicating science
in coherent ways. Accurate description of how the model works and its limitations
is essential to avoid possible confusion about how data should be used. The national
coverage estimates provided by Gavi were adjusted to account for the fact that only a
proportion of a country’s population is at risk. The assumptions behind these adjustments
are not made clear which leads to the next key conclusion from my thesis - the importance
of reproducibility in data science.
The ongoing reproducibility crisis (or replication crisis) the scientific community is
facing is of great concern. Science moves forward by building on existing work by others
and corroboration. However, progress is often obstructed by building on questionable
methods and results. Irreproducible results can arise from either intentional misconduct
[122] or from inaccurate reporting like in the case of Tartof et al. [84]. Specifically
for epidemic models, transparency in reporting the methods and data used is of key
importance to ensure that the results can be replicated by an independent researcher.
Journals have been working on ways to promote transparency by introducing more
rigorous checklists addressing areas of reporting [123].
The work presented in Chapter 4 highlighted the importance of the authors sharing
their computer code when questions regarding the validity of the results arise. Sharing
the code however does not imply that all issues are immediately resolved. Reproducing
the findings of a published paper can be a very time-consuming process [123]. Researchers
may use different programming languages or a specific software may be essential to run a
code on a computer. Further, researchers are not software engineers and this means that
their code may not be perfect and a lot of time is needed to clean it. This is one possible
explanation as to why few researchers publish their codes together with the papers.
7.2 Limitations and future directions
My models only consider carriage and disease solely due to Neisseria meningitidis
serogroup A. I assume that cycles of NmA are independent of the other serogroups, i.e.
in this model there is no potential for serogroup replacement. The protection of people
against the dominant type (selective nature of vaccine protection), allows serogroups with
previously low prevalence to grow rapidly [124] and lead to a possible strain replacement
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[125]. This phenomenon is known as vaccine-induced pathogen strain replacement [126].
After the successful vaccination with MenAfriVac, prevalence of NmA dropped while there
have been outbreaks caused by serogroups W and C [69, 70] creating a new public health
problem. However, genetic epidemiology studies guided WHO to state that MenAfriVac
was unlikely to have driven replacement with group C [127].
Evaluating a totally new vaccine can be challenging. Although my models are
single-strain models focusing only on NmA, insights gained into the potential impact of
vaccination aimed at different ages can be used to guide the design of new carriage studies.
Results from these studies can then be fed into a more complex multi-strain model, more
suitable for the evaluation of impact of the novel polyvalent vaccine. Van Effelterre et al.
[128] developed a multi-strain model to reproduce serogroup specific changes in invasive
pneumococcal disease since vaccination with the 7-valent pneumococcal conjugate vaccine
(PCV7). This model focuses only on <2 year olds and therefore does not account for
herd immunity. Previous models describing the impact of vaccination on Neisseria
meningitidis, including the most recent model by Yaesoubi et al. [86], have pooled all
serogroups into two or three groups [80, 129]. However, this aggregation may have an
impact on the predictions regarding the effectiveness of vaccination [130]. Thus, although
my model is not fully comprehensive of Neisseria meningitidis dynamics, it is sufficient
to answer the research question posed.
The work presented in Chapter 5 is based on the stratification of the countries into
high-medium-low incidence countries. This classification was deemed necessary as there
are insufficiently high quality surveillance datasets over a long period of time to allow
the parameterisation of the model on a country-to-country basis. This is the best we can
do with current data sources. As a result, key parameters such as the transmission rate
and duration of colonisation are difficult to obtain estimates for. With incidence data
limited to annual observations, direct estimation of model parameters is complicated.
Other approaches have been published, e.g. Yeasoubi et al. [86] developed a model
disaggregated by districts and used weekly incidence data on a district level. This district
level data was not available to me and I was addressing different question, so this was
less appropriate.
My initial attempts at model fitting have been made using two long incidence time
series from Burkina Faso and Chad. No results from these attempts have been formally
incorporated into the model as the model fits appeared to have identifiability issues.
These issues could be ameliorated by an estimate of the R0 by re-examining all data
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available. This estimate together with a more recent carriage prevalence curve could be
incorporated into a formal model fitting process.
The results from Chapter 5 highlighted the importance of demography and contact
patterns. Shifts in demography were shown to have an effect on disease incidence even
in the absence of vaccination. This finding is consistent with the results from a study
investigating the effects of demographic changes in disease transmission which showed
that lower fertility levels lead to an increase in the average age at infection [131]. I
made assumptions about the contact patterns in my models. Using empirical data on
age-structured contact patterns would test the validity of my findings. To my knowledge,
none is yet available for the African meningitis belt countries. If further studies to be
conducted, the type of contact measured should be relevant to NmA, that is, close and
prolonged contact is necessary to transmit the bacteria from one person to the other.
An area of improvement to my work for the VIMC is the development of sub-national
models for countries that are only partially at risk. Countries like Nigeria and Cameroon
for example, introduce MenAfriVac through mass immunisation campaigns into part of
the country while they are planning to implement nationwide routine vaccination. This
heterogeneity in vaccine implementation should be captured in the model. Models at a
finer scale have been motivated by the need to support decision making at a province
level [132] or to investigate implications of spatial heterogeneity in vaccination coverage
[133]. Any spatial model aiming to investigate the impact of sub-national campaigns
with either MenAfriVac on the new pentavalent vaccine should allow for connectivity
between regions and/or other countries.
Genomic studies have illustrated the global spread of different strains of meningococci
[134, 135]. Serogroup W strain causing epidemics in sub-Saharan Africa since 2001 has
been shown to be closely related to a Hajj-associated outbreak of MenW disease in 2000.
This Hajj strain has subsequently been detected in isolates from France and Turkey. A
distinct from the Hajj outbreak serogroup W strain is currently endemic in South America,
England and Wales [134]. International human movements are therefore important in
meningococcal epidemiology. In my model I have not allowed for any migration or sort
term travel from one country to the other and have treated each country as a closed
population. The impact of migration could be explored with the addition of an external
force of infection, such as the one used by Tartof et al. in their model [84]. Disease is
transmitted from asymptotic carriers and results from studies estimating overall carriage
prevalence in the African nations vary in the range 3.5%-35% [18]. This wide range in
carriage prevalence estimates makes it not possible to accurately quantify an external
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force of infection. The key reason for not using any external force of infection in the model
is that the vast majority of cases of Neisseria meningitidis serogroup A are concentrated
in the countries of the African meningitis belt and only rare sporadic cases occur in the
rest of the world. All the high incidence African countries implement vaccination with
MenAfriVac in a period of 5 years resulting in the eradication of serogroup A cases from
vaccinated populations. I assumed therefore that the potential transmission from outside
of the country is negligible and was not included in the model in the form of a constant
external force of infection.
7.3 Conclusion
Mathematical models are extremely valuable for the evaluation of current and future
vaccine interventions. This thesis demonstrated two different ways a mathematical
model can be used to support decision making. I developed a model to advise on future
vaccination plans with MenAfriVac by evaluating the impact of a range of possible
immunisation strategies and applied it to estimate disease burden across all the countries
of the African meningitis belt. Mathematical models should be integral to informing
policy makers for the development, investment and implementation of any new vaccine.
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Appendix A
The derivation of the model has three parts. Firstly, the equation of age dependent
population growth, the Lotka-McKendrick model, is defined. Secondly, expressions for
the sizes of each age group are derived. Finally, age groups are incorporated into the
model.
A.1 Age-dependent population growth
Let U(z, t) be a function describing the distribution of ages in a population, so that at








Let the age-specific mortality rate be denoted by d(z) > 0. Then the dynamics of the
age distribution are described by the Lotka-McKendrick model [136], also known as the







= −d(z)U(z, t). (A.3)
The boundary condition of the Lotka-McKendrick model A.3, U(0, t), is the birth
rate B(t), given by




where f(z) is the age-specific fertility rate.
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A.2 Initial sizes of age groups
In order to allow for a comparison with actual data, it is more convenient to use an
alternative representation of the age-structured model, where rather than consider age in
population as a continuous variable, the population is divided into n age classes, with
the jth class covering the age range [zj−1, zj] for 0 = z0 < z1 < z2... < zn−1 < zn = ∞.
It is assumed that all individuals in the age range [zj−1, zj] have the same death and
fertility rates as someone with age zj, so for z ∈ [zj−1, zj], d(z) = d(zj) and f(z) = f(zj).
Denote the size of the jth age group at time t as Nj(t), and at time 0 as Pj (= Nj(0)),





As previously discussed, the age distribution is assumed to be stationary with the
total population increasing at a rate q, that is,
U(z, t) = eqtA(z). (A.6)




U(z, t)dz = eqt
∫ zj
zj−1
A(z)dz = eqtPj, (A.7)
so each age group is growing, but the proportion of the total population that is in each
age group remains constant.
To define the initial population sizes Pj, substitute the expression for the time-




+ qeqtA(z) = −d(z)eqtA(z) ⇒ dA
dz
= A(z)[−q − d(z)]. (A.8)
Since d(z) is constant in the interval [zj−1, zj ], integrating Equation (A.8) on that interval
gives, for z ∈ [zj−1, zj],
A(z) = C exp(−z(dj + q)) (A.9)
where C is a constant that is found by evaluating A(z) at z = zj−1:
A(zj−1) = C exp[−zj−1(dj + q)] ⇒ C = A(zj−1) exp[zj−1(dj + q)]. (A.10)
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Thus the relative population densities at ages z and zj−1 are
A(z) = A(zj−1) exp[−(dj + q)(z − zj−1)]. (A.11)
By integrating this on [zj−1, zj] again, the expression for the initial size of the jth age

























[1 − exp[−(dj + q)(zj − zj−1)]] . (A.16)
Notice that, from (A.11), it follows that
A(zj−1) − A(zj) = A(zj−1)(1 − exp[−(dj + q)(zj − zj−1)]), (A.17)
which can now be written as
A(zj−1) − A(zj) = Pj(dj + q). (A.18)
Next, the rate of progression between age groups is defined. Let the constants Kj be
the rates at which people move from age group j to the age group j + 1. This is given by
the proportion of the people in the age group who have age j. If the age distribution
were flat, this would be given by 1/(zj − zj−1). However, this is not the case here, so a








By substituting the expression for Pj from (A.16) and A(zj) from (A.11) evaluated at zj ,







A(zj−1) [1 − exp[−(dj + q)(zj − zj−1)]] /(dj + q)
(A.21)
= A(zj) exp[−(dj + q)(zj − zj−1)]
A(zj−1) [1 − exp[−(dj + q)(zj − zj−1)]] /(dj + q)
(A.22)
= (dj + q) exp[−(dj + q)(zj − zj−1)]1 − exp[−(dj + q)(zj − zj−1)]
(A.23)
= (dj + q)exp[(dj + q)(zj − zj−1)] − 1
. (A.24)
A.3 SCIRS model with continuous age distribution

























r = ρi + αc − (φ + d(z))r, (A.28)
where λ(z, t) is the age-specific force of infection, d(z) is the age-specific mortality rate,
and s, r, c and i be, respectively, the density of people who are susceptible, immune,
asymptomatic carriers, or have meningitis. The birth rate is described by the boundary




f(z)[s(z, t) + c(z, t) + i(z, t) + r(z, t)]dz, (A.29)
c(0, t) = i(0, t) = r(0, t) = 0. (A.30)
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A.4 SCIRS model with discrete age groups
Finally, the methodology explained in Section A.2 can be used to derive the age-group
representation of model A.25 - A.28. The number of susceptibles in the jth age class





and likewise for cj(t), ij(t) and rj(t). Analogously to the definition of Kj in A.19,
s(zj ,t)
sj
= Kj, c(zj ,t)cj = Kj etc., since people all age in the same way regardless of their
infection status.
Consider initially the equation A.25, for 2 ≤ j ≤ n. Differentiation of A.31 and


















= φrj(t) − (λj + dj)sj(t) − s(zj, t) + s(zj−1, t) (A.34)
= φrj(t) − (λj + dj + Kj)sj(t) + Kj−1sj−1(t). (A.35)
Since the age-distribution is stationary and the number of people in each age group is
growing exponentially, it is more straightforward to work with not the absolute number of
people that is in each compartment, sj, cj , etc., but rather the proportion of the age group
that is in each compartment, Sj, Cj, etc. This is done by normalising the age-dependent











































[φrj(t) − (λj + dj + Kj)sj(t) + Kj−1sj−1(t) − qsj(t)] (A.40)
= φRj(t) + Kj−1Sj−1(t) − (λj + dj + Kj + q)Sj(t). (A.41)
This is valid for 2 ≤ j ≤ n. However, S0 and K0 are currently undefined. People enter








dz = s(z1, t) − s(z0, t) (A.42)
= K1s1 − s(0, t), (A.43)
where s(0, t) is the birth term A(0). An alternative expression for A(0) can be derived
from A.18,
A(z1) − A(z0) = −P1(d1 + q) (A.44)
A(z0) = A(z1) + P1(d1 + q) (A.45)
A(0) = K1P1 + P1(d1 + q) (A.46)
= (K1 + d1 + q)P1, (A.47)
so the birth rate is (K1 + d1 + q)P1, therefore
dS1
dt
= φR1(t) + (K1 + d1 + q)P1 − (λ1 + d1 + K1 + q)S1(t). (A.48)






are derived in a similar way.




β(zj, zk)(Ik + Ck) (A.49)
where β(zj, zk) is the contact rate between people in the jth and kth age classes.
The complete age structured SCIRS model is therefore given by the following system
of coupled ordinary differential equations:
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dS1
dt
= (K1 + d1 + q)P1 + φR1 − (λ1 + d1 + K1 + q)S1 (A.50)
dSj
dt
= Kj−1Sj−1 + φRj − (λj + dj + Kj + q)Sj, 2 ≤ j ≤ n (A.51)
dC1
dt
= λ1S1 − (a + α + d1 + q + K1)C1 (A.52)
dCj
dt
= Kj−1Cj−1 + λjSj − (a + α + dj + q + Kj)Cj, 2 ≤ j ≤ n (A.53)
dI1
dt
= aC1 − (ρ + d1 + q + K1)I1 (A.54)
dIj
dt
= Kj−1Ij−1 + aCj − (ρ + dj + q + Kj)Ij, 2 ≤ j ≤ n (A.55)
dR1
dt
= ρI1 + αC1 − (φ + d1 + q + K1)R1 (A.56)
dRj
dt
= Kj−1Rj−1 + ρIj + αCj − (φ + dj + q + Kj)Rj, 2 ≤ j ≤ n (A.57)
where Kj = 0.
A.5 Calculation of the age distribution
The age-dependent mortality rates dj and the population growth rate q can be estimated




exp[(dj + q)(zj − zj−1)] − 1
. (A.58)
To calculate the initial sizes of the age groups, Pj, recall from A.18 that
A(zj−1) − A(z) = Pj(dj + q). (A.59)
Then, using the definition of Kj from A.19,
Kj−1Pj−1 − KjPj = Pj(dj + q) (A.60)
Pj(Kj + dj + q) = Kj−1Pj−1 (A.61)
Pj =
Kj−1Pj−1
Kj + dj + q
, for j ≥ 2. (A.62)
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Iterating this from j = 2 gives
Pj =
Kj−1Kj−2...K1P1
(Kj + dj + q)...(K2 + d2 + q)
. (A.63)
The values of Pj can be found by choosing an arbitrary P1, calculating the other Pj
from A.62 and then normalising each by their sum. Note that since Sj, Cj, Ij and Rj
are already normalised as the proportion of the initial population, the sum of these
proportions, ∑j[Sj(t) + Cj(t) + Ij(t) + Rj(t)], will remain 1 throughout the duration of
each simulation.
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A.6 Parameter values used in Chapter 3
Age Group K d a
0-3 months 3.9415673 0.08654 0.15535
3-9 months 1.9418546 0.08654 0.15535
9-12 months 3.9415673 0.08654 0.15535
1-4 years 0.22615 0.01842 0.1434
5-9 years 0.183166 0.00377 0.0956
10-14 years 0.184199 0.00158 0.08365
15-19 years 0.183713 0.00261 0.0717
20-24 years 0.183208 0.00368 0.0478
25-29 years 0.182991 0.00414 0.03585
30-34 years 0.182921 0.00429 0.0239
35-39 years 0.182582 0.00501 0.0239
40-44 years 0.182187 0.00585 0.01195
45-49 years 0.18125 0.00785 0.01195
50-54 years 0.179814 0.01093 0.01195
55-59 years 0.176913 0.0172 0.01195
60-64 years 0.173196 0.02534 0.00239
65-69 years 0.165751 0.04202 0.00239
70-74 years 0.153113 0.07159 0.00239
75-79 years 0 0.2 0.00239
Table A.1 Parameter values for the age-dependent mortality rate, dj, the age-dependent
rate at which carriers develop disease, aj and the rates of progression between age groups,
Kj used in the model simulations in Chapter 3. The transfer rates Kj, were calculated
from A.58. All units are year−1.
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S U P P L E M E N T A R T I C L E
Modeling Long-term Vaccination Strategies With
MenAfriVac in the African Meningitis Belt
Andromachi Karachaliou,1 Andrew J. K. Conlan,1 Marie-Pierre Preziosi,2,3 and Caroline L. Trotter1
1Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, United Kingdom; 2Meningitis Vaccine Project, PATH, Ferney-
Voltaire, France; and 3Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African
meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A
(MenA). It is important to consider how best to sustain population protection in the long term.
Methods. We created a mathematical model of MenA transmission and disease to investigate the potential im-
pact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and
immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic
forcing term that models between year variation in rates of transmission. Model parameters were primarily derived
from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with
irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses.
Results. Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease
control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approxi-
mately 15 years (assuming 10 years’ average vaccine protection). Routine immunization at 9 months of age resulted
in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above
approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was
achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months,
5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds.
Conclusions. These results can be used to inform policy recommendations for long-term vaccination strategies
with MenAfriVac.
Keywords. meningitis; vaccine; Africa; mathematical modeling.
The African meningitis belt suffers from frequent large
epidemics of meningococcal meningitis. A novel vac-
cine against Neisseria meningitidis group A (MenA),
the major cause of epidemic meningitis, was developed
through the Meningitis Vaccine Project (MVP), man-
ufactured by the Serum Institute of India, Ltd [1]. The
vaccine, known as MenAfriVac, was first introduced
into Burkina Faso, Mali, and Niger in 2010 in mass
immunization campaigns targeting 1- to 29-year-olds.
MenAfriVac continues to be rolled out across the region,
and >217 million individuals have been immunized to
date. These campaigns have been remarkably successful
in the short term in reducing the incidence of meningitis
and the prevalence of MenA carriage, as shown in
Burkina Faso [2, 3] and Chad [4]. To ensure that this
success continues, long-term immunization strategies
are required to maintain population protection.
Computational models have become an important
tool for vaccine policy makers. By simulating the im-
pact of a vaccine in silico, a wide range of vaccine strat-
egies can be explored and the sensitivity of their
predicted impact to structural and parameter uncer-
tainty can be understood. Transmission dynamic
models are essential to quantify both the direct and
indirect (herd protection) effects of vaccination pro-
grams. For meningococcal infection, most transmis-
sion occurs between asymptomatic carriers, so any
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model attempting to capture the transmission dynamics of
meningococci must essentially include the carrier state. This
is especially relevant when considering the impact of MenAfri-
Vac, given the evidence that MenA carriage is much reduced
following MenAfriVac introduction [2, 4]. This is likely to give
rise to large indirect vaccine effects, as seen with other con-
jugate vaccines [5]. Other key features of the epidemiology of
MenA in the African meningitis belt must also be incorporat-
ed, which include the periodic but irregular nature of epidem-
ics of varying size; the seasonality of meningitis with epidemics
occurring in the dry season and dying out with the onset of the
rains [6]; and the variation in disease risk [7] and carriage prev-
alence [8] by age.
A range of transmission models for meningococcal infection
has been developed [9–11]. Only 2 have specifically examined
MenA in the African meningitis belt. Irving et al [12] explored
the potential mechanisms underlying the striking epidemiology
in this region, showing that the complex and irregular timing of
epidemics could be explained by the interaction of temporary
immunity conferred by carriage of the bacteria together with
seasonal changes in the transmissibility of infection. Tartof
et al [13] used a transmission model to investigate different
strategies using MenAfriVac.
Here we extend the transmission models of Irving et al [12]
by addressing some of the limitations (such as the lack of age
structure and wide parameter space considered), and incor-
porating vaccination. We utilize recently available MenA/
MenAfriVac specific parameters and apply the model to in-




We developed a compartmental model that divides the popula-
tion into the following states: (1) susceptible, (2) carrier of
MenA, (3) disease due to MenA, and (4) recovered and im-
mune, based on our previous investigations of simple determin-
istic models [12], and in vaccinated populations a mirror of
these 4 states (Figure 1). The population is further structured
by age into 19 age groups: 0 to <3 months, 3 to <9 months, 9
to <12 months, 1–4 years, 5–9 years, and 5-year age groups to
age 80 years subsequently, with continuous aging between
groups (rates of aging from one age group to another are
given in Supplementary Table 1). The proportion of the popu-
lation that is in each age group does not change over time.
Vaccination was implemented in different ways according to
the strategy used (Table 1). For mass vaccination campaigns, we
assumed that immunization occurred as a discrete event at one
point in time, whereas routine immunization was implemented
continuously as individuals reached the target age for the Ex-
panded Programme on Immunization (EPI). The narrow age
groups in <1-year-olds allowed routine vaccination to be imple-
mented at different ages.
An important feature of the meningitis belt is the prominent
seasonality [6] of disease, which we implemented through sea-
sonal forcing of the transmission and invasion rates using a si-
nusoidal function [12]. The baseline transmission rate was
varied stochastically drawing from a uniform distribution be-
tween 0.8 and 1.2 (ie, ±20%) each year to reflect between-year
variation in transmission due to climatic [14] or other external
Figure 1. Diagram of the model for Neisseria meningitidis group A transmission and disease. Each compartment is divided into distinct age classes (not
shown). See Table 1 for definition of parameters and Supplementary Material for the full model structure.










variability. To examine the sensitivity of results to this model
structure, we introduced stochasticity in an alternative way,
with weekly variation in transmission rates, drawn from the
same uniform distribution (0.8–1.2). This “noisy” model used
a method similar to the stochastic mechanism used by Tartof
et al [13], but with the stochastic term drawn from a narrower
range.
Full details of the model structure are given in the Supple-
mentary Material, section A.
Model Parameters
Model parameters (Table 2) were based on the available litera-
ture, and African data wherever possible. Demographic para-
meters were based on Burkina Faso, a country at the heart of
the meningitis belt. Different “who acquires infection from
whom” (WAIFW) matrices were used and compared. In the ab-
sence of empirical data on population contact patterns, we used
evidence on the age distribution of carriers during an MenA ep-
idemic to inform these matrices [20]. The WAIFW matrix used
is shown in Supplementary Figure 1; contacts are more intense
between individuals in the same age group and particularly so
for older children and young adults. It was necessary to estimate
values for some parameters where direct evidence was lacking.
In exploring the parameter space, it was apparent that there was
a strong co-linear relationship between the transmission rate
and duration of colonization. Direct estimation of model pa-
rameters is complicated by the intractability of the likelihood
function for this model and the limitations of available inci-
dence data. As a first exploration of model behavior to guide
Table 1. Vaccination Strategies Considered









of 1- to 29-year-olds
Periodic mass





of 1- to 29-year-olds
Routine EPI at 9 mo, 5 y
after introduction
D. Combination Mass immunization
of 1- to 29-year-olds
Routine EPI at 9 mo, 5 y
after introduction,
plus catch-up for 1- to
4-year-olds
Abbreviation: EPI, Expanded Programme on Immunization.
Table 2. Model Parameters
Parameter
Parameter
Name Value Unit Comment [Reference]
Mortality rate d Age-specific Years−1 Census reports (Supplementary Table 2)
Recovery rate from disease ρ 52 Years−1 Disease lasts about a week [15]
Rate of loss of carriage α 12 Years−1 Only 1 study identified, suggesting 1-mo duration of
MenA [16]
Transmission rate β0 10.5 . . . Estimate
Rate at which carriers fall ill a Age-specific Years−1 Systematic review of case: carrier ratios [17], age-
specific parameters estimated (Supplementary
Table 3)
Rate of loss of immunity ϕ 0.0839 Years−1 Estimate, based on previous findings [12]
Seasonal forcing of transmission rate ɛβ 0.6 . . . Estimate, based on previous findings [12]
Seasonal forcing of invasion rate ɛa 0.6 . . . Seasonality in invasion rate based on published
systematic review [17]
Annual growth rate q 0.0309 Years−1 Census reports
Rate of progression between age groups K Age-specific Years−1 Estimated using mortality rates and annual population
growth rate (Supplementary Table 2)
Vaccine efficacy against carriage δ 0.6–0.9 Proportion Range explored, 0.9 from [4]
Vaccine efficacy against disease ξ 0.6–0.9 Proportion Range explored, 0.9 from [4]
Carriage clearage upon vaccination σ 0.9 Proportion Unknown, effect explored in sensitivity analysis
Waning of vaccine protection w 0.1 Years−1 Consistent with findings from unpublished MVP trials.
Varied in sensitivity analysis
Vaccination coverage for initial mass
campaign
vA 0.95 Proportion Coverage surveys [18, 19]
Vaccination coverage for additional mass
campaigns
vB 0.6–0.8 Proportion Unknown, range explored. 80% used in base case
Vaccination coverage for EPI vC 0.5–0.8 Proportion Range taken from typical EPI coverage in meningitis
belt countries. 80% used in base case
Abbreviations: EPI, Expanded Programme on Immunization; MenA, Neisseria meningitidis group A; MVP, Meningitis Vaccine Project.










inference, we found a number of different plausible combina-
tions of parameter values for the transmission rate and duration
of natural immunity, which were able to produce realistic results
when used in our model and defined a possible range for the
unknown parameters.
Model Implementation
The model was coded and run using the R package version
3.1.0, using the package deSolve to perform the numerical inte-
gration of differential equations. The time step was 1 day. For
each simulation, we ran the model for a 20-year burn-in period
before implementing the initial mass vaccination campaign in
year 0. The model was then run for a further 40 years; all results
are reported for this 40-year period. For each vaccination strat-
egy, the average of 300 simulations was taken; this was based on
a comparison of between 100 and 500 simulations that showed
very small marginal differences between 300 and 500 simulations.
Vaccination Strategies
We considered a range of long-term vaccination strategies and
compared these to a scenario without any vaccination and with
only an initial mass vaccination campaign of 1- to 29-year-olds
(Table 1). We also investigated the sensitivity of the results to
changes in the age at EPI immunization and the coverage
achieved for EPI immunization at 9 months.
RESULTS
Base Case
In the absence of preventive vaccination, the model was able to
capture the distinctive epidemiology of meningococcal infection
in the meningitis belt. A typical model run, with irregular epi-
demics of varying size, is shown in Figure 2.
Following initial mass vaccination of 1- to 29-year-olds, the
model predicted a resurgence in disease after approximately 15
years, assuming an average of 10 years of vaccine protection
(Figure 3).
Of the long-term immunization strategies considered, all
were effective in maintaining control of disease. There was con-
siderable overlap in the distribution of results (Figure 4), but
routine EPI immunization at 9 months of age (strategy C) re-
sulted in lower average annual incidence than regular mass
campaigns of 1- to 4-year-olds (strategy B) under base case as-
sumptions. Strategy C was superior to strategy B provided that
EPI coverage was above approximately 60% (Table 3). The strat-
egy with the lowest overall average annual incidence and longest
time to resurgence was introduction into EPI at 9 months, 5
years after the initial mass campaigns, with a catch-up targeting
unvaccinated children aged 1–4 years (strategy D).
Sensitivity Analyses
We investigated the effect of changing some key model param-
eters and assumptions. In the absence of any long-term immu-
nization (strategy A), assuming a shorter duration of protection
resulted in disease incidence increasing more quickly; with 5
years of vaccine protection, the resurgence occurred after
around 10 years (not shown).
For strategy C (routine EPI), as expected, as EPI coverage in-
creased, the incidence of disease decreased (Table 3). For every
10% increase, the average annual incidence decreases by
Figure 2. A typical run of the Neisseria meningitidis group A transmis-
sion model.
Figure 3. Results from 300 simulations of the initial mass immunization
of 1- to 29-year-olds (implemented in year 0). The black dashed line depicts
the mean annual incidence.










approximately 1 case per 100 000 population per year. Also
consistent with expectations, disease control was better when
vaccine effectiveness was higher (not shown).
We observed only marginal differences by varying the age
at which routine MenAfriVac was given. The average disease
incidence across all ages decreased as the age at immunization in-
creased from 3 to 9 to 12 months of age. However, there were more
cases in infants as the age at routine immunization increased.
When averaged across 300 simulations, when MenAfriVac
was given routinely at the age of 3 months, the model predicts
an average annual incidence of 5.43 cases per 100 000 popula-
tion per year in all ages and 4.67 cases per 100 000 individuals in
infants, compared with the base case of immunization at 9
months (average incidence of 5.31 cases/100 000 across all
ages and 8.77 cases/100 000 infants). Immunizing within EPI
at 12 months of age results in an average annual incidence of
5.18 cases per 100 000 population, but 10.53 cases per 100 000
in infants.
The model results were insensitive to changes in the assump-
tion of vaccine effectiveness against disease (ξ) when vaccine ef-
fectiveness against carriage (δ) was high (90%), because in this
situation, carriage acquisitions were rare and so few people were
at risk of disease downstream. Because it is unclear whether the
vaccine can clear an episode of carriage, we also investigated the
sensitivity of the results to changes in clearance upon vaccination.
In the base case, we assumed that 90% of the carriers recover im-
mediately after vaccination; when this proportion was changed to
10%, we found that the results were insensitive to the change.
The duration of natural immunity following carriage or dis-
ease is not known. In the base case, we assumed on average ap-
proximately 12 years’ duration of immunity. When this was
lowered to 7 years, keeping other parameters fixed, the inci-
dence of disease under all scenarios was higher. However, the
relative ranking of each strategy did not change.
The sensitivity of our results to changes in the model struc-
ture were also investigated. The results from the “noisy” model
in which the transmission rate varied stochastically each week
were very similar to the results presented above.
Figure 4. Box plot to show the median, interquartile range, and full
range of the predicted annual incidence per 100 000 for different immuni-
zation strategies in the 40 years following vaccine introduction from 300
model simulations.
Table 3. Estimated Average Annual Neisseria meningitidis Group A Incidence per 100 000 in the 40 Years Following Vaccine Introduction































Plus EPI at 9 mo
and 1–4 y
Catch-up
<1 40.32 27.71 14.87 12.49 10.52 8.77 13.52 7.50
1–4 37.38 25.82 10.12 7.94 6.04 4.43 7.15 3.80
5–9 42.54 28.76 13.26 10.92 8.82 6.92 10.00 5.91
10–14 38.61 26.82 14.66 12.57 10.59 8.71 11.48 7.43
15–19 32.14 23.05 14.86 13.24 11.60 9.96 12.10 8.51
20–24 19.18 14.06 9.89 8.99 8.03 7.05 8.26 6.07
25–29 11.20 8.36 6.02 5.51 4.94 4.36 5.10 3.80
≥30 3.18 2.35 1.55 1.39 1.23 1.07 1.30 0.94
All 24.45 17.06 9.01 7.69 6.46 5.31 7.12 4.56
Unless otherwise stated, the coverage attained in the initial mass campaign among 1- to 29-year-olds was 95%, and routine and subsequent catch-up coveragewas
80%.
Abbreviation: EPI, Expanded Programme on Immunization.











We developed a model of MenA transmission and disease that
was able to describe the epidemiology observed in the African
meningitis belt. We simulated the impact of the initial mass
vaccination campaigns of 1- to 29-year-olds and predicted a
period of very low incidence for at least 10 years, even when
assuming a relatively short duration of protection. The indirect
effects of the vaccine were clearly important in maintaining
this low incidence postintroduction; we assumed a high degree
of protection against carriage, consistent with the observed
data [2, 4]. Following this honeymoon period, the model pre-
dicted a strong resurgence in disease incidence if there was no
long-term immunization strategy. Of the long-term strategies
we investigated, a combination strategy of routine EPI vaccina-
tion after 5 years together with a catch-up campaign targeting
children aged 1–4 years who were born after the initial cam-
paigns was the most effective, although there was considerable
overlap in the distribution of results for different strategies.
Routine EPI alone appeared to be more effective than periodic
mass campaigns, unless EPI coverage was low (less than approx-
imately 60%). The model findings, in addition to comprehen-
sive information from clinical trials in children aged <1 year
were presented to the World Health Organization’s Strategic
Advisory Group of Experts (SAGE) on immunization in Octo-
ber 2014 [21].
These findings suggest, first, that it is essential to implement a
long-term strategy for the continued use of MenAfriVac. It is
not sufficient for the vaccine only to be used in a large one-
off campaign, as this may result in catastrophic resurgences in
disease 10–20 years after vaccine introduction. All of the long-
term strategies considered were effective in maintaining disease
control, although for all strategies incidence was predicted to
rise over the long term as population immunity from the initial
campaigns waned. The inclusion of MenAfriVac into the rou-
tine EPI as a single dose at 9 months of age has the obvious ad-
vantage of using and likely strengthening existing infrastructure.
The option to conduct periodic campaigns may, however, pro-
vide better disease control for those countries with very poor
routine EPI uptake. The combination strategy of introduction
into routine EPI with a one-off catch-up campaign targeting
those born since the initial campaign was the most effective
and also the most equitable option. Indeed, SAGE recommend-
ed that countries should adopt such a strategy within 5 years of
campaign completion [22].
Our work has several strengths and limitations. Our model
structure was based on extensive previous work that used a
range of deterministic models, to explore the importance of sea-
sonality and immunity following colonization [12]. As such, we
feel we have good understanding of the underlying system dy-
namics. We extended these models to incorporate age structure
and vaccination, and included a stochastic term so that the ex-
tent of seasonal forcing varied from year to year, to capture the
effect of external forces (including, eg, dust or humidity condi-
tions) [23].We parameterized the model using appropriate pub-
lished and unpublished data specific to African populations as
far as possible. Some model parameters were unknown, includ-
ing the transmission rate and duration of natural immunity.
Here, we used a variety of methods to estimate a sensible
range and feasible parameter combinations, ensuring that the
model produced realistic results by comparing the model
predictions to evidence on carriage prevalence by age, disease
incidence by age, total annual incidence, seasonality, and peri-
odicity. Further investigation of formal fitting methods such as
Approximate Bayesian Computation is warranted [24], and
more information on a range of parameters would be desirable,
including age-specific contact patterns. Quantifying the dura-
tion of natural immunity following infection is particularly dif-
ficult; estimation is hampered by codependence with other
parameters, and empirical measurement is problematic, not
least because of the lack of an absolute correlate of protection
[25]. We performed sensitivity analyses to investigate parameter
uncertainty and showed that our findings were robust.
Our conclusions are different from another model of
MenAfriVac, which found that mass campaigns were superior
to routine EPI. This is probably largely because the duration
of protection assumed by Tartof et al was much greater
(essentially lifelong) for children immunized in campaigns
than through EPI [13], whereas we assumed that protection
in 1- to 4-year-olds would be similar to those immunized at
the age of 9 months, based on recent data from the MVP’s
MenAfriVac trials. Tartof et al also used a different model
structure, a larger time step, noncontinuous aging, a smaller
number of simulations, and a higher frequency (weekly) and
amplitude (0–0.75) of stochastic forcing. We chose a more
parsimonious model structure that did not consider variable
levels of protection against colonization and disease, as there
was little evidence to inform such a structure and its param-
eterization. We explored the effect of other structural changes
in our model, including the implementation of stochasticity
as weekly variation in transmission rates, but this had mi-
nor effects on the model predictions and did not change
our conclusions on the relative merits of each immunization
strategy.
Following its introduction in 2010, MenAfriVac has been re-
markably successful in controlling MenA disease. This success
will not be maintained without a long-term immunization strat-
egy. The early adopting countries will need to consider immi-
nently how best to sustain population protection against MenA,
and findings from mathematical models such as this can lend
further support to decision makers at both the country level
and internationally.











Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to benefit the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Notes
Acknowledgments. We thank the members of the World Health Orga-
nization (WHO) Immunization and Vaccines-Related Implementation Re-
search Advisory Committee for critical review and helpful comments.
Disclaimers. 1) The authors and editors alone are responsible for the
views expressed in this publication and they do not necessarily represent
the views, decisions, or policies of the institutions with which they are affili-
ated; 2) The designations employed and the presentation of the material in this
publication do not imply the expression of any opinion whatsoever on the part
of PATH or theWorld Health Organization concerning the legal status of any
country, territory, city or area or of its authorities, or concerning the delim-
itation of its frontiers or boundaries. Dotted and dashed lines on maps repre-
sent approximate border lines for which there may not yet be full agreement;
3) The mention of specific companies or of certain manufacturers’ products
does not imply that they are endorsed or recommended by PATH or the
World Health Organization in preference to others of a similar nature that
are not mentioned. Errors and omissions excepted, the names of proprietary
products are distinguished by initial capital letters.
Financial support. This work was funded by a grant from the Menin-
gitis Vaccine Project (via PATH). C. L. T. received salary support from the
MenAfriCar project, funded by grants from the Wellcome Trust and the Bill
& Melinda Gates Foundation.
Supplement sponsorship. This article appears as part of the supplement
“The Meningitis Vaccine Project: The Development, Licensure, Introduc-
tion, and Impact of a New Group A Meningococcal Conjugate Vaccine
for Africa,” sponsored by the Meningitis Vaccine Project through a grant
from the Bill & Melinda Gates Foundation.
Potential conflicts of interest. A. J. K. C. has received institutional sup-
port from PATH and WHO. A. K. has received institutional support from
PATH and WHO, and travel support from WHO to attend the SAGE
meeting. C. L. T. has received institutional support from PATH and
WHO, and Wellcome Trust and the Bill & Melinda Gates Foundation,
and travel support from WHO to attend the SAGE meeting, and also has
received consultancy fees from GlaxoSmithKline. M.-P. P. has received in-
stitutional support from PATH, Gavi the Vaccine Alliance, the Shefa Fund
hosted by the Swiss Philanthropy Foundation, the National Philanthropic
Trust, the Research Council of Norway, United States Agency for Interna-
tional Development, and the Research Council of Norway.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Frasch CE, Preziosi MP, LaForce FM. Development of a group A me-
ningococcal conjugate vaccine, MenAfriVac(TM). Hum Vaccin Im-
munother 2012; 8:715–24.
2. Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A
meningococcal conjugate vaccine, MenAfriVac, on carriage and herd
immunity. Clin Infect Dis 2013; 56:354–63.
3. Novak RT, Kambou JL, Diomandé FVK, et al. Serogroup A meningo-
coccal conjugate vaccination in Burkina Faso: analysis of national sur-
veillance data. Lancet Infect Dis 2012; 12:757–64.
4. Daugla D, Gami J, Gamougam K, et al. Effect of a serogroup A menin-
gococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal
meningitis and carriage in Chad: a community trial. Lancet 2014;
383:40–7.
5. Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of con-
jugate vaccines to prevent disease caused by Haemophilus influenzae
type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine
2008; 26:4434–45.
6. Greenwood B. Manson lecture. Meningococcal meningitis in Africa.
Trans R Soc Trop Med Hyg 1999; 93:341–53.
7. Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux JP.
Epidemiology of bacterial meningitis in Niamey, Niger, 1981–96. Bull
World Health Organ 1999; 77:499–508.
8. Trotter CL, Greenwood BM. Meningococcal carriage in the African
meningitis belt. Lancet Infect Dis 2007; 7:797–803.
9. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococ-
cal carriage and disease. Epidemiol Infect 2006; 134:556–66.
10. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal
carriage, disease, and the impact of serogroup C conjugate vaccination.
Am J Epidemiol 2005; 162:89–100.
11. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing
vaccination against serogroup B meningococcal disease: an economic
and mathematical modelling study of potential impact. Vaccine 2013;
31:2638–46.
12. Irving TJ, Blyuss KB, Colijn C, Trotter CL. Modelling meningococcal
meningitis in the African meningitis belt. Epidemiol Infect 2012;
140:897–905.
13. Tartof S, Cohn A, Tarbangdo F, et al. Identifying optimal vaccination
strategies for serogroup A Neisseria meningitidis conjugate vaccine in
the African meningitis belt. PLoS One 2013; 8:e63605.
14. Agier L, Deroubaix A, Martiny N, Yaka P, Djibo A, Broutin H. Season-
ality of meningitis in Africa and climate forcing: aerosols stand out. J R
Soc Interface 2013; 10:20120814.
15. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, menin-
gococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196–210.
16. Blakebrough IS, Greenwood BM,Whittle HC, Bradley AK, Gilles HM. The
epidemiology of infections due to Neisseria meningitidis and Neisseria lac-
tamica in a northern Nigerian community. J Infect Dis 1982; 146:626–37.
17. Koutangni T, Boubacar Mainassara H, Mueller JE. Incidence, carriage
and case-carrier ratios for meningococcal meningitis in the African
meningitis belt: a systematic review and meta-analysis. PLoS One
2015; 10:e0116725.
18. Centers for Disease Control and Prevention. Serogroup A meningococcal
conjugate vaccine coverage after the first national mass immunization
campaign—Burkina Faso, 2011. MMWR Morb Mortal Wkly Rep
2012; 61:1022–4.
19. Caini S, Beck NS, Yacouba H, et al. From Agadez to Zinder: estimating
coverage of the MenAfriVac conjugate vaccine against meningococcal
serogroup A in Niger, September 2010–January 2012. Vaccine 2013;
31:1597–603.
20. Mueller JE, Yaro S, Njanpop-Lafourcade BM, et al. Study of a localized
meningococcal meningitis epidemic in Burkina Faso: incidence, car-
riage, and immunity. J Infect Dis 2011; 204:1787–95.
21. World Health Organization. Meeting of the Strategic Advisory Group of
Experts on immunization, October 2014—conclusions and recommen-
dations. Wkly Epidemiol Rec 2014; 50:15.
22. World Health Organization. Meningococcal A conjugate vaccine: up-
dated guidance, February 2015. Wkly Epidemiol Rec 2015; 90:57–62.
23. ThomsonMC, Molesworth AM, Djingarey MH, Yameogo KR, Belanger F,
Cuevas LE. Potential of environmental models to predict meningitis ep-
idemics in Africa. Trop Med Int Health 2006; 11:781–8.
24. Toni T, Welch D, Strelkowa N, Ipsen A, Stumpf MP. Approximate Baye-
sian computation scheme for parameter inference and model selection
in dynamical systems. J R Soc Interface 2009; 6:187–202.
25. Trotter CL, Yaro S, Njanpop-Lafourcade B-M, et al. Seroprevalence of
bactericidal, specific IgG antibodies and incidence of meningitis due to
group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS One
2013; 8:e55486.










S U P P L E M E N T A R T I C L E
Costs of Neisseria meningitidis Group A Disease
and Economic Impact of Vaccination in Burkina
Faso
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Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting
1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population
protection. This study aims to estimate the economic impact of a range of vaccination strategies in Burkina Faso.
Methods. We performed a cost-of-illness study, comparing different vaccination scenarios in terms of costs to
both households and health systems over a 26-year time horizon. These scenarios are (1) reactive vaccination cam-
paign (baseline comparator); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a
combination of routine and an initial catchup campaign of children under 5. Costs were estimated from a literature
review, which included unpublished programmatic documents and peer-reviewed publications. The future disease
burden for each vaccination strategy was predicted using a dynamic transmission model of group A Neisseria men-
ingitidis.
Results. From 2010 to 2014, the total costs associated with the preventive campaign targeting 1- to 29-year-olds
with MenAfriVac were similar to the estimated costs of the reactive vaccination strategy (approximately 10 million
US dollars [USD]). Between 2015 and 2035, routine immunization with or without a catch-up campaign of 1- to
4-year-olds is cost saving compared with the reactive strategy, both with and without discounting costs and cases.
Most of the savings are accrued from lower costs of case management and household costs resulting from a lower
burden of disease. After the initial investment in the preventive strategy, 1 USD invested in the routine strategy saves
an additional 1.3 USD compared to the reactive strategy.
Conclusions. Prevention strategies using MenAfriVac will be significantly cost saving in Burkina Faso, both for
the health system and for households, compared with the reactive strategy. This will protect households from cat-
astrophic expenditures and increase the development capacity of the population.
Keywords. meningitis; case management; vaccination; economic impact; Burkina Faso.
Burkina Faso is one of the few countries whose bound-
aries lie wholly within the African “meningitis belt,”
and thus experiences a particularly high incidence of
meningococcal meningitis, with epidemics occurring
regularly [1, 2]. In 2010, Burkina Faso successfully im-
plemented a nationwide preventive campaign with a
new conjugate vaccine, known as MenAfriVac, against
Neisseria meningitidis group A (MenA) [3, 4]. There
have been no confirmed cases due to MenA in Burkina
Faso since 2010 [2–5], and a substantial overall reduc-
tion in the meningitis burden [6], although group W
remains a threat [7]. To sustain population-level protec-
tion against MenA following the 2010 introductory
campaign, the country plans to incorporate MenAfri-
Vac into the routine infant immunization schedule
with 1 dose at the age of 9 months in late 2015 or
early 2016 together with a single campaign among
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cohorts of children born since the campaign. This follows the
recommendation made by the Strategic Advisory Group of Ex-
perts (SAGE) of the World Health Organization (WHO) in Oc-
tober 2014, which advised that meningitis belt countries should
introduce MenAfriVac into the routine childhood immuniza-
tion program within 5 years of campaign completion, together
with a one-time catch-up campaign for young children born
since the initial mass vaccination who would be outside the
age window when the routine immunization program starts [8].
Prior to MenAfriVac introduction in 2010, the public health
response to MenA relied on the detection of localized epidemics
through surveillance and subsequent reactive immunization
campaigns with polysaccharide vaccines [9] (as it still does for
disease due to other meningococcal serogroups [10]). The effec-
tiveness of this strategy is limited, largely because when vaccina-
tion campaigns are implemented, the epidemic may already be
beyond its peak [11, 12]. Because this strategy does not prevent
cases and epidemics from occurring, health systems can be se-
verely disrupted and costs to the affected households can
amount to one-third of the annual gross domestic product
(GDP) per capita in Burkina Faso [13, 14].
This study aims to estimate the costs and savings of alterna-
tive preventive immunization strategies with MenAfriVac in




We estimate the economic impact of different MenA vaccina-
tion strategies in Burkina Faso, in terms of costs and savings
for the health system and households and, as such, take a soci-
etal perspective. The study is a cost-of-illness study. By defini-
tion, cost-of-illness studies measure the economic burden of a
disease and estimate the maximum amount that could be saved
by reducing that burden [15].
We consider a 26-year time period, from 2010 until 2035,
with 2010 being the year of the preventive campaign targeting
1- to 29-year-olds in Burkina Faso and 2015 the anticipated year
of the introduction of routine MenAfriVac immunization. The
study is both retrospective (real costs from 2010 to 2014) and
prospective from 2015 onward, where future costs are projected.
New cases are included during the entire study period. We
therefore differentiate the time horizon into 2 periods: 2010–
2014 and 2015–2035. The 2035 cutoff is based on an expected
10-year duration of protection of MenAfriVac against MenA
and an expected waning of the effects of the 2010 campaign
around 15 years after vaccine introduction, in the absence of
further immunization [16].
The study compares the costs of reactive campaigns for
individuals aged 2–30 years with a polysaccharide A + C
meningococcal vaccine (reactive strategy) to each of the 3 new
vaccination strategies aimed at preventing MenA using MenA-
friVac while targeting different age groups : (1) a single preven-
tive campaign in 2010 for individuals aged 1–29 years
(preventive strategy); (2) routine immunization at 9 months
of age 5 years after the preventive campaign (routine strategy);
and (3) routine immunization at 9 months of age 5 years after
the preventive campaign, and a catch-up of children born since
the preventive campaign (combination strategy).
The incidence of MenA in each of the vaccination strategies is
predicted from a transmission dynamic model of MenA and
MenAfriVac immunization [16]. The model is designed to cap-
ture the typical epidemiology of MenA in the meningitis belt,
with periodic but irregular epidemics occurring in the dry season.
This model estimates the number of cases occurring per year on a
national level and does not predict localized epidemics. Vaccina-
tion with MenAfriVac is implemented according to the
Table 1. Yearly Incidence Rate of Group A Neisseria
meningitidis in Burkina Faso, 2011–2035
Year
Incidence Rate of MenA (per 100 000)
Preventive Campaign Routine 1 Dose Routine + Catch-up
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
11 0 0 0
12 0.0001 0 0
13 0.0022 0 0
14 0.075 0 0
15 1.4 0 0
16 14.1 0.00017 0
17 40.98 0.013 0
18 73.9 0.14 0
19 75.6 0.32 0
20 52.4 0.93 0.0003
21 34.17 3.41 0.038
22 14.19 4.26 0.35
23 5.49 9.59 0.93
24 7.89 16.6 3.17
25 6.85 15.7 5.9
The considered incidence of MenA in the absence of any preventive strategy is
24.7 per 100 000.
Abbreviation: MenA, Neisseria meningitidis group A.










strategies above, and influences disease epidemiology through
effectiveness against disease and carriage (90% in both cases),
thus providing direct and indirect protection. In the model,
MenAfriVac coverage is assumed to be 95% for the 2010 cam-
paign and 80% for routine and subsequent catch-up. The num-
ber of cases of MenA is estimated by applying the annual
incidence rates shown in Table 1 to the population of Burkina
Faso [17].
Costs and cases are primarily undiscounted, but we also ex-
plored the sensitivity of results to 2 alternative discounting sce-
narios: discounting of 3% for both cases and costs and
discounting of costs at 3% with no discounting of cases. All
costs were adjusted to 2012 US dollars (USD). For the period
2015–2035, the price of vaccines is an average of the expected
price during that period.
Cost Calculation
Different types of costs are calculated: (1) the costs of case man-
agement and of vaccination for the health system, and (2) the
direct nonmedical costs (DNMCs) and indirect costs (ICs) for
households. We assume that case management of meningitis is
free for households and is all supported by the health system,
according to the policy promoted by the international commu-
nity during epidemics of meningitis in Burkina Faso [9]. We
further assume that in households there is no self-medication
nor visit to a traditional healer prior to contact with a health
center or hospital. Both these assumptions are conservative.
Costs of sequelae have not been taken into account.
Health System Costs
The case management costs are calculated by multiplying the
estimated number of cases of MenA under each strategy by
an average cost of case management calculated using a multilin-
ear regression analysis including data from 27 countries on the
direct medical costs (DMCs) of meningitis cases in low- and
middle-income countries [18]. Original data for Burkina Faso
come from Colombini et al [13].
The costs of reactive campaigns are based on the total costs of
reactive vaccination estimated in a study performed in Burkina
Faso in 2007 [14], divided by the number of cases in that study
period to give an average cost per case. The average cost per case
is then multiplied by the estimated incidence of cases of MenA
under a reactive strategy between 2010 and 2035. In reality, re-
active vaccination only occurs when an epidemic threshold is
reached, so only cases that occur in areas that reach an epidemic
threshold will yield a reactive vaccination cost. As the model
does not predict the occurrence of localized outbreaks, it is
not possible to mirror the true policy.
As an alternative, we estimated the cost of reactive vac-
cination based on the number of affected districts in Burkina
Faso that were immunized in the last MenA epidemic in
2006–2007. Here we assumed that a similar epidemic would
occur every 10 years, requiring reactive campaigns in 46 dis-
tricts with 1 district per year requiring a reactive campaign in
interepidemic years. The median district population size in
Burkina Faso in 2010 was 233 315, and we assumed that 75%
of the district population would be targeted (as a proxy for
those aged 2–30 years) at a cost of 1.45 USD per person vacci-
nated [14].
The cost of the preventive campaign was derived from the
WHO report on the 2010 preventive campaign in Burkina
Faso and Gavi financial documents and includes total vaccine
costs and total delivery costs. The costs of vaccination of the
other strategies is based on (1) the unit delivery costs derived
from a review of national program documents; (2) the projec-
tion of fully loaded price for vaccines and injection supplies
per dose; and (3) an estimate of the number of doses required
for each strategy given the target population estimated from
United Nations population data [17]. The average delivery
cost per dose of the catch-up campaign is considered to be
the same as for the preventive campaign. The average delivery
cost per dose of routine vaccination is derived from the data
available on the comprehensive multiyear plan of the immuni-
zation program in Burkina Faso [19], which consists of the sum
of the specific costs of all the activities needed to administer
routine vaccines, divided by the total number of vaccine doses
supplied (see Table 2 for more details). We assume that there
are no fixed costs and that the cost of immunization is shared
proportionally to the number of doses.
The number of doses of vaccines required is based on the tar-
get population, the expected coverage rate, and wastage rates of
each vaccination strategy (Table 3).
Household Costs
Two types of costs for households are taken into account:
DNMCs and ICs.
DNMCs are nonmedical costs incurred by the patient and/or
the family carer because of the illness episode. For instance, in
Burkina Faso, hospitals do not provide certain services (meals,
hygiene) and there is hardly any transport or ambulance service.
Consequently, households have to bear these transport costs,
even for seriously ill patients. The family carers also have to
pay for food for the patient and themselves, and buy soap
and other personal hygiene items. Additionally, DNMCs in-
clude phone calls to family and costs for visitors (Table 2).
This DNMC is calculated by multiplying Portnoy et al’s DMC
[18] by the ratio of DNMC and DMC in Burkina Faso from
Colombini et al’s original data (r = 0.61) [13].
ICs are estimated as the loss of income due to a temporary
work interruption, calculated by multiplying the average num-
ber of days of illness (from [13]) by the daily per capita GDP
(from the World Bank [20]). We considered that only 1 adult










Table 2. Elements of the Methodology: Mean Costs Used in the Study and Other Methodological Points on Cost Calculation
Cost
Parametersa Sources of Data Methodological Notes
All Strategies Mean Cost
per Case
Case management costs
for the health system
50.73 Portnoy et al [18] Colombini
et al [13]
Field study in Burkina Faso during the epidemic season (2006–2007)
Cost includes prepositioning and distribution of medicines during epidemics,
district laboratory analyses for case diagnosis and choice of treatment,
patient care
Multiple regression analysis (Portnoy et al [18])
DMCs for households . . . Hypothesis (conservative):
Medical care of meningitis is free of charge for households; all case
management costs are captured at the health system level
Households do not seek informal care
DNMCs for households 31.08 Portnoy et al [18] Colombini
et al [13]
Field study in Burkina Faso during the epidemic season (2006–2007)
Costs includes transport, foods, costs for visitors, phone calls to the family,
personal hygiene items
Prorata of DMCs of Portnoy et al [18] as per the share between DNMCs and
DMCs in Colombini et al [13]
Indirect costs for
households
129.55 World Bank (GDP per capita);
Colombini [13] (duration of
inactivity)
Hypothesis (conservative):
Duration of professional inactivity due to the illness = 21 days
No. of persons impeded to work in the households = 1
Sequelae impact is not included here
Formula of calculation: No. of days of inactivity × GDP/capita/day
Reactive vaccination campaign
Vaccination
Campaigns 263.25 Colombini et al [14] Field study in Burkina Faso during the epidemic season (2006–2007).
Includes meningococcal polysaccharide A/C vaccines and injection
supplies; per diems and allowances for human resources; planning,
training, social mobilization, monitoring, supervision and assessment of
the immunization campaigns; management of cases of AEFIs; waste




14.89 Colombini et al [14] Field study in Burkina Faso during the epidemic season (2006–2007)
Includes training, social communication on meningitis, investigation of
suspected cases, laboratory case confirmation and etiologic identification,
supervision, coordination of actors for surveillance and response activities
Preventive vaccination campaign
Vaccination




Includes per diems and allowances for human resources; planning, training,
social mobilization, monitoring, supervision and assessment of the




Total costs Gavi Includes doses of MenAfriVac and injection supplies




Delivery 0.28 cMYP Burkina Faso 2011–
2015
Includes service delivery, advocacy and communication, monitoring and
disease surveillance, program management. For comparison purpose, it
does not include shared and capital costs (buildings, salaries of personnel,
vehicles, and cold chain equipment)
Vaccine and injection
material
0.90 MVP Fully loaded price—includes doses of MenAfriVac, injection supplies and





Delivery 0.24 Current study Hypothesis:
The average delivery cost per dose for catch-up campaigns is the same as in
the 2010 preventive campaigns
Vaccine and injection
material
0.73 MVP Fully loaded price—includes doses of MenAfriVac, injection supplies, and
freight. Price as of 2015
Abbreviations: AEFI, adverse events following immunization; cMYP, comprehensive multiyear plan; DMC, direct medical cost; DNMC, direct nonmedical cost; GDP,
gross domestic product; MVP, Meningitis Vaccine Project.
a Value in 2012 US dollars.










person per case was affected by work interruption: either the pa-
tient, if the patient is an adult, or 1 adult caregiver if the patient
is a child.
Savings and Economic Impact
The economic impact is estimated from the costs saved by both
households and the health system. Savings are calculated as the
difference between the costs of the baseline strategy (reactive
strategy) and each alternative strategy over the same period of
time; if the differential is positive, the alternative strategy is
cost saving. The savings are subdivided by cost category (case
management, vaccination, DNMCs, ICs).
RESULTS
Impact on Disease Burden
The number of cases of MenA expected in Burkina Faso varies
from one strategy to the other (more detail is given in [12]). In
the absence of preventive vaccination, 122 466 cases are predict-
ed between 2015 and 2035. In contrast, the most effective com-
bination strategy predicts only 3066 cases over the same period
(Table 4). The 3 alternative strategies considerably reduce the
number of cases of MenA, preventing at least 100 000 cases
compared with the reactive strategy.
Impact on Costs
The reactive strategy led to higher total costs both for the health
system and for households, regardless of the comparison strat-
egy (Table 4).
Total Undiscounted Costs
From 2010 to 2014, the costs of the preventive and the reactive
strategy are almost the same, with 9.7 and 10.0 million USD,
respectively (3.1% difference). However, the structure of the
costs are very different: the cost of the preventive campaigns
is 1.7 times that of the reactive campaigns, but there are no
costs associated with cases under the preventive strategy as no
MenA cases occurred during this time period.
Between 2015 and 2035, the cost of the reactive strategy
is calculated as 59.9 million USD. By comparison, from 2015
to 2035 the routine and the combination strategies would
cost a total of 27.4 to 24.6 million USD, respectively. De
facto, the total cost for the reactive strategy is 2.2 times higher
than the routine and the combination strategies. This is
explained both by a higher number of cases of MenA, resulting
in higher costs of case management and of DNMC and IC
for households, and the higher costs of vaccination. The
costs of the routine and the combination strategies are very
similar due both to the low costs of the catch-up campaign
in 2015 and to the lowest incidence of MenA under the com-
bination strategy yielding lower case management costs,
DNMCs, and ICs.
Within each strategy, total vaccination costs are higher than
those linked to care of cases (case management, DNMCs, and
ICs), due to vaccination leading to a decreased number of
cases—and thus to a reduction of the costs linked to illness.
Costs for the Health System
A huge decrease in the costs of case management is observed for
all preventive strategies compared with the reactive strategy, as
many fewer cases are predicted to occur (Table 4). With routine
and combination strategies, the costs of case management are
only 2.7% and 0.6%, respectively, compared with 10.4% for
the reactive strategy between 2015 and 2035.
Between 2010 and 2014, the health system costs associated
with vaccination were higher for the preventive strategy, as all
Table 3. Target Population, Coverage Rate, Wastage Factor, and Buffer Stock for Routine Vaccination and Preventive and Catch-up
Campaigns Against Group A Neisseria meningitidis
Parameters Routine Vaccination (2015–2035) Catch-up Campaign (2015) Preventive Campaigns (2010)
Total target populationa 15 795 911 2 431 328 11 023 447
Coverage rate 80% 100% 100%b
Total effective target populationc 12 212 780 2 995 304 11 023 447
Wastage factor 1.67 1.15 1.15
Buffer stock 25% 0% 0%
Total No. of vaccine dosesd 20 643 066 2 796 027 12 205 400e
a For the preventive campaigns, the target population is the one of 2010 only as the campaign is implemented only once during the total period.
b Rate based on administrative coverage, used for the calculation of costs. A lower rate of 95%, based on a coverage survey estimate, is used for assessment of the
epidemiological impact.
c Routine effective target population = surviving infant population × rollout factor (accounting for partial year introduction in the first year) × coverage. Campaign
effective target population = target population (assuming a plan to cover 100% of the target population).
d Number of doses = [effective target population ×wastage factor] + buffer. Buffer applies to routine only; for year x = 0.25 × [doses year x – Doses year x – 1] if this
difference is positive; otherwise buffer = 0.
e Source: World Health Organization. Summary report on the 2 phase meningitis vaccination campaign in Burkina Faso, January 2011.










1- to 29-year-olds in Burkina Fasowere targeted nationwide, with
costs concentrated in one single month in a single year (Decem-
ber 2010). By contrast, reactive campaigns selectively target dis-
tricts experiencing epidemics and not the national population.
Between 2015 and 2035, vaccination costs of the reactive
strategy are 1.4 to 1.3 times higher than those of the routine
and the combination strategies, respectively (Table 4). The av-
erage vaccination cost per vaccinee is higher for routine vacci-
nation than for preventive campaigns, with 1.99 USD and 0.88
USD respectively.
Costs for Households
The total cost for households is directly linked to the burden of
disease: the fewer the cases, the lower the costs. All of the alter-
native strategies are less costly than the reactive strategy
(Table 4), with the combination strategy resulting in the lowest
household costs. ICs, which represent here the loss of earnings
for the family during the acute illness episode and the recovery,
represent the main costs to households (81%).
Net Savings for Both the Health System and the Households
All the alternative strategies save money compared with the re-
active strategy (Table 5, Figure 1). In total, the savings for the
routine and the combination strategy are similar and amount
to 32.5 and 32.3 million USD between 2015 and 2035, respec-
tively. Savings are higher overall for the households than for the
health system.
Between 2010 and 2014, the savings are much lower (about
300 000 USD); there are no cases of MenA thanks to the preven-
tive campaign, but this mass campaign was costly in terms of
vaccination costs.
Ultimately, each dollar invested in routine immunization
generates savings of an additional 1.3 USD, and each dollar in-
vested in the combination strategy saves 1.2 USD.
Sensitivity Analysis: Impact of Discounting
If discounting the costs at 3%, all the alternative strategies are
still cost-saving both for the health system and for the house-
holds. However, the savings are lower than in the undiscounted











Costs Indirect Costs Subtotal
Reactive strategy
2010–2014 20 453 1 037 575 5 688 847 6 726 422 635 669 2 649 616 3 285 284 10 011 706
2015–2035 122 466 6 212 720 34 063 283 40 276 002 3 806 212 15 865 184 19 671 396 59 947 398
1. Preventive strategy
2010–2014 0 0 9 713 805 9 713 805 0 0 0 9 713 805
2. Routine strategy
2015–2035 14 776 749 577 24 282 338 25 031 915 459 227 1 914 166 2 373 393 27 405 308
3. Combination strategy
2015–2035 3066 155 550 27 000 288 27 155 838 95 298 397 223 492 520 27 648 358
Data are presented as US dollars unless otherwise specified.
Abbreviation: MenA, Neisseria meningitidis group A.
















20 453 1 037 575 −4 024 958 −2 987 383 635 669 2 649 616 3 285 284 297 901
2. Routine strategy,
2015–2035
107 690 5 463 143 9 780 945 15 244 088 3 346 985 13 951 018 17 298 003 32 542 090
3. Combination
strategy, 2015–2035
119 400 6 057 170 7 062 995 13 120 165 3 710 914 15 467 961 19 178 875 32 299 040
Abbreviation: USD, US dollars.










scenario and amount to 17.8–18 million USD for the combina-
tion and the routine strategies, respectively (Figure 2). The only
exception is again for vaccination, strictly speaking, under the
preventive strategy between 2010 and 2014.
When discounting both cases and costs at 3%, the preven-
tive strategy costs 1.2 million USD more than the reactive
strategy between 2010 and 2014. The long-term strategies re-
main cost-saving, with savings amounting to a maximum of
3.9 million USD for the routine strategy between 2015 and
2035. However, in this scenario vaccination costs are higher
for each of the alternative strategies than for the reactive strat-
egies (Figure 3).
DISCUSSION
We find that the introduction and sustained use of MenAfriVac
to prevent MenA has a substantial positive economic impact in
Burkina Faso. Each of the preventive strategies considered
Figure 1. Savings (in millions of US dollars) of the 3 strategies, Burkina Faso, 2010–2035.
Figure 2. Discounted savings (in millions of US dollars) of the 3 strategies, Burkina Faso, 2010–2035. Savings are calculated based on a discounting of
costs at a rate of 3%, but no discounting of cases (discount rate = 0%).










generates considerable savings compared to the reactive strategy
using a polysaccharide vaccine between 2015 and 2035, both
with and without discounting costs at 3%. Indeed, each dollar in-
vested in the combination strategy recommended by SAGE saves
an additional 1.2 USD; in total, up to 32.3 million USD can be
saved. Savings to the health system are accrued by lower costs
of case management, and in the long term, also through reduced
vaccination costs. By preventing MenA, MenAfriVac will reduce
the economic burden on households and save thousands of
households from catastrophic expenditures and pauperization
[11]. Meningitis prevention is also likely to raise population
well-being and development capacity including through the im-
provement of child health [21–24]. The severe disruption to the
health system and communities from meningitis epidemics will
be avoided [14, 25].
Our methodological choices were conservative and, thus, we
may have underestimated the economic benefits of MenAfri-
Vac. The costs to households may be underestimated for several
reasons. We assumed that costs of case management are entirely
supported by the health system; however, although care is sup-
posed to be free of charge during an epidemic, an earlier study
in Burkina Faso [13] estimated that 96% of households paid
for all or part of the care. In addition, 34% of households report
self-medication before going to a health center or a hospital,
and 23% seek traditional care. The ICs were based on the
assumption that only 1 person was prevented from working.
In reality, this can only be true when the patient is a child,
and although most cases occur in children, adults are still
affected by MenA [26]. Household costs do not include either
the direct or ICs associated with sequelae, which affect 9.5%
of survivors [27], and may be severe and costly [13, 28]. More-
over, recent experimental economic studies propose widening
the scope of ICs by also including monetary estimates of inter-
ruptions in education schooling and the impact on cognitive de-
velopment [21–23]. Last, the focus here is on the economic
impact on households and costs and savings for the health sys-
tem. A later study will also include the macroeconomic impact
and the financial risk protection of households [29].
Our estimates of the epidemiological impact of MenAfriVac
from 2015 through 2035 are based on a transmission dynamic
model of MenA [16]. Different MenAfriVac coverage estimates
are used for the transmission model and the economic costs.
For the 2010 campaign, costs are based on administrative cov-
erage, whereas epidemiological impact uses a lower coverage
survey estimate [3]; the overall effect is conservative. The trans-
mission model predicts a national incidence and does not pre-
dict the occurrence of local epidemics that would trigger a
reactive vaccination response. We have estimated the costs of
reactive vaccination on a per-case basis. However, the costs of
reactive vaccination could be lower if the geographical distribu-
tion of MenA cases was such that not all occur in districts that
reach the epidemic response threshold. To address this, we used
an alternative method of estimating costs of reactive vaccina-
tion, based on the number of district-level epidemic response
campaigns conducted in Burkina Faso in the pre-MenAfriVac
era and assuming a major epidemic every 10 years, and estimated
Figure 3. Discounted savings (in millions of US dollars) of the 3 strategies, Burkina Faso, 2010–2035. Savings relied on discounted costs and discounted
cases at a discount rate of 3%.










costs to be around 10% higher. A further consideration is that we
have not estimated the cases prevented through a reactive strategy.
The effectiveness of reactive vaccination has not been systemati-
cally reviewed and critically depends on the speed at which reac-
tive vaccination can be implemented [12]. However, it is not
thought to be a highly effective strategy, hence the development
and introduction of MenAfriVac. In addition, we are using an es-
timate of disease incidence that is typical for a meningitis belt
country, although not necessarily a high-incidence country such
as Burkina Faso. On balance, we therefore conclude that our es-
timates of the costs of reactive vaccination are conservative.
The introduction of MenAfriVac across the African meningi-
tis belt has dramatically reduced the burden of MenA disease.
With appropriate long-term immunization strategies as recom-
mended by SAGE, this remarkable success promises to contin-
ue. The economic impact of MenAfriVac is illustrated here for
Burkina Faso, and adds to the evidence on the remarkable pub-
lic health success of this vaccine.
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= BtN + φR1 − θλ1S1 − (age + µ1,t)S1 + wLSV1 + wSSE1
dC1
dt
= θλ1S1 + (a1 − α − µ1,t − age)C1 + wLCV1 + wSCE1
dI1
dt
= a1C1 − (ρ + age + µ1,t)I1
dR1
dt
= ρI1 + αC1 − (φ + age + µ1,t)R1 + wLRV1 + wSRE1
dSV1
dt
= −(1 − δ)θλ1SV1 + φRV1 − (wL + age + µ1,t)SV1
dCV1
dt
= (1 − δ)θλ1SV1 − ((1 − ξ)a1 + α + wL + age + µ1,t)CV1
dIV1
dt
= (1 − ξ)a1CV1 − (ρ + age + µ1,t)IV1
dRV1
dt
= ρIV1 + αCV1 − (φ + wL + age + µ1,t)RV1
dSE1
dt
= −(1 − δ)θλ1SE1 + φRE1 − (wS + age + µ1,t)SE1
dCE1
dt
= (1 − δ)θλ1SE1 − ((1 − ξ)a1 + α + wS + age + µ1,t)CE1
dIE1
dt
= (1 − ξ)a1CE1 − (ρ + age + µ1,t)IE1
dRE1
dt
= ρIE1 + αCE1 − (φ + wS + age + µ1,t)RE1
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Age groups i = 2, ..., 5 & age groups i = 7, ..., 99
dSi
dt
= ageSi−1 + φRi − θλiSi − (age + µi,t)Si + wLSVi + wSSEi
dCi
dt
= ageCi−1 + θλiSi + (ai − α − µi,t − age)Ci + wLCVi + wSCEi
dIi
dt
= ageIi−1 + aiCi − (ρ + age + µi,t)Ii
dRi
dt
= ageRi−1 + ρIi + αCi − (φ + age + µi,t)Ri + wLRVi + wSREi
dSVi
dt
= ageSVi−1 − (1 − δ)θλiSVi + φRVi − (wL + age + µi,t)SVi
dCVi
dt
= ageCVi−1 + (1 − δ)θλiSVi − ((1 − ξ)ai + α + wL + age + µi,t)CVi
dIVi
dt
= ageIVi−1 + (1 − ξ)aiCVi − (ρ + age + µi,t)IVi
dRVi
dt
= ageRVi−1 + ρIVi + αCVi − (φ + wL + age + µi,t)RVi
dSEi
dt
= ageSEi−1 − (1 − δ)θλiSEi + φREi − (wS + age + µi,t)SEi
dCEi
dt
= ageCEi−1 + (1 − δ)θλiSEi − ((1 − ξ)ai + α + wS + age + µi,t)CEi
dIEi
dt
= ageIEi−1 + (1 − ξ)aiCEi − (ρ + age + µi,t)IEi
dREi
dt




= (1 − γt)ageS5 + φR6 − θλ6S6 − (age + µ6,t)S6 + wLSV6 + wSSE6
dC6
dt
= (1 − γt)ageC5 + θλ6S6 + (a6 − α − µ6,t − age)C6 + wLCV6 + wSCE6
dI6
dt
= ageI5 + a6C6 − (ρ + age + µ6,t)I6
dR6
dt
= (1 − γt)ageR5 + ρI6 + αC6 − (φ + age + µ6,t)R6 + wLRV6 + wSRE6
dSV6
dt
= ageSV5 − (1 − δ)θλ6SV6 + φRV6 − (wL + age + µ6,t)SV6 + γtageS5
dCV6
dt
= ageCV5 + (1 − δ)θλ6SV6 − ((1 − ξ)a6 + α + wL + age + µ6,t)CV6 + γtC5
dIV6
dt
= ageIV5 + (1 − ξ)a6CV6 − (ρ + age + µ6,t)IV6
dRV6
dt




= ageSE5 − (1 − δ)θλ6SE6 + φRE6 − (wS + age + µ6,t)SE6
dCE6
dt
= ageCE5 + (1 − δ)θλ6SE6 − ((1 − ξ)a6 + α + wS + age + µ6,t)CE6
dIE6
dt
= ageIE5 + (1 − ξ)a6CE6 − (ρ + age + µ6,t)IE6
dRE6
dt




= ageS99 + φR100 − θλ100S100 − µ100,tS100 + wLSV100 + wSSE100
dC100
dt
= ageC99 + θλ100S100 + (a100 − α − µ100,t)C100 + wLCV100 + wSCE100
dI100
dt
= ageI99 + a100C100 − (ρ + µ100,t)I100
dR100
dt
= ageR99 + ρI100 + αC100 − (φ + µ100,t)R100 + wLRV100 + wSRE100
dSV100
dt
= ageSV99 − (1 − δ)θλ100SV100 + φRV100 − (wL + µ100,t)SV100
dCV100
dt
= ageCV99 + (1 − δ)θλ100SV100 − ((1 − ξ)a100 + α + wL + µ100,t)CV100
dIV100
dt
= ageIV99 + (1 − ξ)a100CV100 − (ρ + µ100,t)IV100
dRV100
dt
= ageRV99 + ρIV100 + αCV100 − (φ + wL + µ100,t)RV100
dSE100
dt
= ageSE99 − (1 − δ)θλ100SE100 + φRE100 − (wS + µ100,t)SE100
dCE100
dt
= ageCE99 + (1 − δ)θλ100SE100 − ((1 − ξ)a100 + α + wS + µ100,t)CE100
dIE100
dt
= ageIE99 + (1 − ξ)a100CE100 − (ρ + µ100,t)IE100
dRE100
dt
= ageRE99 + ρIE100 + αCE100 − (φ + wS + µ100,t)RE100
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= BtN + φR1 − θλ1S1 − (age + µ1,t)S1 + wLSV1 + wSSE1
dC1
dt
= θλ1S1 + (a1 − α − µ1,t − age)C1 + wLCV1 + wSCE1
dI1
dt
= a1C1 − (ρ + age + µ1,t)I1
dR1
dt
= ρI1 + αC1 − (φ + age + µ1,t)R1 + wLRV1 + wSRE1
dSV1
dt
= −(1 − δ)θλ1SV1 + φRV1 − (wL + age + µ1,t)SV1
dCV1
dt
= (1 − δ)θλ1SV1 − ((1 − ξ)a1 + α + wL + age + µ1,t)CV1
dIV1
dt
= (1 − ξ)a1CV1 − (ρ + age + µ1,t)IV1
dRV1
dt
= ρIV1 + αCV1 − (φ + wL + age + µ1,t)RV1
dSE1
dt
= −(1 − δ)θλ1SE1 + φRE1 − (wS + age + µ1,t)SE1
dCE1
dt
= (1 − δ)θλ1SE1 − ((1 − ξ)a1 + α + wS + age + µ1,t)CE1
dIE1
dt
= (1 − ξ)a1CE1 − (ρ + age + µ1,t)IE1
dRE1
dt
= ρIE1 + αCE1 − (φ + wS + age + µ1,t)RE1
Age groups i = 2, ..., 10 & age groups i = 12, ..., 99
dSi
dt
= ageSi−1 + φRi − θλiSi − (age + µi,t)Si + wLSVi + wSSEi
dCi
dt
= ageCi−1 + θλiSi + (ai − α − µi,t − age)Ci + wLCVi + wSCEi
dIi
dt
= ageIi−1 + aiCi − (ρ + age + µi,t)Ii
dRi
dt
= ageRi−1 + ρIi + αCi − (φ + age + µi,t)Ri + wLRVi + wSREi
dSVi
dt
= ageSVi−1 − (1 − δ)θλiSVi + φRVi − (wL + age + µi,t)SVi
dCVi
dt




= ageIVi−1 + (1 − ξ)aiCVi − (ρ + age + µi,t)IVi
dRVi
dt
= ageRVi−1 + ρIVi + αCVi − (φ + wL + age + µi,t)RVi
dSEi
dt
= ageSEi−1 − (1 − δ)θλiSEi + φREi − (wS + age + µi,t)SEi
dCEi
dt
= ageCEi−1 + (1 − δ)θλiSEi − ((1 − ξ)ai + α + wS + age + µi,t)CEi
dIEi
dt
= ageIEi−1 + (1 − ξ)aiCEi − (ρ + age + µi,t)IEi
dREi
dt




= (1 − γt)ageS10 + φR11 − θλ11S11 − (age + µ11,t)S11 + wLSV11 + wSSE11
dC11
dt




= ageI10 + a11C11 − (ρ + age + µ11,t)I11
dR11
dt
= (1 − γt)ageR10 + ρI11 + αC11 − (φ + age + µ11,t)R11 + wLRV11 + wSRE11
dSV11
dt
= ageSV10 − (1 − δ)θλ11SV11 + φRV11 − (wL + age + µ11,t)SV11 + γtageS10
dCV11
dt




= ageIV10 + (1 − ξ)a11CV11 − (ρ + age + µ11,t)IV11
dRV11
dt
= ageRV10 + ρIV11 + αCV11 − (φ + wL + age + µ11,t)RV11 + γtR10
dSE11
dt
= ageSE10 − (1 − δ)θλ11SE11 + φRE11 − (wS + age + µ11,t)SE11
dCE11
dt
= ageCE10 + (1 − δ)θλ11SE11 − ((1 − ξ)a11 + α + wS + age + µ11,t)CE11
dIE11
dt
= ageIE10 + (1 − ξ)a11CE11 − (ρ + age + µ11,t)IE11
dRE11
dt





= ageS99 + φR100 − θλ100S100 − µ100,tS100 + wLSV100 + wSSE100
dC100
dt
= ageC99 + θλ100S100 + (a100 − α − µ100,t)C100 + wLCV100 + wSCE100
dI100
dt
= ageI99 + a100C100 − (ρ + µ100,t)I100
dR100
dt
= ageR99 + ρI100 + αC100 − (φ + µ100,t)R100 + wLRV100 + wSRE100
dSV100
dt
= ageSV99 − (1 − δ)θλ100SV100 + φRV100 − (wL + µ100,t)SV100
dCV100
dt
= ageCV99 + (1 − δ)θλ100SV100 − ((1 − ξ)a100 + α + wL + µ100,t)CV100
dIV100
dt
= ageIV99 + (1 − ξ)a100CV100 − (ρ + µ100,t)IV100
dRV100
dt
= ageRV99 + ρIV100 + αCV100 − (φ + wL + µ100,t)RV100
dSE100
dt
= ageSE99 − (1 − δ)θλ100SE100 + φRE100 − (wS + µ100,t)SE100
dCE100
dt
= ageCE99 + (1 − δ)θλ100SE100 − ((1 − ξ)a100 + α + wS + µ100,t)CE100
dIE100
dt
= ageIE99 + (1 − ξ)a100CE100 − (ρ + µ100,t)IE100
dRE100
dt
= ageRE99 + ρIE100 + αCE100 − (φ + wS + µ100,t)RE100
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= BtN + φR1 − θλ1S1 − (age + µ1,t)S1 + wLSV1 + wSSE1
dC1
dt
= θλ1S1 + (a1 − α − µ1,t − age)C1 + wLCV1 + wSCE1
dI1
dt
= a1C1 − (ρ + age + µ1,t)I1
dR1
dt
= ρI1 + αC1 − (φ + age + µ1,t)R1 + wLRV1 + wSRE1
dSV1
dt
= −(1 − δ)θλ1SV1 + φRV1 − (wL + age + µ1,t)SV1
dCV1
dt
= (1 − δ)θλ1SV1 − ((1 − ξ)a1 + α + wL + age + µ1,t)CV1
dIV1
dt
= (1 − ξ)a1CV1 − (ρ + age + µ1,t)IV1
dRV1
dt
= ρIV1 + αCV1 − (φ + wL + age + µ1,t)RV1
dSE1
dt
= −(1 − δ)θλ1SE1 + φRE1 − (wS + age + µ1,t)SE1
dCE1
dt
= (1 − δ)θλ1SE1 − ((1 − ξ)a1 + α + wS + age + µ1,t)CE1
dIE1
dt
= (1 − ξ)a1CE1 − (ρ + age + µ1,t)IE1
dRE1
dt




= (1 − γ1,t)ageS1 + φR2 − θλ2S2 − (age + µ2,t)S2 + wLSV2 + wSSE2
dC2
dt
= (1 − γ1,t)ageC1 + θλ2S2 + (a2 − α − µ2,t − age)C2 + wLCV2 + wSCE2
dI2
dt
= ageI1 + a2C2 − (ρ + age + µ2,t)I2
dR2
dt
= (1 − γ1,t)ageR1 + ρI2 + αC2 − (φ + age + µ2,t)R2 + wLRV2 + wSRE2
dSV2
dt
= ageSV1 − (1 − δ)θλ2SV2 + φRV2 − (wL + age + µ2,t)SV2
dCV2
dt




= ageIV1 + (1 − ξ)a2CV2 − (ρ + age + µ2,t)IV2
dRV2
dt
= ageRV1 + ρIV2 + αCV2 − (φ + wL + age + µ2,t)RV2
dSE2
dt
= ageSE1 − (1 − δ)θλ2SE2 + φRE2 − (wS + age + µ2,t)SE2 + γ1,tageS1
dCE2
dt




= ageIE1 + (1 − ξ)a2CE2 − (ρ + age + µ2,t)IE2
dRE2
dt
= ageRE1 + ρIE2 + αCE2 − (φ + wS + age + µ2,t)RE2 + γ1,tR1
Age groups i = 3, ..., 5 & age groups i = 7, ..., 99
dSi
dt
= ageSi−1 + φRi − θλiSi − (age + µi,t)Si + wLSVi + wSSEi
dCi
dt
= ageCi−1 + θλiSi + (ai − α − µi,t − age)Ci + wLCVi + wSCEi
dIi
dt
= ageIi−1 + aiCi − (ρ + age + µi,t)Ii
dRi
dt
= ageRi−1 + ρIi + αCi − (φ + age + µi,t)Ri + wLRVi + wSREi
dSVi
dt
= ageSVi−1 − (1 − δ)θλiSVi + φRVi − (wL + age + µi,t)SVi
dCVi
dt
= ageCVi−1 + (1 − δ)θλiSVi − ((1 − ξ)ai + α + wL + age + µi,t)CVi
dIVi
dt
= ageIVi−1 + (1 − ξ)aiCVi − (ρ + age + µi,t)IVi
dRVi
dt
= ageRVi−1 + ρIVi + αCVi − (φ + wL + age + µi,t)RVi
dSEi
dt
= ageSEi−1 − (1 − δ)θλiSEi + φREi − (wS + age + µi,t)SEi
dCEi
dt
= ageCEi−1 + (1 − δ)θλiSEi − ((1 − ξ)ai + α + wS + age + µi,t)CEi
dIEi
dt
= ageIEi−1 + (1 − ξ)aiCEi − (ρ + age + µi,t)IEi
dREi
dt





= (1 − γ2,t)ageS5 + φR6 − θλ6S6 − (age + µ6,t)S6 + wLSV6 + wSSE6
dC6
dt
= (1 − γ2,t)ageC5 + θλ6S6 + (a6 − α − µ6,t − age)C6 + wLCV6 + wSCE6
dI6
dt
= ageI5 + a6C6 − (ρ + age + µ6,t)I6
dR6
dt
= (1 − γ2,t)ageR5 + ρI6 + αC6 − (φ + age + µ6,t)R6 + wLRV6 + wSRE6
dSV6
dt




= ageCV5 + (1 − δ)θλ6SV6 − ((1 − ξ)a6 + α + wL + age + µ6,t)CV6
+ γ2,tC5 + γ2,tCE5
dIV6
dt
= ageIV5 + (1 − ξ)a6CV6 − (ρ + age + µ6,t)IV6
dRV6
dt
= ageRV5 + ρIV6 + αCV6 − (φ + wL + age + µ6,t)RV6 + γ2,tR5 + γ2,tRE5
dSE6
dt
= (1 − γ6,t)ageSE5 − (1 − δ)θλ6SE6 + φRE6 − (wS + age + µ6,t)SE6
dCE6
dt
= (1 − γ2,t)ageCE5 + (1 − δ)θλ6SE6
− ((1 − ξ)a6 + α + wS + age + µ2,t)CE6 + γ1,tC6
dIE6
dt
= ageIE5 + (1 − ξ)a6CE6 − (ρ + age + µ6,t)IE6
dRE6
dt




= ageS99 + φR100 − θλ100S100 − µ100,tS100 + wLSV100 + wSSE100
dC100
dt
= ageC99 + θλ100S100 + (a100 − α − µ100,t)C100 + wLCV100 + wSCE100
dI100
dt
= ageI99 + a100C100 − (ρ + µ100,t)I100
dR100
dt
= ageR99 + ρI100 + αC100 − (φ + µ100,t)R100 + wLRV100 + wSRE100
dSV100
dt




= ageCV99 + (1 − δ)θλ100SV100 − ((1 − ξ)a100 + α + wL + µ100,t)CV100
dIV100
dt
= ageIV99 + (1 − ξ)a100CV100 − (ρ + µ100,t)IV100
dRV100
dt
= ageRV99 + ρIV100 + αCV100 − (φ + wL + µ100,t)RV100
dSE100
dt
= ageSE99 − (1 − δ)θλ100SE100 + φRE100 − (wS + µ100,t)SE100
dCE100
dt
= ageCE99 + (1 − δ)θλ100SE100 − ((1 − ξ)a100 + α + wS + µ100,t)CE100
dIE100
dt
= ageIE99 + (1 − ξ)a100CE100 − (ρ + µ100,t)IE100
dRE100
dt
= ageRE99 + ρIE100 + αCE100 − (φ + wS + µ100,t)RE100
